

South Dakota Department of Social Services

Medicaid P&T Committee Meeting

March 24, 2023



Table of Contents

Agenda	2
Minutes	3
PA update.....	5
Top 15 Therapeutic Classes	8
Top 50 Drugs	9
Fleqsuvy & baclofen review	11
Selgentis & tramadol review	12
Vuity & pilocarpine review	13
Opioid update	14
Dermatological PA review	18
Mupirocin trend	22
Epinephrine trend	24
PA forms & criteria	26
Xelstrym	154



South Dakota
Department of
Social Services

DEPARTMENT OF SOCIAL SERVICES

DIVISION OF MEDICAL SERVICES
700 GOVERNORS DRIVE
PIERRE, SD 57501-2291
PHONE: 605-773-3495
FAX: 605-773-5246
WEB: dss.sd.gov

**SOUTH DAKOTA
MEDICAID P&T COMMITTEE MEETING
AGENDA**

March 24, 2023
1:00 – 3:00 PM CT
12:00 – 2:00 PM MT

Meeting Link:

https://teams.microsoft.com/l/meetup-join/19%3ameeting_ODM5OWRjNWEtMTQzMCM00MTgzLWE5ZTEtOWRiNjZmY2M0NGZh%40thread.v2/0?context=%7b%22id%22%3a%22db05faca-c82a-4b9d-b9c5-0f64b6755421%22%2c%22oid%22%3a%22b6efd724-b34e-4a86-b34c-e34f07dd4ceb%22%7d

Join with a video conferencing device

425899727@t.plcm.vc
Video Conference ID: 116 419 500 14

Join by phone

+1 952-222-7450
Phone Conference ID: 645 616 569#

Call to order

Approval of previous meeting minutes

PA update

Review of top 15 therapeutic categories/top 50 drugs

Old business

- Fleqsuvy & baclofen review**
- Selgentis & tramadol review**
- Vuity & pilocarpine review**
- Opioid update**

New business

- Dermatological PA review**
- Mupirocin trend**
- Epinephrine trend**
- Review PA forms & criteria**
- Xelstym**

Public input accepted after individual topic discussion
Next meeting date June 9, 2023 & adjournment

**South Dakota Department of Social Services, Division of Medicaid Services
Pharmacy & Therapeutics (P&T) Committee Meeting Minutes**

Friday, December 2, 2022

1:00 – 3:00 pm CT

Members and DSS Staff

Michelle Baack, MD	X	Heather Preuss, MD	X
Dana Darger, RPh, Chair	X	Matthew Stanley, DO	X
Mikel Holland, MD	X	Deidre Van Gilder, PharmD	X
Bill Ladwig, RPh	X	Mike Jockheck, DSS Staff	X
Kelley Oehlke, PharmD	X	Matthew Ballard, DSS Staff	X
Lenny Petrik, PharmD		Sarah Aker, DSS Staff	

Administrative Business

Darger called the meeting to order at 1:02 pm. The minutes of the September meeting were presented. Ladwig made a motion to approve. Holland seconded the motion. The motion was unanimously approved.

Biosimilar presentation

Mike Einodshoder, Chief Pharmacy Officer from OptumRx, provided an in-depth presentation on biosimilars.

Prior Authorization Update (PA) and Statistics

The committee reviewed the PA activity report from July 1, 2022, to September 30, 2022. A total of 1,852 PAs were reviewed of which 117 requests (6.3%) were received via telephone and 1,031 requests (55.7%) were received via fax, and 704 (38%) were reviewed via electronically. There was a 3.4% increase of PAs received compared to the previous quarter. Baack inquired if there were any cost savings from dermatological PA changes made the previous year.

Analysis of the Top 15 Therapeutic Classes and Drug Spend

The committee reviewed the top 15 therapeutic classes by total cost of claims from July 1, 2022, to September 30, 2022. The top five therapeutic classes based on paid amount were atypical antipsychotics, disease-modifying anti-rheumatic agents, skin and mucous membrane agents, cystic fibrosis correctors, and amphetamines. These top 15 therapeutic classes make up 25.27 % of total claims. The committee also reviewed the top 50 drugs based on amount paid and number of claims. The top 50 drugs by amount paid make up 9.64% of total claims. Darger commented on the increase of mupirocin claims during this quarter. A more in-depth analysis was requested which would be aligned with the dermatological PA reviews. The increase of epinephrine paid amount was also discussed. Van Gilder added that the increase may be due to the start of the school year. Past third quarter trends will be reviewed to confirm epinephrine increase. Darger inquired if there was any public comment. There was none.

Old Business

Narrow Therapeutic Index Drugs

The committee reviewed the NTI utilization of claims with DAW 1. Baack made a motion to remove the NTI list. Van Gilder seconded the motion. Darger inquired if there was any public comment. There was none. The motion was approved unanimously. Committee discussed pros and cons to adding electronic

PA to levothyroxine capsules. Baack made another motion to add manual review PA to levothyroxine capsules with no grandfathering. Van Gilder seconded the motion. Darger inquired if there was any public comment. There was none. The motion was approved unanimously.

Performance Measures

Samantha Moon from the Department of Medical Services provided follow up on two Performance Measures that the State is tracking: Follow up Care for Children Prescribed ADHD Medication; Ages 6-12 years old and Metabolic Monitoring for Children and Adolescents on Antipsychotics; Ages 1-17 years old. Baack questioned the lab tests included in the lipid panel. Moon will send list included in the lab tests. Stanley provided insight on antipsychotics prescribed in hospital settings and metabolic testing performed there. A new measure to the CORE Set is the Avoidance of Antibiotic Treatment for Acute Bronchitis which Moon will be presenting in the future.

Opioid update

The committee reviewed 3Q2022 opioid outcomes compared to previous quarters from the opioid initiatives. The opioid figures for 2Q2022 excluded IHS utilization with the last similar comparison during 4Q2019. There was an increase in opioid utilization and utilizers during 2Q2022 with corresponding increase in total eligibility and utilizers. Darger inquired if there was any public comment. There was none.

Adjournment

The next meeting scheduled on March 24, 2023. The June meeting is tentatively scheduled for June 9, 2023. The Committee made a motion to adjourn the meeting, and everyone seconded the motion. The motion passed unanimously, and the meeting adjourned at 2:58 pm.

PA Report

10/1/2022 – 12/31/2022

Compliance Summary


Priority	Total PAs	PAs Compliant	PAs Not Compliant	% PAs Compliant	% PAs Not Compliant
Standard	1,922	1,922	0	100.00%	0.00%
Urgent	46	46	0	100.00%	0.00%
Grand Total	1,968	1,968	0		

Drug Class	# of Requests	Phone Requests		Fax Requests		Real-Time PA	
		#	%	#	%	#	%
Total	1,968	100	5.1%	1,297	65.9%	571	29%

PA Initial Requests Summary

Month	Approved	Denied	Total
Oct-22	474	173	647
Nov-22	481	210	691
Dec-22	439	191	630
4Q22	1,394	574	1,968
Percent of Total	70.83%	29.17%	

PA Requests Details



Top Therapeutic Classes for PA

Drug Class	Approved	Denied	Total	Approval Rate	% of Total Requests	Most Requested Products
ANTIPSYCHOTIC/ANTIMANIC	330	21	351	94.02%	17.84%	, INVEGA SUSTENNA
ANTIDIABETICS	198	122	320	61.88%	16.26%	, OZEMPIC
DERMATOLOGICALS	126	87	213	59.15%	10.82%	DUPIXENT, SPINOSAD
ANTIDEPRESSANTS	160	27	187	85.56%	9.50%	, SERTRALINE
ANALGESICS - OPIOID	83	76	159	52.20%	8.08%	HYDROCODONE/APAP, TRAMADOL
OTHERS -	497	241	738	67.34%	37.50%	
4Q22	1,394	574	1,968	70.83%		

PA Drug Class Summary

Drug Class	Approved	Denied	Total	Approval Rate
59 - ANTIPSYCHOTICS/ANTIMANIC AGENTS*	330	21	351	94.02%
27 - ANTIDIABETICS*	198	122	320	61.88%
90 - DERMATOLOGICALS*	126	87	213	59.15%
58 - ANTIDEPRESSANTS*	160	27	187	85.56%
65 - ANALGESICS - OPIOID*	83	76	159	52.20%
67 - MIGRAINE PRODUCTS*	55	42	97	56.70%
52 - GASTROINTESTINAL AGENTS - MISC.*	75	16	91	82.42%
61 - ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREX	56	26	82	68.29%
66 - ANALGESICS - ANTI-INFLAMMATORY*	55	9	64	85.94%
49 - ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERG	44	14	58	75.86%
60 - HYPNOTICS/SEDATIVES/SLEEP DISORDER AGENT	10	38	48	20.83%
16 - ANTI-INFECTIVE AGENTS - MISC.*	29	0	29	100.00%
30 - ENDOCRINE AND METABOLIC AGENTS - MISC.*	18	11	29	62.07%
41 - ANTIHISTAMINES*	21	5	26	80.77%
54 - URINARY ANTISPASMODICS*	17	9	26	65.38%
72 - ANTICONVULSANTS*	18	8	26	69.23%
12 - ANTIVIRALS*	2	20	22	9.09%
21 - ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	16	4	20	80.00%
50 - ANTIEMETICS*	12	3	15	80.00%
75 - MUSCULOSKELETAL THERAPY AGENTS*	5	9	14	35.71%
44 - ANTI-ASTHMATIC AND BRONCHODILATOR AGENTS*	9	3	12	75.00%
62 - PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENT	11	0	11	100.00%
83 - ANTICOAGULANTS*	9	1	10	90.00%
03 - MACROLIDES*	5	3	8	62.50%
45 - RESPIRATORY AGENTS - MISC.*	4	3	7	57.14%
33 - BETA BLOCKERS*	3	3	6	50.00%
39 - ANTIHYPERLIPIDEMICS*	3	3	6	50.00%
36 - ANTIHYPERTENSIVES*	3	2	5	60.00%
34 - CALCIUM CHANNEL BLOCKERS*	2	2	4	50.00%
02 - CEPHALOSPORINS*	2	1	3	66.67%
42 - NASAL AGENTS - SYSTEMIC AND TOPICAL*	0	3	3	0.00%
82 - HEMATOPOIETIC AGENTS*	3	0	3	100.00%
40 - CARDIOVASCULAR AGENTS - MISC.*	2	0	2	100.00%
51 - DIGESTIVE AIDS*	2	0	2	100.00%
74 - NEUROMUSCULAR AGENTS*	0	2	2	0.00%
86 - OPHTHALMIC AGENTS*	2	0	2	100.00%
15 - ANTHELMINTICS*	1	0	1	100.00%
26 - PROGESTINS*	1	0	1	100.00%
32 - ANTIANGINAL AGENTS*	1	0	1	100.00%
87 - OTIC AGENTS*	1	0	1	100.00%
97 - MEDICAL DEVICES AND SUPPLIES*	0	1	1	0.00%
4Q22	1,394	574	1,968	
Percent of Total	70.83%	29.17%		

PA Appeals Summary

Month	Approved	Approved %	Denied	Denied %	Total
Oct-22	14	58.33%	10	41.67%	24
Nov-22	15	75.00%	5	25.00%	20
Dec-22	14	37.84%	23	62.16%	37
4Q22	43	53.09%	38	46.91%	81

Appeals Detail

Drug Class	Approved	Denied	Total	Approval Rate
MAVYRET	2	8	10	20.00%
LUBIPROSTONE	7	1	8	87.50%
EMGALITY	3	2	5	60.00%
EPCLUSA	1	4	5	20.00%
AIMOVIG	2	2	4	50.00%
AJOVY	1	3	4	25.00%
BELSOMRA	2	2	4	50.00%
EPIDIOLEX	2	2	4	50.00%
STELARA	4	0	4	100.00%
OZEMPIC	0	3	3	0.00%
DAYVIGO	0	2	2	0.00%
ESCITALOPRAM OXALATE	0	2	2	0.00%
EVRYSDI	2	0	2	100.00%
NURTEC	1	1	2	50.00%
NUTROPIN AQ NUSPIN 10	1	1	2	50.00%
TRAMADOL HCL	2	0	2	100.00%
ABILIFY MAINTENA	1	0	1	100.00%
AMPHETAMINE/DEXTROAMPHETAMINE	1	0	1	100.00%
CITALOPRAM HYDROBROMIDE	1	0	1	100.00%
DEXLANSOPRAZOLE	1	0	1	100.00%
DUPIXENT	1	0	1	100.00%
HUMATROPE	1	0	1	100.00%
IVERMECTIN	0	1	1	0.00%
METOPROLOL SUCCINATE ER	1	0	1	100.00%
MODAFINIL	1	0	1	100.00%
MOUNJARO	0	1	1	0.00%
MYRBETRIQ	1	0	1	100.00%
NINLARO	1	0	1	100.00%
NORDITROPIN FLEXP	1	0	1	100.00%
OTEZLA	0	1	1	0.00%
OXYCONTIN	1	0	1	100.00%
QUVIVIQ	0	1	1	0.00%
TRAMADOL HYDROCHLORIDE	1	0	1	100.00%
TRULICITY	0	1	1	0.00%
4Q22	43	38	81	

Top 15 Therapeutic Classes & Top 50 Drugs

TOP 15 THERAPEUTIC CLASSES BASED ON NUMBER OF CLAIMS FROM 10/1/2022 – 12/31/2022					
	AHFS Description	Total Rxs	Plan Paid Amount	Paid/Rx	% Total Claims
1	SELECTIVE-SEROTONIN REUPTAKE INHIBITORS	15,513	\$201,897.83	\$13.01	6.54%
2	ANTICONVULSANTS, MISCELLANEOUS	12,133	\$1,097,018.81	\$90.42	5.11%
3	SELECTIVE BETA-2-ADRENERGIC AGONISTS	9,801	\$533,319.51	\$54.41	4.13%
4	AMINOPENICILLIN ANTIBIOTICS	9,697	\$143,948.47	\$14.84	4.09%
5	ATYPICAL ANTIPSYCHOTICS	9,658	\$3,167,156.70	\$327.93	4.07%
6	ADRENALS	8,111	\$719,543.10	\$88.71	3.42%
7	RESPIRATORY AND CNS STIMULANTS	8,025	\$616,317.84	\$76.80	3.38%
8	SECOND GENERATION ANTIHISTAMINES	7,870	\$88,327.81	\$11.22	3.32%
9	AMPHETAMINES	7,682	\$1,361,203.93	\$177.19	3.24%
10	PROTON-PUMP INHIBITORS	6,656	\$179,237.94	\$26.93	2.80%
11	OPIATE AGONISTS	5,695	\$172,008.20	\$30.20	2.40%
12	ANXIOLYTICS, SEDATIVES, AND HYPNOTICS, MISC	5,114	\$68,704.07	\$13.43	2.16%
13	CENTRAL NERVOUS SYSTEM AGENTS, MISC	4,223	\$232,673.39	\$55.10	1.78%
14	CONTRACEPTIVES	4,130	\$126,873.28	\$30.72	1.74%
15	ANTIDEPRESSANTS, MISCELLANEOUS	3,926	\$77,785.19	\$19.81	1.65%
Total		118,234	\$8,786,016.07	\$74.31	49.82%

TOP 15 THERAPEUTIC CLASSES BASED ON AMOUNT PAID FROM 10/1/2022 – 12/31/2022					
	AHFS Description	Total Rxs	Plan Paid Amount	Paid/Rx	% Total Claims
1	ATYPICAL ANTIPSYCHOTICS	9,658	\$3,167,156.70	\$327.93	4.07%
2	SKIN AND MUCOUS MEMBRANE AGENTS, MISC	750	\$2,569,555.81	\$3,426.07	0.32%
3	DISEASE-MODIFYING ANTIRHEUMATIC AGENTS	381	\$2,364,929.47	\$6,207.16	0.16%
4	HEMOSTATICS	48	\$1,367,604.55	\$28,491.76	0.02%
5	AMPHETAMINES	7,682	\$1,361,203.93	\$177.19	3.24%
6	CYSTIC FIBROSIS (CFTR) CORRECTORS	59	\$1,297,418.21	\$21,990.14	0.02%
7	ANTICONVULSANTS, MISCELLANEOUS	12,133	\$1,097,018.81	\$90.42	5.11%
8	INCRETIN MIMETICS	1,122	\$952,192.73	\$848.66	0.47%
9	ANTINEOPLASTIC AGENTS	283	\$896,081.70	\$3,166.37	0.12%
10	ADRENALS	8,111	\$719,543.10	\$88.71	3.42%
11	LONG-ACTING INSULINS	1,445	\$619,053.13	\$428.41	0.61%
12	RESPIRATORY AND CNS STIMULANTS	8,025	\$616,317.84	\$76.80	3.38%
13	GI DRUGS, MISCELLANEOUS	423	\$580,608.99	\$1,372.60	0.18%
14	RAPID-ACTING INSULINS	1,354	\$544,513.33	\$402.15	0.57%
15	SELECTIVE BETA-2-ADRENERGIC AGONISTS	9,801	\$533,319.51	\$54.41	4.13%
Total		61,275	\$18,686,517.81	\$304.96	25.82%

Total Rx Claims from 10/1/2022 – 12/31/2022	237,299
--	----------------

TOP 50 DRUGS BASED ON NUMBER OF CLAIMS FROM 10/1/2022 – 12/31/2022

	AHFS Description	Drug Label Name	Total Rxs	Plan Paid Amount	Paid/Rx	% Total Claims
1↑	AMINOPENICILLIN ANTIBIOTICS	AMOXICILLIN	7,034	\$93,023.81	\$13.22	2.96%
2	SELECTIVE-SEROTONIN REUPTAKE INHIBITOR	FLUOXETINE	5,507	\$69,833.48	\$12.68	2.32%
3	RESPIRATORY AND CNS STIMULANTS	METHYLPHENIDATE HCL	5,401	\$267,629.73	\$49.55	2.28%
4	SELECTIVE-SEROTONIN REUPTAKE INHIBITOR	SERTRALINE HCL	4,853	\$59,595.61	\$12.28	2.05%
5	SELECTIVE BETA-2-ADRENERGIC AGONISTS	ALBUTEROL SULFATE HFA	4,824	\$186,093.46	\$38.58	2.03%
6	SECOND GENERATION ANTIHISTAMINES	CETIRIZINE HCL	4,241	\$44,128.86	\$10.41	1.79%
7	PROTON-PUMP INHIBITORS	OMEPRAZOLE	3,958	\$45,688.21	\$11.54	1.67%
8	AMPHETAMINES	VYVANSE	3,865	\$1,235,736.89	\$319.72	1.63%
9	SELECTIVE-SEROTONIN REUPTAKE INHIBITORS	ESCITALOPRAM OXALATE	3,669	\$46,371.34	\$12.64	1.55%
10	AMPHETAMINES	AMPHETAMINE/DEXTROAMP	3,588	\$93,892.80	\$26.17	1.51%
11	SEROTONIN MODULATORS	TRAZODONE HCL	3,524	\$37,622.25	\$10.68	1.49%
12	ANTICONVULSANTS, MISCELLANEOUS	GABAPENTIN	3,409	\$55,856.78	\$16.39	1.44%
13	LEUKOTRIENE MODIFIERS	MONTELUKAST SODIUM	3,398	\$44,173.57	\$13.00	1.43%
14	THYROID AGENTS	LEVOTHYROXINE SODIUM	3,280	\$43,680.79	\$13.32	1.38%
15↑	SELECTIVE BETA-2-ADRENERGIC AGONISTS	ALBUTEROL SULFATE	3,047	\$58,241.67	\$19.11	1.28%
16	CENTRAL ALPHA-AGONISTS	CLONIDINE HCL	2,999	\$37,760.28	\$12.59	1.26%
17↑	OTHER MACROLIDE ANTIBIOTICS	AZITHROMYCIN	2,781	\$45,918.28	\$16.51	1.17%
18	ANTIDEPRESSANTS, MISCELLANEOUS	BUPROPION HCL	2,731	\$50,140.53	\$18.36	1.15%
19↑	AMINOPENICILLIN ANTIBIOTICS	AMOXICILLIN/CLAVULANATE	2,662	\$50,870.81	\$19.11	1.12%
20	BIGUANIDES	METFORMIN HCL	2,582	\$32,008.16	\$12.40	1.09%
21	OPIATE AGONISTS	HYDROCODONE BIT/AC	2,317	\$35,067.21	\$15.13	0.98%
22	ATYPICAL ANTIPSYCHOTICS	ARIPIRAZOLE	2,302	\$33,826.91	\$14.69	0.97%
23↑	3RD GENERATION CEPHALOSPORIN ANTIBIOT	CEFDINIR	2,221	\$45,475.99	\$20.48	0.94%
24	ADRENALS	PREDNISONE	2,201	\$20,477.31	\$9.30	0.93%
25	ANGIOTENSIN-CONVERTING ENZYME INHIBIT	LISINAPRIL	2,187	\$21,301.19	\$9.74	0.92%
26	HMG-COA REDUCTASE INHIBITORS	ATORVASTATIN CALCIUM	2,185	\$25,601.77	\$11.72	0.92%
27	1ST GENERATION CEPHALOSPORIN ANTIBIOT	CEPHALEXIN	2,044	\$35,097.58	\$17.17	0.86%
28	CENTRAL NERVOUS SYSTEM AGENTS, MISC.	GUANFACINE ER	2,043	\$35,206.84	\$17.23	0.86%
29	SEL. SEROTONIN, NOREPI REUPTAKE INHIBIT	DULOXETINE HCL	2,032	\$31,926.11	\$15.71	0.86%
30	5-HT3 RECEPTOR ANTAGONISTS	ONDANSETRON ODT	1,982	\$27,712.62	\$13.98	0.84%
31	ANXIOLYTICS, SEDATIVES, & HYPNOTICS	HYDROXYZINE HCL	1,898	\$23,705.54	\$12.49	0.80%
32	ATYPICAL ANTIPSYCHOTICS	RISPERIDONE	1,879	\$22,786.17	\$12.13	0.79%
33	ANTICONVULSANTS, MISCELLANEOUS	LAMOTRIGINE	1,831	\$25,077.84	\$13.70	0.77%
34	SECOND GENERATION ANTIHISTAMINES	LORATADINE	1,734	\$18,857.15	\$10.87	0.73%
35↑	ADRENALS	PREDNISOLONE SODIUM	1,726	\$26,852.43	\$15.56	0.73%
36	ATYPICAL ANTIPSYCHOTICS	QUETIAPINE FUMARATE	1,587	\$20,116.49	\$12.68	0.67%
37	CORTICOSTEROIDS (EENT)	FLUTICASONE PROPIONATE	1,569	\$23,144.47	\$14.75	0.66%
38	ANXIOLYTICS, SEDATIVES, & HYPNOTICS	BUSPIRONE HCL	1,550	\$19,704.50	\$12.71	0.65%
39	BENZODIAZEPINES (ANTICONVULSANTS)	CLONAZEPAM	1,515	\$16,735.22	\$11.05	0.64%
40↑	NEURAMINIDASE INHIBITOR ANTIVIRALS	OSELTAMIVIR PHOSPHATE	1,442	\$49,620.60	\$34.41	0.61%
41	COMPOUNDS	-	1,408	\$32,355.73	\$22.98	0.59%
42	CENTRALLY ACTING SKELETAL MUSCLE RELAX	CYCLOBENZAPRINE HCL	1,354	\$13,521.21	\$9.99	0.57%
43	ANTICONVULSANTS, MISCELLANEOUS	LEVETIRACETAM	1,331	\$27,908.94	\$20.97	0.56%
44	PROTON-PUMP INHIBITORS	PANTOPRAZOLE SODIUM	1,292	\$16,350.00	\$12.65	0.54%
45	CORTICOSTEROIDS-SKIN, MUCOUS MEMBRA	TRIAMCINOLONE ACETONIDE	1,273	\$18,478.19	\$14.52	0.54%
46	ANTICONVULSANTS, MISCELLANEOUS	TOPIRAMATE	1,263	\$16,676.67	\$13.20	0.53%
47	DIHYDROPYRIDINES	AMLODIPINE BESYLATE	1,236	\$12,176.55	\$9.85	0.52%
48↑	RESPIRATORY AND CNS STIMULANTS	DEXMETHYLPHENIDATE HCL	1,213	\$57,326.06	\$47.26	0.51%
49	ANGIOTENSIN II RECEPTOR ANTAGONISTS	LOSARTAN POTASSIUM	1,184	\$13,859.08	\$11.71	0.50%
50	ANTIDEPRESSANTS, MISCELLANEOUS	MIRTAZAPINE	1,179	\$16,714.98	\$14.18	0.50%
	Total Top 50 Drugs		128,331	\$3,381,928.66	\$26.35	54.08%

TOP 50 DRUGS BASED ON AMOUNT PAID FROM 10/1/2022 – 12/31/2022

	AHFS Description	Drug Label Name	Total Rxs	Plan Paid Amount	Paid/Rx	% Total Claims
1	DISEASE-MODIFYING ANTIRHEUMATIC AGT	HUMIRA/PEN & STARTER	151	\$1,310,212.89	\$8,676.91	0.06%
2	AMPHETAMINES	VYVANSE	3,865	\$1,235,736.89	\$319.72	1.63%
3	SKIN & MUCOUS MEMBRANE AGENTS	STELARA	52	\$1,184,790.12	\$22,784.43	0.02%
4	CYSTIC FIBROSIS (CFTR) CORRECTORS	TRIKAFTA	45	\$1,033,075.39	\$22,957.23	0.02%
5	ATYPICAL ANTIPSYCHOTICS	INVEGA SUSTENNA/TRINZA	335	\$942,992.35	\$2,814.90	0.14%
6	INTERLEUKIN ANTAGONISTS	DUPIXENT	242	\$815,348.58	\$4,314.01	0.08%
7	ATYPICAL ANTIPSYCHOTICS	LATUDA	473	\$615,714.80	\$1,301.72	0.20%
8	INCRETIN MIMETICS	OZEMPIC	656	\$555,521.28	\$846.83	0.28%
9	ATYPICAL ANTIPSYCHOTICS	ARISTADA & INITIO	171	\$470,760.59	\$2,752.99	0.07%
10↑	HEMOSTATICS	NOVOSEVEN RT	4	\$461,318.90	\$115,329.73	0.00%
11	ATYPICAL ANTIPSYCHOTICS	VRAYLAR	345	\$396,294.28	\$1,148.68	0.15%
12	ANTICONVULSANTS, MISCELLANEOUS	EPIDIOLEX	121	\$353,933.99	\$2,925.07	0.05%
13	DISEASE-MODIFYING ANTIRHEUMATIC AGT	ENBREL & MINI/SURECLICK	53	\$330,139.65	\$6,229.05	0.02%
14	HEMOSTATICS	HEMLIBRA	6	\$303,221.52	\$50,536.92	0.00%
15	SKIN & MUCOUS MEMBRANE AGENTS	TALTZ	38	\$288,854.00	\$7,601.42	0.02%
16	DISEASE-MODIFYING ANTIRHEUMATIC AGT	COSENTYX & SENSOREADY	47	\$283,834.62	\$6,039.03	0.02%
17	ATYPICAL ANTIPSYCHOTICS	REXULTI	230	\$277,463.54	\$1,206.36	0.10%
18↑	VESICULAR MONOAMINE TRANSPORT2 INH	INGREZZA	37	\$276,269.95	\$7,466.76	0.02%
19	RESPIRATORY AND CNS STIMULANTS	METHYLPHENIDATE HCL	5,401	\$267,629.73	\$49.55	2.28%
20	CYSTIC FIBROSIS (CFTR) CORRECTORS	ORKAMBI	14	\$264,342.82	\$18,881.63	0.01%
21	SODIUM-GLUC COTRANSPORT 2 INHIBITOR	JARDIANCE	499	\$259,269.60	\$519.58	0.21%
22	GI DRUGS, MISCELLANEOUS	GATTEX	6	\$257,544.00	\$42,924.00	0.00%
23	MUCOLYTIC AGENTS	PULMOZYME	59	\$250,568.14	\$4,246.92	0.02%
24↑	SKIN & MUCOUS MEMBRANE AGENTS	SKYRIZI & PEN	13	\$234,477.60	\$18,036.74	0.01%
25	HIV INTEGRASE INHIBITOR ANTIRETROVIRA	BIKTARVY	66	\$229,587.54	\$3,478.60	0.03%
26	HEMOSTATICS	ADVATE	8	\$204,246.43	\$25,530.80	0.00%
27	LONG-ACTING INSULINS	LANTUS & SOLOSTAR	505	\$199,094.80	\$394.25	0.21%
28	INCRETIN MIMETICS	TRULICITY	229	\$199,055.87	\$869.24	0.10%
29	SELECTIVE BETA-2-ADRENERGIC AGONISTS	ALBUTEROL SULFATE HFA	4,824	\$186,093.46	\$38.58	2.03%
30↓	SOMATOTROPIN AGONISTS	NORDITROPIN FLEXPRO	54	\$181,390.52	\$3,359.08	0.02%
31	LONG-ACTING INSULINS	TRESIBA FLEXTOUCH	328	\$170,527.56	\$519.90	0.14%
32	RIFAMYCIN ANTIBIOTICS	XIFAXAN	64	\$158,130.72	\$2,470.79	0.03%
33	HEMOSTATICS	RECOMBINATE	3	\$150,811.35	\$50,270.45	0.00%
34	SKIN & MUCOUS MEMBRANE AGENTS	TREMFYA	12	\$149,372.48	\$12,447.71	0.01%
35	SELECTIVE BETA-2-ADRENERGIC AGONISTS	ADVAIR HFA	400	\$146,902.10	\$367.26	0.17%
36	DIRECT FACTOR XA INHIBITORS	ELIQUIS & STARTER PACK	242	\$145,122.22	\$599.68	0.10%
37	GI DRUGS, MISCELLANEOUS	CHOLBAM	7	\$140,973.85	\$20,139.12	0.00%
38	ATYPICAL ANTIPSYCHOTICS	ABILIFY MAINTENA	57	\$135,515.65	\$2,377.47	0.02%
39↑	VASODILATING AGENTS (RESPIRATORY)	OPSUMIT	12	\$134,325.12	\$11,193.76	0.01%
40	HIV INTEGRASE INHIBITOR ANTIRETROVIRA	GENVOYA	37	\$129,337.34	\$3,495.60	0.02%
41	HEMOSTATICS	XYNTHA SOLOFUSE	4	\$128,275.70	\$32,068.93	0.00%
42	LONG-ACTING INSULINS	LEVEMIR & FLEXTOUCH	263	\$122,497.99	\$465.77	0.11%
43↑	ANTICONVULSANTS, MISCELLANEOUS	FINTEPLA	7	\$121,252.37	\$17,321.77	0.00%
44	RAPID-ACTING INSULINS	INSULIN ASPART FLEXPEN	352	\$121,037.51	\$343.86	0.15%
45↓	OTHER MISCELLANEOUS THERAPEUTIC AGT	EVRYSDI	5	\$117,409.25	\$23,481.85	0.00%
46↑	ADRENALS	FLUTICASONE PROPIONAT HF	638	\$109,919.66	\$172.29	0.27%
47	ADRENALS	FLOVENT HFA	477	\$109,053.46	\$228.62	0.20%
48↑	RESPIRATORY TRACT AGENTS, MISC	XOLAIR	36	\$109,009.28	\$3,028.04	0.02%
49	ANTIMUSCARINICS/ANTISPASMODICS	SPIRIVA RESPIMAT	230	\$105,025.95	\$456.63	0.10%
50	RAPID-ACTING INSULINS	NOVOLOG FLEXPEN	174	\$101,965.39	\$586.01	0.07%
	Total Top 50 Drugs		21,897	\$16,475,248.80	\$752.40	9.23%

Old Business

Fleqsuvy & baclofen

Time frame: 10/1/2022 to 12/31/2022

Drug Name	Total Rx	Paid Amount	Paid/Rx	Avg Quantity/DS	Utilizers	Age Range
baclofen tab 5mg	63	\$1,775.60	\$28.18	#79/26 days	29	2 – 63
baclofen tab 10mg	699	\$9,796.46	\$14.02	#91/27 days	309	2 – 72
baclofen tab 20mg	171	\$3,294.51	\$19.27	#99/29 days	68	5 – 64
baclofen sol 5mg/5ml	22	\$10,046.57	\$456.66	#428/27 days	10	2 – 26
FLEQSUVY susp 25mg/5ml	26	\$30,117.30	\$1,158.36	#209/28 days	9	2 – 26
LYVISPAH granules (5mg, 10mg, 20mg)	0					
OZOBAX solution 5mg/5ml*	0					

*not rebateable manufacturer

Indications:

- Solution (Ozobax), tablet: Management of reversible spasticity associated with multiple sclerosis or spinal cord lesions.
- Granules (Lyvispah), suspension (Fleqsuvy): Treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity; may also be of some value in patients with spinal cord injuries and other spinal cord diseases.

State A: PA criteria for baclofen solution:

1. Member is 12 to 17 years of age or unable to swallow tablets OR
2. Try baclofen tab, chlorzoxazone, cyclobenzaprine IR, methocarbamol, orphenadrine, tizanidine tabs first
3. Age 18 and over: provide rationale for not being able to swallow

State A: PA criteria for Fleqsuvy, and Lyvispah:

1. Member is 12 to 17 years of age or unable to swallow tablets OR
2. Try baclofen tab, chlorzoxazone, cyclobenzaprine IR, methocarbamol, orphenadrine, tizanidine tabs first
3. Try baclofen solution first
4. Age 18 and over: provide rationale for not being able to swallow

State B: PA criteria for baclofen oral solution, Fleqsuvy, and Lyvispah:

1. Age
2. Diagnosis of dysphagia

Seglentis & tramadol

Time frame: 10/1/2022 to 12/31/2022

Drug Name	Total Rx	Paid Amount	Paid/Rx	Avg Quantity/DS	Utilizers	Age Range
tramadol tab 50mg	1,157	\$12,384.19	\$10.70	#59/16 days	572	14 – 94
tramadol tab 100mg	6	\$642.05	\$107.01	#90/24 days	2	55, 62
tramadol tab 100mg ER	10	\$486.57	\$48.66	#33/24 days	3	38 – 61
tramadol tab 200mg ER	9	\$557.09	\$61.90	#27/27 days	3	35 – 48
tramadol tab 300mg ER	5	\$334.17	\$66.84	#30/30 days	2	41, 46
tramadol/APAP tab 37.5-325	2	\$25.05	\$12.53	#25/5 days	2	47, 59
CONZIP (tramadol SR biphasic cap)	0					
SYNAPRYN (tramadol susp)	0					
QDOLO (tramadol sol 5mg/ml)*	0					
SEGLENTIS 56-44mg (celecoxib/tramadol tab)	1	\$399.53	\$399.53	#90/34 days	1	37
celecoxib cap 50mg	7	\$117.75	\$16.82	#47/30 days	3	2 – 49
celecoxib cap 100mg	64	\$1,000.54	\$15.64	#53/28 days	38	11 – 63
celecoxib cap 200mg	312	\$4,827.22	\$15.47	#46/30 days	159	14 – 65

Red font denotes drug is on PA; *not rebateable manufacturer

Conzip, Synaprn, and tramadol ER (Ultram ER) PA criteria:

- o 30-day trial of tramadol IR in the past 120 days

Seglentis Indication:

- **Pain, acute:** Management of acute pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

State A criteria for Seglentis:

1. Prescriber must provide documentation that separate components are unsuitable for use

State B: PA criteria for Seglentis:

1. Inform provider of generic celecoxib and generic tramadol
2. Letter of medical necessity must be submitted stating the reasons generic celecoxib and generic tramadol as separate products are not appropriate for the member

Health Plan: PA criteria for Seglentis:

1. Step Therapy: Patient has tried and failed, or is intolerant to three other non-opioid analgesics (e.g., meloxicam, ibuprofen) in the last 120 days

Vuity & pilocarpine drops

Time frame: 2Q2022 to 4Q2022


Drug Name	2Q2022				3Q2022				4Q2022			
	Total Rx	Paid Amount	Paid/Rx	Mbr	Total Rx	Paid Amount	Paid/Rx	Mbr	Total Rx	Paid Amount	Paid/Rx	Mbr
VUITY sol 1.25%	11	\$866.06	\$78.73	7	13	\$1,014	\$77.98	6	10	\$786.40	\$78.64	5
pilocarpine sol 1%	0				1	\$0	\$0	1	0			
pilocarpine sol 2%	0				0				0			
pilocarpine sol 4%	0				0				0			

Indications:

- pilocarpine 1%, 2%, 4% solution
 - Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
 - Induction of miosis
 - Prevention of postoperative elevated IOP associated with laser surgery

- Vuity 1.25% solution
 - Treatment of presbyopia in adults
 - \$32.30 per ml (2.5ml per bottle) vs pilocarpine \$5.00 per ml

Opioid Summary



- 1Q2018 to 4Q2019 excludes IHS
- 1Q2020 to current includes IHS
- March 13, 2020 – Pandemic Closure

Opioid Initiatives:

1. June 1, 2018 – early refill threshold for controlled substance changed from 75% to 85%
2. July 1, 2018 – PA for more than one LAO and one SAO
3. August 1, 2018 – opioid Naïve PA (initial 7-day supply and 60 MED limit)
4. October 1, 2018 to October 1, 2019 – decrease from 300 MED to 90 MED (cancer diagnosis excluded)

Other Initiatives:

- Buprenorphine PA (Bunavail/Suboxone/Zubsolv/Subutex)/ST (Belbuca/Butrans) removed 10/14/2019
- Lidoderm PA removed 8/1/2020

Total Eligibility and Utilizers

Quarter	Avg eligible members	Avg utilizing members of all drugs	% utilizing members of all drugs
1Q2020	123,573	27,089	21.9%
2Q2020	126,777	20,747	16.4%
3Q2020	132,373	23,417	17.7%
4Q2020	136,262	23,488	17.2%
1Q2021	139,748	24,405	17.5%
2Q2021	142,872	26,162	18.3%
3Q2021	146,023	27,847	19.1%
4Q2021	149,034	29,257	19.3%
1Q2022	151,735	28,892	19.0%
2Q2022	154,608	28,338	18.3%
3Q2022	157,627	29,109	18.5%
4Q2022	160,060	32,089	20.0%



Opioid Claims **10,500**

2.9% prescription claims filled for an opioid
0.9% higher than Medicaid FFS benchmark



Opioid Claims **10,688**

3.1% prescription claims filled for an opioid
0.9% higher than Medicaid FFS benchmark



Utilizers **4,216**
30.3% are high utilizers¹

1.0% higher than high utilizers Medicaid FFS




Utilizers **4,275**
30.1% are high utilizers¹

0.5% higher than high utilizers Medicaid FFS


Utilizers by Cumulative MED⁴

Current CDC Guidelines⁵ urge doses of 90 MME⁶ or less in chronic opioid utilizers⁵



Utilizers by Cumulative MED⁴

Current CDC Guidelines⁵ urge doses of 90 MME⁶ or less in chronic opioid utilizers⁵



Shoppers: Poly Pharmacy
50 opioid utilizing members with 3+ pharmacies



Shoppers: Poly Pharmacy
49 opioid utilizing members with 3+ pharmacies



326 Shoppers: Poly Prescriber
opioid utilizing members with 3+ prescribers



357 Shoppers: Poly Prescriber
opioid utilizing members with 3+ prescribers

Opioid Utilization

SDM 4Q2022





Opportunities date range: Sep - Dec 2022
 Benchmark: MEDICAID FEE FOR SERVICE

Utilizers: 4,216

2.9% of all Rx claims are filled for an Opioid

Opioid dependence can start in just a few days, and the risk of chronic opioid use increases with each additional day of opioid supplied, starting with the third day. Our Opioid Risk Management program, which includes point of sale, utilization management and retrospective drug utilization edits, are tightly aligned with CDC opioid prescribing guidelines which can help reduce exposure to excessive doses and prevent more members from transitioning from acute to chronic use.

- Opioid prescriptions account for 2.9% of all prescriptions this period, which is 0.9% higher than the benchmark
- 1,279 high opioid utilizers were identified this period, which is 0.1% higher than the benchmark



Opioid Opportunity Assessment


SDM 4Q2022

Opportunities date range: **Sep - Dec 2022**
 Benchmark: MEDICAID FEE FOR SERVICE

Percent non-compliant: 9.5%

Utilizers non-compliant to opioid Rx CDC guidelines

(new to therapy and chronic use)



[NTT - view definition](#) | [SAO - view definition](#) | [LAO - view definition](#) | [MME - view definition](#)




DID YOU KNOW?

50 opioid utilizing members use 3 or more pharmacies and 326 opioid utilizing members use 3 or more prescribers.

Identification, management and prevention of fraudulent or potential abuse of opioid medications are monitored and addressed by OptumRx through various means in pharmacy network audit capabilities and high touch clinical programs that include care coordination with opioid prescribers.

Opioid utilizers with potentially contraindicated medication use



[Anticonvulsants - view definition](#)

New Business

Dermatologic PA Review

- Adbry, Cibinco, Opzelura – PA effective 7/1/2022

Opzelura PA Review

Time Frame: 7/1/2022 – 1/31/2023

Indication	Drug Class	Approved	Denied	Total	Mbr
Atopic Dermatitis	OPZELURA – PA effective 7/1/2022	2	9	11	7
	APPEALS	2	0	2	2

Opzelura Utilization

Time Frame: 1/1/2022 to 1/31/2023

Drug Name	January 2022 to June 2022				July 2022 to January 2023				Age Range
	Total Rx	Paid Amount	Paid/Rx	Mbr	Total Rx	Paid Amount	Paid/Rx	Mbr	
Opzelura cream 1.5% (ruxolitinib) avg qty 60gm/30 days	11	\$21,546	\$1,959	7	4	\$7,588	\$1,897	4	14 – 63
EUCRISA oint 2% (crisaborole) avg qty 80/28 days	125	\$93,861	\$751	87	107	\$89,514	\$837	74	0 – 57
pimecrolimus cream 1% avg qty 46gm/24 days	86	\$18,987	\$221	71	121	\$21,601	\$179	89	0 – 68
tacrolimus oint 0.03% avg qty 45gm/25 days	38	\$3,701	\$98	34	45	\$2,834	\$63	38	0 – 28
tacrolimus oint 0.1% avg qty 60gm/25 days	95	\$12,826	\$135	73	102	\$10,731	\$105	82	0 – 60

Red font denotes drug is on PA; Includes IHS (1 claim – pre-PA)

PA Criteria

1. Diagnosis of mild to moderate atopic dermatitis AND
2. Member is 12 years of age or older AND
3. One of the following:
 - Greater than or equal to 3% body surface area involvement
 - Involvement of sensitive body areas (e.g., face, hands, feet, scalp, groin)

AND

4. Greater than or equal to 90 days of topical drug therapy with **one** of the following: corticosteroids, pimecrolimus and/or tacrolimus, crisaborole AND
5. Member is not using concurrently with therapeutic biologics, other Janus kinase inhibitors, or potent immunosuppressants such as azathioprine or cyclosporine AND
6. Requested quantity does not exceed 240 g/30 days

Psoriasis & Atopic Dermatitis PA Review

Time Frame: 1/1/2022 – 12/31/2022

Indication	PA REVIEW	Approvals	Denials	Total	Utilizer
Psoriasis & other indications	CIMZIA/STARTER KIT	9	1	10	8
	COSENTYX/SENSOREADY PEN	20	0	20	19
	ENBREL/MINI/SURECLICK	27	2	29	27
	HUMIRA/PEN/STARTER PACK	108	29	137	111
	SKYRIZI/PEN	12	1	13	12
	OTEZLA	7	5	12	12
	SIMPONI	4	1	5	4
	STELARA	37	12	49	40
	TALTZ	14	1	15	14
	TREMFYA	9	0	9	9
Atopic Dermatitis & other indications	DUPIXENT	108	23	131	117
	RINVOQ	4	0	4	4
	ELIDEL (DAW PA)	0	1	1	1

Indication	APPEALS	Approvals	Denials	Total
Psoriasis, Atopic Dermatitis & other indications	DUPIXENT	11	1	12
	ENBREL SURECLICK	0	1	1
	HUMIRA PEN/STARTER	1	1	2
	OTEZLA	2	1	3
	STELARA	8	1	9

Utilization

Time Frame: 1/1/2022 to 12/31/2022

PA	Drug Name	Total Rx	Paid Amount	Paid/Rx	Utilizers	Avg Qty	Age Range
Psoriasis & other indications	CIMZIA (certolizumab pegol)	65	\$321,956	\$4,953	10	~1	22 – 50
	COSENTYX (secukinumab)	199	\$1,309,209	\$6,579	24	~2	6 – 61
	ENBREL (etanercept)	191	\$1,149,238	\$6,017	29	~3.8	6 – 64
	HUMIRA (adalimumab)	607	\$5,161,909	\$8,504	97	~2.6	7 – 64
	ILYUMYA (tildrakizumab-asmn)	0					
	OTEZLA tab (apremilast)	58	\$222,463	\$3,836	9	~59	23 – 61
	SILIQ (brodalumab)	0					
	SIMPONI (golimumab)	39	\$212,575	\$5,451	5	0.5	27 – 63
	SKYRIZI (risankizumab-rzaa)	43	\$780,765	\$18,157	11	1	20 – 60
	STELARA (ustekinumab)	167	\$3,725,045	\$22,306	37	1	10 – 63
	TALTZ (ixekizumab)	119	\$898,896	\$7,554	16	~1.2	15 – 57
	TREMFYA (guselkumab)	45	\$563,579	\$12,524	8	1	21 – 55
VTAMA cream 1% (tapinarof)	3	\$3,997	\$1,332	2	60	21, 50	
Atopic Dermatitis & other indications*	ADBRY (tralokinumab-ldrm)	0					
	CIBINQO tab (abrocitinib)	0					
	DUPIXENT (dupilumab)*	818	\$2,695,984	\$3,296	125	~3.6	0 – 62
	RINVOQ tab (upadacitinib)*	25	\$137,131	\$5,485	5	30	40 – 53

Red font denotes drug is on PA; Excludes IHS

Rosacea & Topical Acne PA Review

- Rosacea – PA effective 2/1/2020

Time Frame: 1/1/2022 to 12/31/2022

Indication	Drug Name	Approvals	Denials	Total	Utilizer
Rosacea	azelaic acid 15% gel	13	1	14	13
	ivermectin cream (Soolantra)	1	17	18	14
	MIRAVASO	1	0	1	1
Topical Acne	ACZONE (dapsone)	6	7	13	13
	adapalene	17	30	47	43
	adapalene-benzoyl peroxide	6	17	23	17
	ARAZLO (tazarotene)	1	0	1	1
	AZELEX 20% cream (azelaic acid)	3	1	4	4
	clindamycin-tretinoin	0	4	4	4
	EPIDUO/EPIDUO FORTE	2	0	2	2
	TAZORAC/tazarotene	5	10	15	12

Indication	APPEALS	Approvals	Denials	Total
Rosacea & Topical Acne	adapalene-benzoyl peroxide	1	0	1
	ivermectin cream (Soolantra)	1	0	1

Rosacea Utilization

Time Frame: 1/1/2022 to 12/31/2022

PA	Drug Name	Total Rx	Paid Amount	Paid/Rx	Utilizers	Avg Qty	Age Range
Rosacea	azelaic gel 15%	27	\$1,687	\$62.45	18	50	12 – 49
	AZELEX cream 20% (azelaic)	6	\$3,931	\$655.02	3	43.3	30 – 44
	FINACEA AER 15% (azelaic)	9	\$3,533	\$392.52	3	50	19 – 48
	MIRAVASO gel (brimonidine)	4	\$2,220	\$550.03	1	30	42
	ivermectin cream 1%	15	\$4,028	\$268.51	5	45	22 – 51
	metronidazole cream 0.75%	50	\$2,145	\$42.89	41	45	14 – 20
	metronidazole lotion 0.75%	5	\$672	\$134.40	4	59	6 – 33
	metronidazole gel 0.75%	54	\$1,807	\$33.46	44	45	0 – 63
	metronidazole gel 1%	22	\$1,639	\$75.50	11	60	12 – 61
RHOFADE cream 1% (oxymetazoline)	8	\$4,428	\$553.14	2	30	29 – 49	

Red font denotes drug is on PA; Excludes IHS

Rosacea ST Criteria

Trial of a generic topical acne agent (benzoyl peroxide, clindamycin phosphate, erythromycin, sulfacetamide sodium/sulfur, sulfacetamide sodium, tretinoin, metronidazole cream/gel/lotion 0.75%) in the past 120 days.

Topical Acne Utilization

Time Frame: 1/1/2022 to 12/31/2022

PA	Drug Name	Total Rx	Paid Amount	Paid/Rx	Utilizer	Avg Qty	Age Range
Topical Acne	adapalene cream 0.1%	17	\$2,644.17	\$155.54	10	45	14 – 20
	AKLIEF cream (trifarotene)	3	\$1,294.92	\$431.64	2	45	12 – 19
	AMZEEQ AER (minocycline micronized)	10	\$2,301.38	\$230.14	4	30	12 – 19
	DIFFERIN cream 0.1%	1	\$125.23	\$125.23	1	45	13
	adapalene gel 0.1%	6	\$700.23	\$116.71	6	45	14 – 19
	DIFFERIN gel 0.1%	2	\$63.10	\$31.55	1	45	14
	adapalene gel 0.3%	41	\$2,618.97	\$63.88	25	45	19 – 27
	adapalene-benzoyl gel 0.1-2.5%	27	\$1,114.98	\$41.30	13	45	9 – 60
	adapalene-benzoyl gel 0.3-2.5%	15	\$6,140.42	\$409.36	10	45	12 – 26
	EPIDUO FORTE gel 0.3-2.5%	6	\$2,499.58	\$416.60	1	45	15
	benzoyl peroxide gel 2.5%, 5%, 10% (OTC covered for foster care)	24	\$354.58	\$14.78	16	~48	11 – 20
	benzoyl peroxide wash (OTC covered for foster care)	15	\$246.83	\$16.45	7	~202	14 – 19
	benzoyl-erythromycin gel 3-5%	101	\$5,479.17	\$54.25	42	~41	11 – 52
	clindamycin lotion, aerosol, gel	2,418	\$96,075.29	\$39.74	1,155	~57	0– 63
	clindamycin-benzoyl peroxide gel	160	\$7,482.91	\$46.77	79	~44	10 – 48
	ONEXTON gel (clindamycin-benzoyl)	1	\$648.07	\$648.07	1	50	12
	dapsone gel 5% or 7.5%	42	\$12,036.67	\$286.59	22	~69	14 – 39
	erythromycin gel & solution 2%	71	\$3,019.02	\$42.52	43	~52	0 – 53
	sulfacetamide cream 10-5%	1	\$216.39	\$216.39	1	57	44
	sulfacetamide liquid 10-5%	2	\$106.88	\$53.44	2	~284	30, 43
	sulfacetamide lotion 10%	9	\$802.31	\$89.15	3	118	15 – 44
	sulfacetamide wash	5	\$1,953.15	\$390.63	2	473	27, 30
	tretinoin cream	1,537	\$121,560.38	\$79.09	836	~38	0 – 63
	tretinoin gel 0.1%	226	\$25,771.50	\$114.03	110	~34	6 – 57
	tretinoin microsphere gel/pump	22	\$9,527.49	\$433.07	7	~44	14 – 55
	RETIN-A cream 0.05%	2	\$195.16	\$97.58	2	45	18, 20
	RETIN-A MICRO gel 0.08%	2	\$189.72	\$94.86	1	45	39
	TWYNEO cream 1-3% (tretinoin-benzoyl)	2	\$871.10	\$435.55	2	30	12, 16
	tazarotene cream	28	\$3,159.74	\$112.85	8	~38	5 – 60
	TAZORAC cream 0.05%	1	\$454.49	\$454.49	1	30	17
	tazarotene gel	1	\$849.07	\$849.07	1	60	22
	TAZORAC gel 0.1%	1	\$482.19	\$482.19	1	30	24
	ARAZLO lotion 0.045% (tazarotene)	2	\$929.00	\$464.50	2	45	12, 18
WINLEVI cream 1% (clascoterone)	35	\$18,857.64	\$538.79	23	60	11 – 46	

Red font denotes drug is on PA; Excludes IHS

Topical Acne ST Criteria

Trial of a generic topical acne agent (benzoyl peroxide, clindamycin phosphate, erythromycin, metronidazole cream/gel/lotion sulfacetamide sodium/sulfur, sulfacetamide sodium, tretinoin) in the past 120 days

TAZORAC (tazarotene) Criteria

Patient has diagnosis of plaque psoriasis


Mupirocin Trend

Time Frame: 1/1/2022 to 1/31/2023

Drug Name	2Q2022				3Q2022				4Q2022			
	Total Rx	Paid Amount	Paid/Rx	Mbr	Total Rx	Paid Amount	Paid/Rx	Mbr	Total Rx	Paid Amount	Paid/Rx	Mbr
mupirocin cream 2% avg qty 23gm/14 days	18	\$1,959	\$130	18	27	\$3,313	\$123	25	23	\$1,832	\$84	23
mupirocin oint 2% avg qty 23gm/12 days	981	\$14,162	~\$15	887	1,231	\$17,576	~\$15	1,148	1,043	\$15,034	~\$15	960


Excludes IHS

Time Frame: 1/1/2022 to 1/31/2023




-Includes IHS

Time Frame: Year 2019 to 2022



Includes IHS

Time Frame: 1/1/2022 to 12/31/2022



Includes IHS; Age in years on X-axis; Utilizers on Y-axis


Epinephrine Trend

Time Frame: 1/1/2022 to 12/31/2022

Drug Name	2Q2022				3Q2022				4Q2022			
	Total Rx	Paid Amount	Paid/Rx	Mbr	Total Rx	Paid Amount	Paid/Rx	Mbr	Total Rx	Paid Amount	Paid/Rx	Mbr
adrenalin 1mg/ml	0				0				30	\$765.30	\$25.51	29
adrenalin 30mg/30ml	0				0				0			
AUVI-Q 0.1mg	0				0				0			
epinephrine 0.15mg	90	\$27,125	\$307	86	143	\$41,567	\$306	136	77	\$22,343	\$290	72
epinephrine 0.3mg	200	\$60,360	\$302	186	253	\$71,985	\$285	232	129	\$36,791	\$285	125
EPIPEN-JR 0.15mg	0				1	\$294	\$294	1	0			
EPIPEN 2-pak 0.3mg	0				1	\$294	\$294	1	0			


Excludes IHS

Time Frame: 1/1/2022 to 1/31/2023




Includes IHS

Time Frame: Year 2019 to 2022



Includes IHS

Time Frame: 1/1/2022 to 1/31/2023



Includes IHS; Age in years on X-axis; Utilizers on Y-axis

Table of Contents

1. Administrative PA	
a. DAW	28
b. General PA	29
c. Max Units Override	30
d. Medications > \$5000	31
2. Acne Agents Topical	32
3. Rosacea Agents Topical	33
4. Allergen Extract (Grastek/Oralair/Ragwitek)	34
5. Altabax	35
6. Antidepressants	36
7. Brisdelle	37
8. Antipsychotics	38
9. Antiemetics: Akynzeo, Bonjesta , Diclegis, Sancuso, Zuplenz	39-43
10. Antihistamines: Non-Sedating Antihistamines	44
11. ARBS (Edarbi/Edarbyclor)	45
12. Amrix/Fexmid	46
13. Brexafemme	47
14. Cambia/Zipsor/Zorvolex	48
15. Chronic Constipation Agents (Amitiza/Linzess/Movantik)	49
16. CGRP Inhibitors (Aimovig/Ajovy/Emgality)	50
17. Desoxyn	51
18. Difcid	52
19. Durlaza	53
20. Emflaza	54
21. Epidiolex	55
22. Evrysdi	56-58
23. Genitourinary Smooth Muscle Relaxant	59
24. GLP-1 Agonists	60
25. Gralise/Horizant	61
26. Growth Hormone: Adult-Pediatric, Serostim, Zorbtive	62-66
27. Head Lice Medication (Lindane shampoo/Ovide/Natroba/Skllice)	67
28. Hemangeol	68
29. Hepatitis C	69-70
30. Brand Name Narcotics	71
31. Hydrocodone-APAP	72
32. Opioid MED Limit	73
33. Opioid Naïve	74
34. Opioid LAO-SAO	75
35. Idiopathic Pulmonary Fibrosis (Esbriet/Ofev)	76
36. TIM, JAK, Monoclonal Antibody, etc	
a. Actemra	77
b. Adbry	78
c. Cibinqo	79
d. Cimzia	80-81
e. Cosentyx	82
f. Dupixent	83-84
g. Enbrel	85-86
h. Enspryng	87
i. Fasrena.....	88
j. Humira	89-90
• Amjevita	91-92
k. Ilaris	93
l. Ilumya	94
m. Kevzara	95
n. Kineret	96

o. Nucala	97
p. Olumiant	98
q. Orencia	99
r. Otezla	100
s. Rinvoq	101
t. Siliq	102
u. Simponi	103
v. Skyrizi	104
w. Sterlara	105-106
x. Taltz	107
y. Tremfya	108
z. Xeljanz/XR	109
aa. Xolair.....	110
37. Juxtapid	111
38. Ketoconazole Agents Topical (Extina/Xolegel & Duo)	112
39. Onychomycosis Agents Topical (Jublia, Kerydin/Onmel)	113
40. Luzu	114
41. Oravig	115
42. Vusion	116
43. Makena	117
44. Metozolv	118
45. Multiple Sclerosis.....	119-120
46. Tysabri	121
47. Nasal Steroids	122
48. Nascobal	123
49. Nuplazid	124
50. Nuessa	125
51. Hetlioz	126
52. Nuvigil/Provigil	127
53. Sunosi/Wakix	128
54. Xyrem	129
55. Onfi	130
56. Ophthalmic Antihistamines (Bepreve/Lastacaft/Pataday/Patanol/Pazeo)	131
57. Opzelura	132
58. Oracea/Solodyn/Seysara	133
59. Otrexup	134
60. PCSK9 Inhibitors (Praluent/Repatha)	135
61. Proton Pump Inhibitors	136
62. Duexis/Vimovo	137
63. Quaaluaquin	138
64. Rayos	139
65. Relistor	140
66. Soma 250	141
67. Tivorbex	142
68. Tramadol: Conzip/Synapryn/Ultram ER/tramadol ER	143
69. Triptans (ODT/NS/Tablet)	144
70. Triptans (Onzetra Xsail).....	145
71. Nurtec ODT/Qulipta/Reyvow/Ubrelvy	146
72. Uloric	147
73. Viberzi	148
74. Xenazine	149
75. Xepi	150
76. Xifaxan	151
77. Zolpidem (Ambien CR/Edluar/Intermezzo SL/Zolpimist)	152
78. Belsomra, Dayvigo, Quiviq	153



Dispense As Written (DAW) Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)
<p>Clinical information:</p> <p>Has the patient had a trial and failure with the generic product? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Has the patient had a trial with the generic product and experienced an adverse reaction (a MedWatch form must be completed)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Does the patient have a contraindication to the generic product? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Is the generic product unavailable? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information <small>(required)</small>	Provider Information <small>(required)</small>
--	--

Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information <small>(required)</small>
--

Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information <small>(required)</small>
--

What is the patient's diagnosis for the medication being requested?

ICD-10 Code(s): _____

What medication(s) has the patient tried and failed?

Are there any supporting labs or test results? (Please specify)

Quantity limit requests:
 What is the quantity requested per DAY? _____

What is the reason for exceeding the plan limitations?

Titration or loading dose purposes

Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)

Requested strength/dose is not commercially available

Patient requires a greater quantity for the treatment of a larger surface area **[Topical applications only]**

Other: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
 For urgent or expedited requests please call 1-855-401-4262.
 This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Quantity Limit Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)

What is the patient's diagnosis for the medication being requested?

ICD-10 Code(s): _____

What is the quantity requested per DAY? _____

What is the reason for exceeding the plan limitations?

- Titration or loading dose purposes
- Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)
- Requested strength/dose is not commercially available
- Patient requires a greater quantity for the treatment of a larger surface area [**Topical applications only**]
- Other: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



High Dollar/Claim Dollar Amount Override Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)
<p>What is the patient's diagnosis for the medication being requested?</p> <p style="text-align: right;">ICD-10 Code(s): _____</p>
<p>What is the requested quantity per day/fill/prescription/ or month? _____</p> <p>Please indicate the daily dosages and the quantity requested per prescription/fill/ or month and the duration (i.e., 3 capsules per day, 4 capsules per prescription/per 30 days). Use/take as directed is not sufficient information.</p>

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Topical Acne Agents Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Acne vulgaris	
<input type="checkbox"/> Plaque psoriasis [Tazorac (tazarotene) only]	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	

<p>Medication history: Has the patient had a trial and failure of a generic topical acne agent (benzoyl peroxide, tretinoin, clindamycin phosphate, erythromycin, sulfacetamide sodium/sulfur, sulfacetamide sodium) in the last 120 days? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
--

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Topical Rosacea Agents Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:	Dosage Form:	
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information (required)					
Select the diagnosis below:					
<input type="checkbox"/> Acne rosacea					
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
Medication history:					
Has the patient had a trial of a generic topical acne agent (benzoyl peroxide, clindamycin phosphate, erythromycin, sulfacetamide sodium/sulfur, sulfacetamide sodium, tretinoin, metronidazole cream/gel/lotion) in the past 120 days? <input type="checkbox"/> Yes <input type="checkbox"/> No					

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Please note: All information below is required to process this request.

Fax to 1-844-403-1029
Mon-Sat: 7am to 7pm Central

Grastek[®], Oralair[®], Ragwitek[®] Prior Authorization Request Form
 DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)

What is the patient's diagnosis for the medication being requested? (Mandatory)

ICD-10 Code(s): _____

Clinical information:
 Is the patient's diagnosis confirmed by a positive skin test or in vitro testing for pollen-specific IgE antibodies? Yes No
 Has the patient had a history of failure or intolerance to subcutaneous allergen immunotherapy (allergy shots)? Yes No
 Does the patient have severe, unstable or uncontrolled asthma? Yes No

Select the medication categories that the patient has tried and failed:

- Intranasal antihistamines (e.g., azelastine, olopatadine, azelastine/fluticasone)
- Intranasal corticosteroids (e.g., beclomethasone, budesonide, ciclesonide, flunisolide, fluticasone, mometasone, triamcinolone)
- Leukotriene inhibitors (e.g., montelukast, zafirlukast, zileuton)
- Oral antihistamines (e.g., cetirizine, desloratadine, fexofenadine, levocetirizine, or loratadine)

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
 For urgent or expedited requests please call 1-855-401-4262.
 This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Altabax® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)
<p>Select the diagnosis below:</p> <p><input type="checkbox"/> Methicillin resistant Staphylococcus aureus (MRSA)</p> <p><input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____</p>
<p>Medication history:</p> <p>Has the patient tried and failed generic mupirocin ointment or cream for a minimum of 5 days within the last 90 days? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Quantity limit requests:</p> <p>What is the quantity requested per MONTH? _____</p> <p>What is the reason for exceeding the plan limitations?</p> <p><input type="checkbox"/> Patient requires a larger quantity to cover a larger surface area</p> <p><input type="checkbox"/> Other: _____</p>

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Antidepressants Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)
What is the patient's diagnosis for the medication being requested? _____ <div style="text-align: right;">ICD-10 Code(s): _____</div>
Clinical information: Is the patient already stabilized on therapy with the requested medication? <input type="checkbox"/> Yes <input type="checkbox"/> No Please list ALL medications the patient has had a trial of within the past 12 months: _____ _____
For Drizalma Sprinkle, Lexapro solution, Paxil suspension, Prozac solution, Remeron SolTab, and Zoloft concentrate requests, also answer the following: Does the patient have a diagnosis which confirms a difficulty in swallowing? <input type="checkbox"/> Yes <input type="checkbox"/> No
Quantity limit requests: What is the quantity requested per DAY? _____ What is the reason for exceeding the plan limitations? <input type="checkbox"/> Titration or loading dose purposes <input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime) <input type="checkbox"/> Requested strength/dose is not commercially available <input type="checkbox"/> Other: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
 For urgent or expedited requests please call 1-855-401-4262.
 This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Brisdelle™ Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)
Medication history: Has the patient had a 60 day trial and failure of paroxetine oral tablets within the past 6 months? <input type="checkbox"/> Yes <input type="checkbox"/> No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Atypical Antipsychotics Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)
Continuation of therapy:
Is this for a continuation of a second generation atypical antipsychotic agent? <input type="checkbox"/> Yes <input type="checkbox"/> No
What is the patient's diagnosis for the medication being requested? (Mandatory)

ICD-10 Code(s) [Mandatory]: _____
Clinical information:
For patients with a diagnosis of depression, has the patient tried and failed 2 different antidepressants? <input type="checkbox"/> Yes <input type="checkbox"/> No
For patients younger than 6 years of age, is a psychiatrist, developmental pediatrician, child/adolescent psychiatrist or pediatric neurologist involved in care? <input type="checkbox"/> Yes <input type="checkbox"/> No
For alternative dosage forms (e.g., rapid dissolve tablets, injectables, extended-release), also answer the following:
Is the patient unable to swallow? <input type="checkbox"/> Yes <input type="checkbox"/> No
Has the patient failed a standard dosage form from this drug class in the last 30 days? <input type="checkbox"/> Yes <input type="checkbox"/> No
Quantity limit requests:
What is the quantity requested per DAY? _____
What is the reason for exceeding the plan limitations?
<input type="checkbox"/> Titration or loading dose purposes
<input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)
<input type="checkbox"/> Requested strength/dose is not commercially available
<input type="checkbox"/> Other: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Akynzeo® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information <small>(required)</small>			Provider Information <small>(required)</small>		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information <small>(required)</small>			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information <small>(required)</small>	
Select the diagnosis below:	
<input type="checkbox"/> Prophylaxis of chemotherapy-induced nausea/vomiting	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	
Clinical information:	
Has the patient received highly emetogenic chemotherapy regimens or regimens including anthracyclines and cyclophosphamide in the past 90 days? <input type="checkbox"/> Yes <input type="checkbox"/> No	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Bonjesta® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Hyperemesis gravidarum	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	
Quantity limit requests:	
What is the quantity requested per MONTH? _____	
What is the reason for exceeding the plan limitations?	
<input type="checkbox"/> Titration or loading dose purposes	
<input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)	
<input type="checkbox"/> Requested strength/dose is not commercially available	
<input type="checkbox"/> Other: _____	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Diclegis® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Hyperemesis gravidarum	
<input type="checkbox"/> Other diagnosis: _____	ICD-10 Code(s): _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Sancuso® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Prophylaxis of chemotherapy-induced nausea/vomiting	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	

<p>Clinical information:</p> <p>Has the patient had a trial of a generic -Hydroxytryptamine type 3 (5-HT3) receptor antagonist for 14 days in the past 90 days? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Is the patient receiving moderately and/or highly emetogenic chemotherapy for up to 5 consecutive days? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Is the patient unable to tolerate oral medications for chemotherapy-induced nausea and vomiting due to a diagnosis of difficulty swallowing? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
--

<p>Quantity limit requests:</p> <p>What is the quantity requested per MONTH? _____</p> <p>What is the reason for exceeding the plan limitations?</p> <p><input type="checkbox"/> Titration or loading dose purposes</p> <p><input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)</p> <p><input type="checkbox"/> Requested strength/dose is not commercially available</p> <p><input type="checkbox"/> Other: _____</p>
--

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Zuplenz[®] Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)
<p>Clinical information:</p> <p>Has the patient had a trial of a generic -Hydroxytryptamine type 3 (5-HT3) receptor antagonist for 14 days in the past 90 days? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Is the patient receiving moderately and/or highly emetogenic chemotherapy for up to 5 consecutive days? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Non-Sedating Antihistamines Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information <small>(required)</small>			Provider Information <small>(required)</small>		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information <small>(required)</small>			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information <small>(required)</small>
<p>Select the diagnosis below:</p> <input type="checkbox"/> Chronic idiopathic urticaria <input type="checkbox"/> Perennial allergic rhinitis <input type="checkbox"/> Seasonal allergic rhinitis <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____
<p>Medication history: Has the patient tried and failed a 14-day trial of one of the following: cetirizine, cetirizine & pseudoephedrine, fexofenadine, fexofenadine & pseudoephedrine, loratadine, or loratadine & pseudoephedrine? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Clinical information: Does the patient have a documented difficulty in swallowing diagnosis? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Quantity limit requests: What is the quantity requested per DAY? _____ What is the reason for exceeding the plan limitations? <input type="checkbox"/> Titration or loading dose purposes <input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime) <input type="checkbox"/> Requested strength/dose is not commercially available <input type="checkbox"/> Other: _____</p>

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
 For urgent or expedited requests please call 1-855-401-4262.
 This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Edarbi and Edarbyclor Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)
<p>Clinical information:</p> <p>Has the patient been stable on the requested angiotensin II receptor blocker (ARB) for more than 60 days? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Has the patient tried an angiotensin-converting enzyme (ACE) inhibitor or a generic ARB within the last 120 days? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Does the patient have an additional diagnosis of chronic obstructive pulmonary disease (COPD) or acute/chronic renal failure? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Amrix® & Fexmid® (cyclobenzaprine) Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)
<p>Select the diagnosis below:</p> <p><input type="checkbox"/> Adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions</p> <p><input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____</p>
<p>Medication history:</p> <p>Has the patient had at least a 60 day trial and failure of cyclobenzaprine 5 mg tablets OR cyclobenzaprine 10 mg tablets within the past 120 days? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Quantity limit requests:</p> <p>What is the quantity requested per DAY? _____</p> <p>What is the reason for exceeding the plan limitations?</p> <p><input type="checkbox"/> Titration or loading dose purposes</p> <p><input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)</p> <p><input type="checkbox"/> Requested strength/dose is not commercially available</p> <p><input type="checkbox"/> Other: _____</p>

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Brexafemme® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)
<p>Select the diagnosis below:</p> <p><input type="checkbox"/> Vulvovaginal candidiasis</p> <p><input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____</p>
<p>Clinical information:</p> <p>Has the patient tried and failed 3 trials of fluconazole or clotrimazole in the past 14 days? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Quantity limit requests:</p> <p>What is the quantity requested per MONTH? _____</p> <p>What is the reason for exceeding the plan limitations?</p> <p><input type="checkbox"/> Titration or loading dose purposes</p> <p><input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)</p> <p><input type="checkbox"/> Requested strength/dose is not commercially available</p> <p><input type="checkbox"/> Other:</p> <p>_____</p>

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Cambia[®], Zipsor[®], Zorvolex[®] Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)
Medication history: Has the patient had a documented 30 day trial of a generic diclofenac product within the last 120 days? <input type="checkbox"/> Yes <input type="checkbox"/> No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Amitiza[®], Linzess[®], Movantik[™] Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Chronic idiopathic constipation [Amitiza and Linzess only]	
<input type="checkbox"/> Irritable bowel syndrome with constipation (IBS-C) [Amitiza and Linzess only]	
<input type="checkbox"/> Opioid-induced constipation in an adult patient with chronic pain [Amitiza and Movantik only]	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	

For opioid-induced constipation in an adult patient with chronic pain, answer the following:
Is the pain associated with cancer? Yes No

Quantity limit requests:
What is the quantity requested per DAY? _____

What is the reason for exceeding the plan limitations?

Titration or loading dose purposes

Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)

Requested strength/dose is not commercially available

Other: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Aimovig™, Ajovy™, Emgality™ Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information (required)					
Select the diagnosis below: <input type="checkbox"/> Chronic migraines <input type="checkbox"/> Episodic migraines <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
Clinical information: Is the requested medication prescribed by or in consultation with a neurologist or pain/headache specialist? <input type="checkbox"/> Yes <input type="checkbox"/> No Will the requested medication be used in combination with another CGRP inhibitor? <input type="checkbox"/> Yes <input type="checkbox"/> No Select the prophylactic therapies the patient has had a trial and failure, (defined as at least 2 months of therapy with greater than 80% adherence), or an intolerance/contraindication to: <input type="checkbox"/> Antidepressants (i.e., venlafaxine or tricyclic antidepressant such as amitriptyline or nortriptyline) Please specify: _____ <input type="checkbox"/> Anti-epileptics (i.e., topiramate or divalproex sodium). Please specify: _____ <input type="checkbox"/> Beta-blockers (i.e., atenolol, propranolol, nadolol, timolol, or metoprolol). Please specify: _____					
For chronic migraines, also answer the following: Has the patient been evaluated for rebound headaches caused by medication overuse (more than 12 doses per month of narcotics, triptans, caffeine, or NSAIDs)? <input type="checkbox"/> Yes <input type="checkbox"/> No If diagnosed, will treatment include a plan to taper off the offending medication? <input type="checkbox"/> Yes <input type="checkbox"/> No Does the patient have greater than or equal to 15 headache days per month, of which at least 8 must be migraine days for at least 3 months? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For episodic migraines, also answer the following: Does the patient have 4 to 14 migraines per month (but no more than 14 headache days per month)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Reauthorization: If this is a reauthorization request, answer the following: Has the patient experienced a positive response to therapy, demonstrated by a reduction in headache frequency and/or intensity? <input type="checkbox"/> Yes <input type="checkbox"/> No Has the use of acute migraine medications (e.g., NSAIDs, triptans, narcotics) decreased since the start of CGRP therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No Is the requested medication prescribed by or in consultation with a neurologist or pain/headache specialist? <input type="checkbox"/> Yes <input type="checkbox"/> No					



Desoxyn® (methamphetamine) Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Attention Deficit Disorder with Hyperactivity	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	

<p>Medication history: Has the patient had a trial and failure (after a minimum of a 60 day trial), contraindication, or intolerance to any four medications from any of the following options in the past 90 days? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <ul style="list-style-type: none"> Atomoxetine Guanfacine Long-acting amphetamine salts product Long-acting methylphenidate product

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Dificid® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)
<p>Select the diagnosis below:</p> <p><input type="checkbox"/> Clostridium difficile-associated diarrhea (CDAD)</p> <p><input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____</p>
<p>Clinical information:</p> <p>Has the patient been treated per the current guidelines? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Select the following that the patient has failed:</p> <p><input type="checkbox"/> Initial episode (mild to moderate severity) – metronidazole</p> <p><input type="checkbox"/> Initial episode (severe) – vancomycin</p> <p><input type="checkbox"/> Initial episode (severe, complicated) – vancomycin and metronidazole</p> <p><input type="checkbox"/> First recurrence – same regimen as first episode</p> <p><input type="checkbox"/> Second recurrence – oral vancomycin in tapered regimen</p>

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Durlaza™ Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Chronic coronary artery disease (CAD)	
<input type="checkbox"/> Ischemic stroke	
<input type="checkbox"/> Transient ischemic attack	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	

Clinical information:
 Has the patient had a 90 day trial and failure with immediate release aspirin? Yes No
 Please submit clinical rationale explaining why a failure with the extended-release product is not expected:

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
 For urgent or expedited requests please call 1-855-401-4262.
 This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Emflaza™ Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Duchenne muscular dystrophy	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Epidiolex® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)
Select the diagnosis below:
<input type="checkbox"/> Seizures associated with Dravet syndrome, list ICD-10 Code(s): _____
<input type="checkbox"/> Seizures associated with Lennox-Gastaut syndrome, list (LGS) ICD-10 Code(s): _____
<input type="checkbox"/> Seizures associated with Tuberous Sclerosis Complex (TSC), list ICD-10 Code(s): _____
<input type="checkbox"/> Refractory epilepsy, list ICD-10 Code(s): _____
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____
Clinical information:
Is Epidiolex prescribed by or in consultation with a neurologist? <input type="checkbox"/> Yes <input type="checkbox"/> No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Evrydi™ Prior Authorization Request Form (Page 1 of 3)
DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)

Select the diagnosis below:

Spinal muscular atrophy (SMA): Type _____

Other diagnosis: _____ ICD-10 Code(s): _____

Clinical information:

- Select if the requested medication is prescribed by or in consultation with one of the following specialists:
 - Neurologist with expertise in the diagnosis and treatment of SMA
 - Other _____
- How many SMN2 copies? _____
- Does the mutation or deletion of genes in chromosomes 5q result in the following:
 - Homozygous gene deletion or mutation (e.g., homozygous deletion of exon 7 at locus 5q13) _____
 - Compound heterozygous mutation (e.g., deletion of SMN1 exon 7 [allele 1] and mutation of SMN1 [allele 2]) _____
 - Other _____
- Is the patient dependent on invasive ventilation or tracheostomy? **Yes** **No**
- Is the patient dependent on use of non-invasive ventilation beyond use for naps and nighttime sleep? **Yes** **No**
- Has one of the other exams listed below (based on patient's age and motor ability) been conducted to establish baseline motor ability by a board-certified neurologist?
 - Hammersmith Functional Motor Scale Expanded (HFMSE)
 - Hammersmith Infant Neurological Exam (HINE) (infant to early childhood)
 - Upper Limb Module (ULM) Test (Non ambulatory)
 - Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)
 - Motor Function Measure 32 (MFM-32) Scale
- Is the patient on concomitant chronic survival motor neuron (SMN) modifying therapy for the treatment of SMA (e.g., Spinraza)? **Yes** **No**
- Has the patient previously received gene replacement therapy for the treatment of SMN (e.g., Zolgensma)? **Yes** **No**



Evrysdi™ Prior Authorization Request Form (Page 2 of 3)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

9. If patient has previously received gene therapy for the treatment of SMA (e.g., Zolgensma), provider to attest that there has been an inadequate response to gene therapy (e.g., sustained decrease in at least one motor test score over a period of 6 months) or worsening in clinical status since receiving gene therapy as demonstrated by a decline of minimally clinical important difference from highest score achieved on one of the following exams:
- HFMSE: decline of at least _____ points on kicking and _____ points on any other milestones (excluding voluntary grasp)
 - HINE-2: decline of at least _____ points
 - CHOP INTEND: decline of at least _____ points

Quantity limit requests:

What is the quantity requested per DAY? _____

What is the reason for exceeding the plan limitations?

- Titration or loading dose purposes
- Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)
- Requested strength/dose is not commercially available
- Other: _____

Reauthorization:

If this is a reauthorization request, answer the following:

1. Provide documentation of positive clinical response to therapy (e.g., chart notes, laboratory values) from pretreatment baseline status as demonstrated by the most recent results (less than 1 month prior to reauthorization request) from one of the following exams:
 - One of the following HINE-2 milestones _____
 - Improvement or maintenance of previous improvement of at least a 2-point (or maximal score) increase in ability to kick
 - Improvement or maintenance of previous improvement of at least a 1-point increase in any other HINE-2 milestone (e.g., head control, rolling, sitting, crawling, etc.), excluding voluntary grasp
 - Patient exhibited improvement, or maintenance of previous improvement in more HINE motor milestones than worsening, from pretreatment baseline (net positive improvement)
 - Patient has achieved and maintained any new motor milestones when they would otherwise be unexpected to do so (e.g., sit unassisted, stand, walk)
 - One of the following HFMSE milestones _____
 - Improvement or maintenance of a previous improvement of at least a 3-point increase in score from pretreatment baseline
 - Patient has achieved and maintained any new motor milestone from pretreatment baseline when they would otherwise be unexpected to do so (e.g., sit unassisted, stand, walk)
 - One of the following ULM test milestones _____
 - Improvement or maintenance of a previous improvement of at least a 2-point increase in score from pretreatment baseline
 - Patient has achieved and maintained any new motor milestone from pretreatment baseline when they would otherwise be unexpected to do so (e.g., sit unassisted, stand, walk)
 - One of the following CHOP-INTEND milestones _____
 - Improvement or maintenance of a previous improvement of at least a 4-point increase in score from pretreatment baseline
 - Patient has achieved and maintained any new motor milestone from pretreatment baseline when they would otherwise be unexpected to do so (e.g., sit unassisted, stand, walk)
 - One of the following MFM-32 milestones _____
 - Improvement or maintenance of a previous improvement of at least a 3-point increase in score from pretreatment baseline
 - Patient has achieved and maintained any new motor milestone from pretreatment baseline when they would otherwise be unexpected to do so (e.g., sit unassisted, stand, walk)
2. Is the patient dependent on invasive ventilation or tracheostomy? Yes No
3. Is the patient dependent on the use of non-invasive ventilation beyond use for naps and nighttime sleep? Yes No



Evrysdi™ Prior Authorization Request Form (Page 3 of 3)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

- 4. Is the requested medication prescribed by or in consultation with a neurologist with expertise in the diagnosis and treatment of SMA?
 Yes No
- 5. Is the patient is receiving concomitant chronic survival motor neuron (SMN) modifying therapy for the treatment of SMA (e.g., Spinraza)? Yes No
- 6. Has the patient previously received gene replacement therapy for the treatment of SMA (e.g., Zolgensma)? Yes No
- 7. Was there inadequate response to gene therapy (e.g., sustained decrease in at least one motor test score over a period of 6 months)? If so, submit medical records (e.g., chart notes) documenting the inadequate response to gene therapy.

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Genitourinary smooth muscle relaxants Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information <small>(required)</small>			Provider Information <small>(required)</small>		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information <small>(required)</small>			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information <small>(required)</small>
What is the patient's diagnosis for the medication being requested? (Mandatory)

ICD-10 Code(s) [Mandatory]: _____
Medication history: Has the patient had a 30-day trial of oxybutynin, oxybutynin ER, darifenacin ER, fesoterodine ER, solifenacin, tolterodine, tolterodine ER, trospium, or trospium ER ? <input type="checkbox"/> Yes <input type="checkbox"/> No
List drug(s) tried _____
For Gelnique, Myrbetriq suspension, Oxytrol, or Vesicare LS requests, also answer the following: Does the patient have a diagnosis which confirms a difficulty in swallowing? <input type="checkbox"/> Yes <input type="checkbox"/> No
Quantity limit requests: What is the quantity requested per MONTH? _____
What is the reason for exceeding the plan limitations? <input type="checkbox"/> Titration or loading dose purposes <input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime) <input type="checkbox"/> Requested strength/dose is not commercially available <input type="checkbox"/> Other: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



GLP-1 Agonists Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Type 2 diabetes mellitus	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	
Quantity limit requests:	
What is the quantity requested per MONTH? _____	
What is the reason for exceeding the plan limitations?	
<input type="checkbox"/> Titration or loading dose purposes	
<input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)	
<input type="checkbox"/> Requested strength/dose is not commercially available	
<input type="checkbox"/> Other: _____	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.

Gralise® & Horizant® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information <small>(required)</small>			Provider Information <small>(required)</small>		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information <small>(required)</small>			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information <small>(required)</small>
<p>Select the diagnosis below:</p> <p><input type="checkbox"/> Moderate to severe primary restless leg syndrome (RLS) [Horizant only]</p> <p><input type="checkbox"/> Neuropathic pain associated with postherpetic neuralgia (PHN)</p> <p><input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____</p>
<p>Moderate to severe primary RLS:</p> <p>Has the patient had a trial and failure (to a minimum of a 90 day trial), contraindication, or intolerance to ropinirole or pramipexole in the past 180 days? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Neuropathic pain associated with PHN:</p> <p>Has the patient had a trial and failure (to a minimum of a 90 day trial), contraindication, or intolerance to an immediate-release gabapentin in the past 180 days? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Growth Hormones Prior Authorization Request Form (Page 1 of 3)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information <small>(required)</small>			Provider Information <small>(required)</small>		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information <small>(required)</small>					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information <small>(required)</small>					
Select the requested medication below: <input type="checkbox"/> Genotropin <input type="checkbox"/> Humatrope <input type="checkbox"/> Norditropin <input type="checkbox"/> Nutropin AQ <input type="checkbox"/> Omnitrope <input type="checkbox"/> Saizen <input type="checkbox"/> Zomacton					
Select the diagnosis below: <u>For Pediatric Patients (less than 18 years of age):</u> <input type="checkbox"/> Growth hormone deficiency in children <input type="checkbox"/> Growth failure due to chronic renal insufficiency <input type="checkbox"/> Growth failure due to panhypopituitarism <input type="checkbox"/> Growth failure due to Prader-Willi syndrome <input type="checkbox"/> Idiopathic short stature in children <input type="checkbox"/> Noonan syndrome <input type="checkbox"/> Septo-optic dysplasia sequence <input type="checkbox"/> Short stature homeobox containing gene (SHOX) deficiency <input type="checkbox"/> Small for gestational age <input type="checkbox"/> Turner's syndrome <u>For Adults (18 years of age or older):</u> <input type="checkbox"/> Growth hormone deficiency in adults <input type="checkbox"/> Panhypopituitarism <input type="checkbox"/> Prader-Willi syndrome <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
Contraindications/Exclusions: Does the patient have acute critical illness due to complications following open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure? <input type="checkbox"/> Yes <input type="checkbox"/> No Does the patient have active malignancy? <input type="checkbox"/> Yes <input type="checkbox"/> No Does the patient have active proliferative or severe non-proliferative diabetic retinopathy? <input type="checkbox"/> Yes <input type="checkbox"/> No					



Growth Hormones Prior Authorization Request Form (Page 2 of 3)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

For Pediatric Patients (less than 18 years of age):

Is the requested medication prescribed by or in consultation with a pediatric endocrinologist? Yes No

Are the patient's epiphyses open? Yes No

Has the patient been screened for intracranial malignancy or tumor? Yes No

For growth hormone deficiency in children, also answer the following:

Has growth hormone deficiency been confirmed with provocative test and/or IGF-1 levels? Yes No

Has the patient had an inadequate response to two (2) pharmacological growth hormone stimulation tests* with peak level below 10 ng/mL? Yes No

Has the patient had an inadequate response to at least one (1) pharmacological growth hormone stimulation test* with peak level below 10 ng/mL for a patient with defined CNS pathology, multiple pituitary hormone deficiencies, history of irradiation, or proven genetic cause? Yes No

**Please note: acceptable tests include: arginine, clonidine, glucagon, insulin, and levodopa*

Is the patient's height more than 3 standard deviations (SDs) below the mean for same age and gender? Yes No

Is the patient's height more than 2 SDs below the mean for same age and gender AND the patient has decreased growth velocity more than 1 SD below the mean for the same age and gender? Yes No

Is the patient's growth velocity measured 2 SDs below the mean over one year or 1.5 SDs below the mean sustained over 2 years for the same age and gender? Yes No

Have other causes of growth failure been ruled out (e.g., hypothyroidism, chronic systemic disease, skeletal disorders, malnutrition)? Yes No

For growth failure due to chronic renal insufficiency, also answer the following:

Has the patient's nutritional status been optimized and metabolic abnormalities been corrected? Yes No

Has the patient had a kidney transplant? Yes No

Is the patient's height less than the 3rd percentile? Yes No

Is the patient's growth velocity measured over 1 year > 2 standard deviations below the mean for same age and gender? Yes No

For growth failure due to panhypopituitarism or Prader-Willi syndrome, also answer the following:

Has the patient's diagnosis of panhypopituitarism or Prader-Willi syndrome been confirmed by appropriate genetic testing? Yes No

Is the diagnosis of panhypopituitarism caused by cranipharyngioma surgery? Yes No

Does the patient have severe obesity, history of upper airway obstruction or sleep apnea, or severe respiratory impairment? Yes No

Is the patient's height more than 2 standard deviations below the mean for same age and gender? Yes No

For idiopathic short stature, also answer the following:

Is the patient's height more than 2.25 standard deviations below the mean? Yes No

Is the patient's predicted height less than or equal to 65 inches for male or less than or equal to 60 inches for females? Yes No

For short stature homeobox-containing gene (SHOX) deficiency or Noonan syndrome, also answer the following:

Is the patient's height more than 3 standard deviations (SDs) below the mean for same age and gender? Yes No

Is the patient's height more than 2 SDs below the mean for same age and gender AND the patient has decreased growth velocity more than 1 SD below the mean for the same age and gender? Yes No

Is the patient's growth velocity measured 2 SDs below the mean over one year or 1.5 SDs below the mean sustained over 2 years for the same age and gender? Yes No

For small for gestational age (SGA), also answer the following:

Did the patient have post-natal growth failure at one year? Yes No

Is the patient below the 5th percentile for height? Yes No

Was the patient's birth weight or length at least 2 standard deviations below the mean for gestational age? Yes No

For Turner's syndrome, also answer the following:

Has the patient's diagnosis of Turner's syndrome been confirmed by chromosome analysis? Yes No

Is the patient's height less than the 5th percentile for same age and gender? Yes No

Growth Hormones Prior Authorization Request Form (Page 3 of 3)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

For Adult Patients (18 years of age or older):

Is the requested medication prescribed by or in consultation with an endocrinologist? Yes No

For growth hormone deficiency in adults, also answer the following:

Has growth hormone deficiency been confirmed with two provocative tests and IGF-1 levels? Yes No

Has the patient been screened for intracranial malignancy or tumor? Yes No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note:

This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Serostim® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> HIV infection/AIDS wasting	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	

Clinical information:

Is Serostim prescribed by or in consultation with an infectious disease specialist? Yes No

Has the patient tried and had an inadequate response or intolerance to dronabinol or megestrol? Yes No

Is the patient currently receiving treatment with antiretrovirals? Yes No

Does the patient have acute critical illness due to complications following open heart surgery, abdominal surgery, multiple accidental trauma, or those with acute respiratory failure? Yes No

Has the patient been screened to verify the absence of any active malignancy? Yes No

Does the patient have active proliferative or severe non-proliferative diabetic retinopathy? Yes No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Zorbtive® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Short bowel syndrome	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	
Clinical information:	
Is Zorbtive prescribed by or in consultation with a gastroenterologist? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Is the patient receiving specialized nutritional support (i.e., parenteral nutrition)? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Does the patient have acute critical illness due to complications following open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Has the patient been screened to verify the absence of any active malignancy? <input type="checkbox"/> Yes <input type="checkbox"/> No	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Lindane shampoo, Ovide[®] (malathion), Natroba[™] (spinosad), Sklice[®]
Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)
<p>Medication history: Has the patient had a trial and failure, contraindication, or intolerance to a permethrin or pyrethrins-piperonyl butoxide product in the past 90 days? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Hemangeol™ Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)
Select the diagnosis below:
<input type="checkbox"/> Proliferating infantile hemangioma requiring systemic therapy
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____
Clinical information:
Is the patient's weight 2 kilograms (kg) or greater? <input type="checkbox"/> Yes <input type="checkbox"/> No
Does the patient have asthma or a history of bronchospasm? <input type="checkbox"/> Yes <input type="checkbox"/> No
Does the patient have bradycardia (less than 80 beats per minute)? <input type="checkbox"/> Yes <input type="checkbox"/> No
Does the patient have greater than first-degree heart block, decompensated heart failure? <input type="checkbox"/> Yes <input type="checkbox"/> No
Does the patient have blood pressure less than 50/30 mmHg? <input type="checkbox"/> Yes <input type="checkbox"/> No
Does the patient have pheochromocytoma? <input type="checkbox"/> Yes <input type="checkbox"/> No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.

Hepatitis C Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information <small>(required)</small>			Provider Information <small>(required)</small>		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information <small>(required)</small>					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information <small>(required)</small>					
Select the diagnosis below: <input type="checkbox"/> Hepatitis C virus infection <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
Clinical information: Document the patient's genotype: _____ Document the patient's weight: _____ Kg Patient must have one of the following (providers may be asked to provide documentation): Does the patient have cirrhosis? <input type="checkbox"/> Yes <input type="checkbox"/> No Does the patient have compensated liver disease (Child-Pugh A)? <input type="checkbox"/> Yes <input type="checkbox"/> No Does the patient have decompensated liver disease (Child-Pugh B or C)? <input type="checkbox"/> Yes <input type="checkbox"/> No Is the patient treatment naïve? <input type="checkbox"/> Yes <input type="checkbox"/> No If the patient is female and prescribed ribavirin, does the patient have a negative pregnancy test within 30 days prior to initiation of therapy and will receive a monthly pregnancy test during treatment? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For Epclusa or generic sofosbuvir/velpatasvir, also answer the following: Is the patient ineligible or has an intolerance to ribavirin? <input type="checkbox"/> Yes <input type="checkbox"/> No Has the patient had prior treatment failure with sofosbuvir or NS5A-based treatment? <input type="checkbox"/> Yes <input type="checkbox"/> No Is the patient taking P glycoprotein (P-gp) inducers? <input type="checkbox"/> Yes <input type="checkbox"/> No Is the patient taking anticancers (e.g., topotecan)? <input type="checkbox"/> Yes <input type="checkbox"/> No Is the patient taking moderate to potent CYP inducers (e.g., rifampin, St. John's wort, carbamazepine, phenytoin, phenobarbital, oxcarbazepine)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For Harvoni or generic ledipasvir/sofosbuvir, also answer the following: Select if the patient is taking any of the following medications: <input type="checkbox"/> Anticonvulsants (e.g., carbamazepine, oxcarbazepine, phenobarbital, phenytoin) <input type="checkbox"/> P-glycoprotein (P-gp) inducers (e.g., rifampin, St. John's wort) <input type="checkbox"/> HIV antiretrovirals (e.g., tipranavir/ritonavir) <input type="checkbox"/> Tenofovir-containing HIV regimens <input type="checkbox"/> Anticancers (e.g., topotecan)					
For Mavyret (glecaprevir-pibrentasvir), also answer the following: Select if the patient has been previously treated with a regimen containing the following (select all that applies): <input type="checkbox"/> An HCV NS5A inhibitor <input type="checkbox"/> An NS3/4A protease inhibitor (PI) <input type="checkbox"/> Interferon (including pegylated formulations), ribavirin, and/or Sovaldi (sofosbuvir)					

Hepatitis C Prior Authorization Request Form (Page 2 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

For Sovaldi (sofosbuvir), also answer the following:

Select if the patient will use Sovaldi in combination with the following:

- Pegylated interferon and ribavirin
- Ribavirin

Does the patient have severe renal impairment (eGFR < mL/min/1.73 m²)? Yes No

Does the patient have end-stage renal disease? Yes No

Does the patient have hepatocellular carcinoma that meets criteria for liver transplant? Yes No

For Vosevi (sofosbuvir-velpatasvir-voxilaprevir), also answer the following:

Has the patient been previously treated with a regimen containing an NS5A inhibitor? Yes No

Has the patient been previously treated with a regimen containing Sovaldi (sofosbuvir) without an NS5A inhibitor? Yes No

For Zepatier (elbasvir-grazoprevir), also answer the following:

Has the patient been tested for the presence of NS5A resistance-associated polymorphisms? Yes No

If yes to the above question, does the patient have baseline NS5A polymorphisms? Yes No

Does the patient have moderate to severe hepatic impairment? Yes No

Has the patient failed the 2-drug regimen of peginterferon alfa and ribavirin? Yes No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Brand Name narcotics Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information (required)					
Medication history:					
Has the patient had a trial and failure (at least a 30 day trial) of a generic narcotic in the past 90 days? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Clinical information:					
Does the patient have a diagnosis of cancer in the past 365 days? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Does the patient have a diagnosis of a terminal illness? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Does the patient have an <u>illness</u> associated with significant pain (e.g., sickle cell anemia, etc)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
If yes , please list the diagnosis: _____					
Does the patient have an <u>injury</u> associated with significant pain? <input type="checkbox"/> Yes <input type="checkbox"/> No					
If yes , please list the diagnosis: _____					
Have efforts been made to taper the patient to the lowest effective dose? <input type="checkbox"/> Yes <input type="checkbox"/> No					
If yes , please provide documentation: _____					

Reauthorization:					
If this is a reauthorization request, answer the following:					
Is the prescriber maintaining the most conservative, effective treatment? <input type="checkbox"/> Yes <input type="checkbox"/> No					
If yes , please provide documentation: _____					

Quantity limit requests:					
What is the patient's diagnosis for the medication being requested?					
_____			ICD-10 Code(s): _____		
What is the quantity requested per MONTH? _____					
What is the reason for exceeding the plan limitations?					
<input type="checkbox"/> Titration or loading dose purposes					
<input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)					
<input type="checkbox"/> Requested strength/dose is not commercially available					
<input type="checkbox"/> Other: _____					



**Hydrocodone-acetaminophen (APAP) Products
Prior Authorization Request Form (Page 1 of 2)**

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)

Medication history:
Has the patient had a history of a 60 day trial (in the past 90 days) with one of the following generics listed below? **Yes** **No**

- Hydrocodone-APAP 5-325
- Hydrocodone-APAP 7.5-325
- Hydrocodone-APAP 10-325

Clinical information:

Does the patient have a diagnosis of cancer in the past 365 days? **Yes** **No**

Does the patient have a diagnosis of a terminal illness? **Yes** **No**

Does the patient have an illness associated with significant pain (e.g., sickle cell anemia, etc)? **Yes** **No**
If **yes**, please list the diagnosis: _____

Does the patient have an injury associated with significant pain? **Yes** **No**
If **yes**, please list the diagnosis: _____

Have efforts been made to taper the patient to the lowest effective dose? **Yes** **No**
If **yes**, please provide documentation: _____

Reauthorization:

If this is a reauthorization request, answer the following:

Is the prescriber maintaining the most conservative, effective treatment? **Yes** **No**
If **yes**, please provide documentation: _____



Morphine Equivalent Dose (MED) Limit Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)
<p>Clinical information:</p> <p>Does the patient have a diagnosis of cancer in the past 365 days? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Does the patient have a diagnosis of a terminal illness? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Does the patient have an <u>illness</u> associated with significant pain (e.g., sickle cell anemia, etc)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>If yes, please list the diagnosis: _____</p> <p>Does the patient have an <u>injury</u> associated with significant pain? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>If yes, please list the diagnosis: _____</p> <p>Have efforts been made to taper the patient to the lowest effective dose? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>If yes, please provide documentation: _____</p> <p>_____</p> <p>_____</p>
<p>Reauthorization:</p> <p>If this is a reauthorization request, answer the following:</p> <p>Is the prescriber maintaining the most conservative, effective treatment? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>If yes, please provide documentation: _____</p> <p>_____</p> <p>_____</p>

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Opioid Naïve Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information <small>(required)</small>			Provider Information <small>(required)</small>		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information <small>(required)</small>			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information <small>(required)</small>
Clinical information:
Does the patient have a diagnosis of cancer in the past 365 days? <input type="checkbox"/> Yes <input type="checkbox"/> No
Does the patient have a diagnosis of a terminal illness? <input type="checkbox"/> Yes <input type="checkbox"/> No
Does the patient have an <u>illness</u> associated with significant pain (e.g., sickle cell anemia, major surgery, etc)? <input type="checkbox"/> Yes <input type="checkbox"/> No
If yes , please list the diagnosis: _____
Does the patient have an <u>injury</u> associated with significant pain? <input type="checkbox"/> Yes <input type="checkbox"/> No
If yes , please list the diagnosis: _____
Have efforts been made to taper the patient to the lowest effective dose? <input type="checkbox"/> Yes <input type="checkbox"/> No
If yes , please provide documentation: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Long Acting and Short Acting Opioid Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information <small>(required)</small>			Provider Information <small>(required)</small>		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information <small>(required)</small>					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information <small>(required)</small>					
<p>Clinical information:</p> <p>Does the patient have a diagnosis of cancer in the past 365 days? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Does the patient have a diagnosis of a terminal illness? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Does the patient have an <u>illness</u> associated with significant pain (e.g., sickle cell anemia, etc)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>If yes, please list the diagnosis: _____</p> <p>Does the patient have an <u>injury</u> associated with significant pain? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>If yes, please list the diagnosis: _____</p> <p>Have efforts been made to taper the patient to the lowest effective dose? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>If yes, please provide documentation:</p> <p>_____</p> <p>_____</p>					
<p>Reauthorization:</p> <p>If this is a reauthorization request, answer the following:</p> <p>Is the prescriber maintaining the most conservative, effective treatment? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>If yes, please provide documentation:</p> <p>_____</p> <p>_____</p>					

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Esbriet® & Ofev® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Idiopathic pulmonary fibrosis (IPF)	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	
Clinical information:	
Does the patient have a forced vital capacity (FVC) greater than or equal to 50% of predicted in the last 60 days? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Is the requested medication prescribed by or in consultation with a pulmonologist? <input type="checkbox"/> Yes <input type="checkbox"/> No	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Actemra® Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Active polyarticular juvenile idiopathic arthritis (pJIA)	
<input type="checkbox"/> Active systemic juvenile idiopathic arthritis (sJIA)	
<input type="checkbox"/> Chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS)	
<input type="checkbox"/> Moderately to severely active rheumatoid arthritis (RA)	
<input type="checkbox"/> Temporal arteritis or giant cell arteritis (GCA)	
<input type="checkbox"/> Systemic sclerosis-associated interstitial lung disease	
<input type="checkbox"/> Other diagnosis: _____	ICD-10 Code(s): _____

Clinical information:
Select if Actemra is prescribed by or in consultation with one of the following specialists:
<input type="checkbox"/> Allergist/immunologist
<input type="checkbox"/> Rheumatologist
<input type="checkbox"/> Other _____
Will Actemra be used in combination with another biologic agent or targeted immunomodulator? <input type="checkbox"/> Yes <input type="checkbox"/> No

For active polyarticular juvenile idiopathic arthritis (pJIA), also answer the following:
Has the patient had an inadequate response to, intolerance to, or contraindication to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs)? <input type="checkbox"/> Yes <input type="checkbox"/> No

For active systemic juvenile idiopathic arthritis (sJIA), also answer the following:
Has the patient had an inadequate response or intolerance to at least one oral systemic agent [i.e., non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroid]? <input type="checkbox"/> Yes <input type="checkbox"/> No

For moderately to severely active rheumatoid arthritis (RA), also answer the following:
Has the patient had an inadequate response to, intolerance to, or contraindication to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs)? <input type="checkbox"/> Yes <input type="checkbox"/> No

For temporal arteritis or giant cell arteritis (GCA), also answer the following:
Has the patient had an inadequate response to, intolerance to, or contraindication to oral or parenteral corticosteroid? <input type="checkbox"/> Yes <input type="checkbox"/> No



Adbry® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)
Select the diagnosis below: <input type="checkbox"/> Atopic dermatitis (describe severity level) _____ <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____
Clinical information: Select if the requested medication is prescribed by or in consultation with one of the following specialists: <input type="checkbox"/> Dermatologist <input type="checkbox"/> Allergist/Immunologist <input type="checkbox"/> Other _____
Medication history: Will the requested medication be used in combination with another biologic agent or targeted immunomodulator? <input type="checkbox"/> Yes <input type="checkbox"/> No Has the patient have a documented 14-day trial of a topical corticosteroid, pimecrolimus cream, tacrolimus ointment, or Eurisa (crisaborole)? _____ _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
 For urgent or expedited requests please call 1-855-401-4262.
 This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Cibinqo™ Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)
<p>Select the diagnosis below:</p> <p><input type="checkbox"/> Atopic dermatitis (describe severity level) _____</p> <p><input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____</p>
<p>Clinical information:</p> <p>Select if the requested medication is prescribed by or in consultation with one of the following specialists:</p> <p><input type="checkbox"/> Dermatologist <input type="checkbox"/> Allergist/Immunologist <input type="checkbox"/> Other _____</p>
<p>Medication history:</p> <p>Will the requested medication be used in combination with another biologic agent or targeted immunomodulator? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Has the patient have a documented 14-day trial of a topical corticosteroid, pimecrolimus cream, tacrolimus ointment, or Eurisa (crisaborole)? _____</p> <p>_____</p>

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
 For urgent or expedited requests please call 1-855-401-4262.
 This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Cimzia® Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)
<p>Select the diagnosis below:</p> <p><input type="checkbox"/> Active ankylosing spondylitis</p> <p><input type="checkbox"/> Active psoriatic arthritis</p> <p><input type="checkbox"/> Moderate to severe chronic plaque psoriasis</p> <p><input type="checkbox"/> Moderately to severely active Crohn's disease</p> <p><input type="checkbox"/> Moderately to severely active rheumatoid arthritis</p> <p><input type="checkbox"/> Active non-radiographic axial spondyloarthritis</p> <p><input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____</p>
<p>Clinical information:</p> <p>Select if the requested medication is prescribed by or in consultation with one of the following specialists:</p> <p><input type="checkbox"/> Dermatologist <input type="checkbox"/> Gastroenterologist <input type="checkbox"/> Rheumatologist <input type="checkbox"/> Other _____</p> <p>Will the requested medication be used in combination with another biologic agent or targeted immunomodulator? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>For active ankylosing spondylitis, also answer the following:</p> <p>Has the patient had an inadequate response to, intolerance to, or contraindication to one or more non-steroidal anti-inflammatory drugs (NSAIDs)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>For active psoriatic arthritis, also answer the following:</p> <p>Has the patient had an inadequate response to, intolerance to, or contraindication to methotrexate? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>For moderate to severe chronic plaque psoriasis, also answer the following:</p> <p>Has the patient had an inadequate response to, intolerance to, or contraindication to conventional therapy with at least one of the following: phototherapy or one or more oral systemic treatments (i.e., methotrexate, cyclosporine, acitretin, sulfasalazine)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>For moderately to severely active Crohn's disease, also answer the following:</p> <p>Has the patient had an inadequate response to, intolerance to, or contraindication to one or more immunosuppressive agents (e.g., azathioprine, mercaptopurine, methotrexate)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>For moderately to severely active rheumatoid arthritis, also answer the following:</p> <p>Has the patient had an inadequate response to, intolerance to, or contraindication to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>For active non-radiographic axial spondyloarthritis, also answer the following:</p> <p>Has the patient had an inadequate response to, intolerance to, or contraindication to one or more immunosuppressive agents (e.g., azathioprine, mercaptopurine, methotrexate)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>



Cimzia® Prior Authorization Request Form (Page 2 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Quantity limit requests:

What is the quantity requested per MONTH? _____

What is the reason for exceeding the plan limitations?

- Titration or loading dose purposes
- Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)
- Requested strength/dose is not commercially available
- Other: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note:

This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Cosentyx® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information (required)					
Select the diagnosis below: <input type="checkbox"/> Active ankylosing spondylitis <input type="checkbox"/> Active psoriatic arthritis <input type="checkbox"/> Moderate to severe plaque psoriasis <input type="checkbox"/> Active Non-radiographic axial spondyloarthritis <input type="checkbox"/> Active enthesitis-related arthritis <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
Clinical information: Select if the requested medication is prescribed by or in consultation with one of the following specialists: <input type="checkbox"/> Dermatologist <input type="checkbox"/> Rheumatologist <input type="checkbox"/> Other _____ Will the requested medication be used in combination with another biologic agent or targeted immunomodulator? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For active ankylosing spondylitis, also answer the following: Has the patient had an inadequate response, contraindication, or intolerance to one or more non-steroidal anti-inflammatory drugs (NSAIDs)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For active psoriatic arthritis, also answer the following: Has the patient had an inadequate response, contraindication, or intolerance to methotrexate? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For moderate to severe plaque psoriasis, also answer the following: Has the patient had an inadequate response, contraindication, or intolerance to conventional therapy with at least one of the following: phototherapy or one or more oral systemic treatments (i.e., methotrexate, cyclosporine, acitretin, sulfasalazine)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For active non-radiographic axial spondyloarthritis or enthesitis-related arthritis, also answer the following: Has the patient had an inadequate response, contraindication, or intolerance to one or more non-steroidal anti-inflammatory drugs (NSAIDs)? <input type="checkbox"/> Yes <input type="checkbox"/> No					

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
 For urgent or expedited requests please call 1-855-401-4262.
 This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Dupixent® Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)
<p>Select the diagnosis below:</p> <p><input type="checkbox"/> Atopic dermatitis</p> <p><input type="checkbox"/> Chronic rhinosinusitis with nasal polyposis (CRSwNP)</p> <p><input type="checkbox"/> Moderate to severe asthma</p> <p><input type="checkbox"/> Eosinophilic esophagitis</p> <p><input type="checkbox"/> Prurigo nodularis</p> <p><input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____</p>
<p>Atopic dermatitis:</p> <p>Has the patient had a documented trial of a topical corticosteroid, pimecrolimus cream, tacrolimus ointment, Eurisa (crisaborole) ointment within the last 120 days? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Was Dupixent prescribed by or in consultation with a dermatologist or allergist/immunologist? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Chronic rhinosinusitis with nasal polyposis (CRSwNP):</p> <p>Does the patient have a diagnosis of inadequately controlled CRSwNP? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Has the patient had a documented trial of an intranasal corticosteroid (INCS) within the last 120 days? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Was Dupixent prescribed by or in consultation with an allergist/immunologist, pulmonologist, or otolaryngologist (i.e., ENT)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Moderate to severe asthma:</p> <p>Has the patient had a documented trial of an inhaled corticosteroid (ICS) within the last 120 days? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Select if the patient has had a documented trial of one of the following controller medications within the last 120 days:</p> <p><input type="checkbox"/> Long-acting beta 2 agonist (LABA)</p> <p><input type="checkbox"/> LABA/ICS combination</p> <p><input type="checkbox"/> Long-acting muscarinic antagonists (LAMA)</p> <p><input type="checkbox"/> Leukotriene modifiers</p> <p><input type="checkbox"/> Theophylline</p> <p>Was Dupixent prescribed by or in consultation with an allergist/immunologist or gastroenterologist? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>



Dupixent® Prior Authorization Request Form (Page 2 of 2)
DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Eosinophilic esophagitis:

Has the patient had a documented trial of a high-dose proton pump inhibitor for at least 8 weeks or swallowed topical steroid (e.g., fluticasone propionate or oral budesonide suspension)? **Yes** **No**

Was Dupixent prescribed by or in consultation with an allergist/immunologist, pulmonologist, or otolaryngologist?
 Yes **No**

Prurigo nodularis

Has the patient had a documented trial of a topical corticosteroids or antihistamines within the last 120 days? **Yes** **No**

Was Dupixent prescribed by or in consultation with a dermatologist or allergist/immunologist? **Yes** **No**

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Enbrel® Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:	Dosage Form:	
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information (required)					
Select the diagnosis below:					
<input type="checkbox"/> Active ankylosing spondylitis (AS)					
<input type="checkbox"/> Active psoriatic arthritis (PsA)					
<input type="checkbox"/> Moderate to severe chronic plaque psoriasis (PsO)					
<input type="checkbox"/> Moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA)					
<input type="checkbox"/> Moderately to severely active rheumatoid arthritis (RA)					
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
Clinical information:					
Select if the requested medication is prescribed by or in consultation with one of the following specialists:					
<input type="checkbox"/> Dermatologist					
<input type="checkbox"/> Rheumatologist					
Will the requested medication be used in combination with another biologic agent or targeted immunomodulator? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For active ankylosing spondylitis (AS), also answer the following:					
Has the patient had an inadequate response to, intolerance to, or contraindication to one or more non-steroidal anti-inflammatory drugs (NSAIDs)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For active psoriatic arthritis (PsA), also answer the following:					
Has the patient had an inadequate response to, intolerance to, or contraindication to methotrexate? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For moderate to severe chronic plaque psoriasis (PsO), also answer the following:					
Has the patient had an inadequate response to, intolerance to, or contraindication to conventional therapy with at least one of the following: phototherapy or one or more oral systemic treatments (i.e., methotrexate, cyclosporine, acitretin, sulfasalazine)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA), also answer the following:					
Has the patient had an inadequate response to, intolerance to, or contraindication to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For moderately to severely active rheumatoid arthritis (RA), also answer the following:					
Has the patient had an inadequate response to, intolerance to, or contraindication to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs)? <input type="checkbox"/> Yes <input type="checkbox"/> No					



Enbrel® Prior Authorization Request Form (Page 2 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Quantity limit requests:

What is the quantity requested per MONTH? _____

What is the reason for exceeding the plan limitations?

- Titration or loading dose purposes
- Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)
- Requested strength/dose is not commercially available
- Other: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
 For urgent or expedited requests please call 1-855-401-4262.
 This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Enspryng[®] Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information (required)					
Select the diagnosis below: <input type="checkbox"/> Neuromyelitis optical disorder (NMOSD) <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
Clinical information: Select if the requested medication is prescribed by or in consultation with one of the following specialists: <input type="checkbox"/> Neurologist <input type="checkbox"/> Other _____ Will the requested medication be used in combination with another biologic agent? <input type="checkbox"/> Yes <input type="checkbox"/> No					

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
 For urgent or expedited requests please call 1-855-401-4262.
 This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Fasenra™ Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information <small>(required)</small>			Provider Information <small>(required)</small>		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information <small>(required)</small>			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information <small>(required)</small>	
Select the diagnosis below:	
<input type="checkbox"/> Severe asthma with an eosinophilic phenotype	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	
Clinical information:	
Has the patient experienced inadequate control of asthmatic symptoms after a minimum of three months use of a high-dose inhaled corticosteroid (ICS) and controlled medication (long-acting beta2 agonist (LABA) or high-dose LABA/ICS combination product or leukotriene receptor antagonist)? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Is Fasenra prescribed by or in consultation with a rheumatologist, pulmonologist, allergist, or immunologist? <input type="checkbox"/> Yes <input type="checkbox"/> No	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Humira® Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Active ankylosing spondylitis	
<input type="checkbox"/> Active psoriatic arthritis (PsA)	
<input type="checkbox"/> Moderate to severe chronic plaque psoriasis	
<input type="checkbox"/> Moderate to severe hidradenitis suppurativa (e.g., Hurley Stage II or III)	
<input type="checkbox"/> Moderately to severely active Crohn's disease	
<input type="checkbox"/> Moderately to severely active polyarticular juvenile idiopathic arthritis (JIA)	
<input type="checkbox"/> Moderately to severely active rheumatoid arthritis (RA)	
<input type="checkbox"/> Moderately to severely active ulcerative colitis	
<input type="checkbox"/> Non-infectious uveitis	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	
Clinical information:	
Select if the requested medication is prescribed by or in consultation with one of the following specialists:	
<input type="checkbox"/> Dermatologist <input type="checkbox"/> Gastroenterologist <input type="checkbox"/> Ophthalmologist <input type="checkbox"/> Rheumatologist	
Will the requested medication be used in combination with another biologic agent or targeted immunomodulator? <input type="checkbox"/> Yes <input type="checkbox"/> No	
For active ankylosing spondylitis (AS), also answer the following:	
Has the patient had an inadequate response to, intolerance to, or contraindication to one or more non-steroidal anti-inflammatory drugs (NSAIDs)? <input type="checkbox"/> Yes <input type="checkbox"/> No	
For active psoriatic arthritis (PsA), also answer the following:	
Has the patient had an inadequate response to, intolerance to, or contraindication to methotrexate? <input type="checkbox"/> Yes <input type="checkbox"/> No	
For moderate to severe chronic plaque psoriasis (PsO), also answer the following:	
Has the patient had an inadequate response to, intolerance to, or contraindication to conventional therapy with at least one of the following: phototherapy or one or more oral systemic treatments (i.e., methotrexate, cyclosporine, acitretin, sulfasalazine)? <input type="checkbox"/> Yes <input type="checkbox"/> No	
For moderate to severe hidradenitis suppurativa, also answer the following:	
Has the patient had an inadequate response to, intolerance to, or contraindication to one or more of the following: oral or topical antibiotic therapy OR oral or injectable steroid therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No	
For moderately to severely active Crohn's disease, also answer the following:	
Has the patient had an inadequate response to, intolerance to, or contraindication to one or more immunosuppressive agents (e.g., azathioprine, mercaptopurine, methotrexate)? <input type="checkbox"/> Yes <input type="checkbox"/> No	

Humira® Prior Authorization Request Form (Page 2 of 2)
DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

For moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA), also answer the following:

Has the patient had an inadequate response to, intolerance to, or contraindication to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs)? Yes No

For moderately to severely active rheumatoid arthritis (RA), also answer the following:

Has the patient had an inadequate response to, intolerance to, or contraindication to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs)? Yes No

For moderately to severely active ulcerative colitis, also answer the following:

Has the patient had an inadequate response to, intolerance to, or contraindication to conventional therapy with one or more of the following: corticosteroids (i.e., prednisone, methylprednisolone), 5-ASAs (i.e., mesalamine, sulfasalazine, balsalazide, olsalazine), non-biologic DMARDs (i.e., azathioprine, methotrexate, mercaptopurine)? Yes No

For non-infectious uveitis, also answer the following:

Has the patient had an inadequate response to, intolerance to, or contraindication to one or more of the following: methotrexate, mycophenolate, azathioprine, cyclosporine, tacrolimus, cyclophosphamide? Yes No

Quantity limit requests:

What is the quantity requested per MONTH? _____

What is the reason for exceeding the plan limitations?

- Titration or loading dose purposes
- Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)
- Requested strength/dose is not commercially available
- Other: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Amjevita™ Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:	Dosage Form:	
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information (required)					
<p>Select the diagnosis below:</p> <input type="checkbox"/> Active ankylosing spondylitis <input type="checkbox"/> Active psoriatic arthritis (PsA) <input type="checkbox"/> Moderate to severe chronic plaque psoriasis <input type="checkbox"/> Moderately to severely active Crohn's disease <input type="checkbox"/> Moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) <input type="checkbox"/> Moderately to severely active rheumatoid arthritis (RA) <input type="checkbox"/> Moderately to severely active ulcerative colitis <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
<p>Clinical information:</p> <p>Select if the requested medication is prescribed by or in consultation with one of the following specialists: <input type="checkbox"/> Dermatologist <input type="checkbox"/> Gastroenterologist <input type="checkbox"/> Rheumatologist</p> <p>Will the requested medication be used in combination with another biologic agent or targeted immunomodulator? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>					
<p>For active ankylosing spondylitis (AS), also answer the following:</p> <p>Has the patient had an inadequate response to, intolerance to, or contraindication to one or more non-steroidal anti-inflammatory drugs (NSAIDs)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>					
<p>For active psoriatic arthritis (PsA), also answer the following:</p> <p>Has the patient had an inadequate response to, intolerance to, or contraindication to methotrexate? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>					
<p>For moderate to severe chronic plaque psoriasis (PsO), also answer the following:</p> <p>Has the patient had an inadequate response to, intolerance to, or contraindication to conventional therapy with at least one of the following: phototherapy or one or more oral systemic treatments (i.e., methotrexate, cyclosporine, acitretin, sulfasalazine)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>					
<p>For moderately to severely active Crohn's disease, also answer the following:</p> <p>Has the patient had an inadequate response to, intolerance to, or contraindication to one or more immunosuppressive agents (e.g., azathioprine, mercaptopurine, methotrexate)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>					
<p>For moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA), also answer the following:</p> <p>Has the patient had an inadequate response to, intolerance to, or contraindication to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>					



Amjevita™ Prior Authorization Request Form (Page 2 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

For moderately to severely active rheumatoid arthritis (RA), also answer the following:

Has the patient had an inadequate response to, intolerance to, or contraindication to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs)? Yes No

For moderately to severely active ulcerative colitis, also answer the following:

Has the patient had an inadequate response to, intolerance to, or contraindication to conventional therapy with one or more of the following: corticosteroids (i.e., prednisone, methylprednisolone), 5-ASAs (i.e., mesalamine, sulfasalazine, balsalazide, olsalazine), non-biologic DMARDs (i.e., azathioprine, methotrexate, mercaptopurine)? Yes No

Quantity limit requests:

What is the quantity requested per MONTH? _____

What is the reason for exceeding the plan limitations?

- Titration or loading dose purposes
- Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)
- Requested strength/dose is not commercially available
- Other: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note:

This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Ilaris® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Active systemic juvenile idiopathic arthritis	
<input type="checkbox"/> Cryopyrin-associated periodic syndromes (CAPS) [including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS)]	
<input type="checkbox"/> Tumor necrosis factor receptor associated periodic syndrome or hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD) or familial mediterranean fever	
<input type="checkbox"/> Still's disease	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	
Clinical information:	
Select if the requested medication is diagnosed by, or upon consultation with or recommendation of the following specialists: <input type="checkbox"/> Allergist/Immunologist <input type="checkbox"/> Dermatologist <input type="checkbox"/> Neurologist <input type="checkbox"/> Rheumatologist <input type="checkbox"/> Other _____	
Will the requested medication be used in combination with another biologic agent? <input type="checkbox"/> Yes <input type="checkbox"/> No	
For active systemic juvenile idiopathic arthritis or Still's disease, answer the following:	
Has the patient had an inadequate response or intolerance to at least one oral systemic agent [i.e., non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroid]? <input type="checkbox"/> Yes <input type="checkbox"/> No	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
 For urgent or expedited requests please call 1-855-401-4262.
 This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Ilumya™ Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)
Select the diagnosis below:
<input type="checkbox"/> Moderate-to-severe plaque psoriasis
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____
Clinical information:
Is Ilumya prescribed by or in consultation with a dermatologist? <input type="checkbox"/> Yes <input type="checkbox"/> No
Will Ilumya be used in combination with another biologic agent? <input type="checkbox"/> Yes <input type="checkbox"/> No
Has the patient had an inadequate response to, intolerance to, or contraindication to conventional therapy with at least one of the following: phototherapy or one or more oral systemic treatments (i.e., methotrexate, cyclosporine, acitretin, sulfasalazine)? <input type="checkbox"/> Yes <input type="checkbox"/> No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Kevzara® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Moderately to severely active rheumatoid arthritis (RA)	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	
Clinical information:	
Is Kevzara prescribed by or in consultation with a rheumatologist? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Will Kevzara be used in combination with another biologic agent? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Has the patient had an inadequate response to, intolerance to, or contraindication to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs)? <input type="checkbox"/> Yes <input type="checkbox"/> No	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Kineret® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Cryopyrin-associated periodic syndromes (CAPS)	
<input type="checkbox"/> Moderately to severely active rheumatoid arthritis (RA)	
<input type="checkbox"/> Deficiency of interleukin-1 receptor antagonist (DIRA)	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	
Clinical information:	
Is Kineret diagnosed by, or upon consultation with or recommendation of, an immunologist, allergist, dermatologist, rheumatologist, neurologist, or other medical specialist? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Will the requested medication be used in combination with another biologic agent? <input type="checkbox"/> Yes <input type="checkbox"/> No	
For moderately to severely active rheumatoid arthritis (RA), also answer the following:	
Has the patient had an inadequate response to, intolerance to, or contraindication to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs)? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Quantity limit requests:	
What is the quantity requested per MONTH? _____	
What is the reason for exceeding the plan limitations?	
<input type="checkbox"/> Titration or loading dose purposes	
<input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)	
<input type="checkbox"/> Requested strength/dose is not commercially available	
<input type="checkbox"/> Other: _____	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Nucala® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)
<p>Select the diagnosis below:</p> <p><input type="checkbox"/> Severe asthma with an eosinophilic phenotype</p> <p><input type="checkbox"/> Eosinophilic granulomatosis with polyangiitis (Churg-Strauss Syndrome)</p> <p><input type="checkbox"/> Hypereosinophilic syndrome</p> <p><input type="checkbox"/> Chronic rhinosinusitis with nasal polyps (CRSwNP)</p> <p><input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____</p>
<p>Clinical information:</p> <p>Is Nucala prescribed by or in consultation with a rheumatologist, pulmonologist, allergist, or immunologist? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>For severe asthma with an eosinophilic phenotype, also answer the following:</p> <p>Has the patient experienced inadequate control of asthmatic symptoms after a minimum of three months use of a high dose corticosteroid and controller medication? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Has the patient had at least two asthma exacerbations requiring medical intervention within the past 12 months? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>For chronic rhinosinusitis with nasal polyps (CRSwNP), also answer the following:</p> <p>Has the patient experienced inadequate response to nasal corticosteroids? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Olumiant® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Moderately to severely active rheumatoid arthritis (RA)	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	
Clinical information:	
Is Olumiant prescribed by or in consultation with a rheumatologist? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Will Olumiant be used in combination with another biologic agent? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Has the patient had an inadequate response to, intolerance to, or contraindication to methotrexate? <input type="checkbox"/> Yes <input type="checkbox"/> No	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Orencia® Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required) Provider Information (required)

Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)

Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)

Select the diagnosis below:

Active psoriatic arthritis (PsA)

Moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA)

Moderately to severely active rheumatoid arthritis (RA)

Other diagnosis: _____ ICD-10 Code(s): _____

Clinical information:

Select if the requested medication is prescribed by or in consultation with one of the following specialists:

Dermatologist

Rheumatologist

Will the requested medication be used in combination with another biologic agent? Yes No

For active psoriatic arthritis (PsA), also answer the following:

Has the patient had an inadequate response to, intolerance to, or contraindication to methotrexate? Yes No

For moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA), also answer the following:

Has the patient had an inadequate response to, intolerance to, or contraindication to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs)? Yes No

For moderately to severely active rheumatoid arthritis (RA), also answer the following:

Has the patient had an inadequate response to, intolerance to, or contraindication to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs)? Yes No

Quantity limit requests:

What is the quantity requested per MONTH? _____

What is the reason for exceeding the plan limitations?

Titration or loading dose purposes

Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)

Requested strength/dose is not commercially available

Other: _____

Otezla® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Active psoriatic arthritis (PsA)	
<input type="checkbox"/> Moderate to severe chronic plaque psoriasis (PsO)	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	
Clinical information:	
Select if the requested medication is prescribed by or in consultation with one of the following specialists:	
<input type="checkbox"/> Dermatologist <input type="checkbox"/> Rheumatologist	
Will the requested medication be used in combination with another biologic agent? <input type="checkbox"/> Yes <input type="checkbox"/> No	
For active psoriatic arthritis (PsA), also answer the following:	
Has the patient had an inadequate response, contraindication, or intolerance to methotrexate? <input type="checkbox"/> Yes <input type="checkbox"/> No	
For moderate to severe plaque psoriasis (PsO), also answer the following:	
Has the patient had an inadequate response, contraindication, or intolerance to conventional therapy with at least one of the following: phototherapy or one or more oral systemic treatments (i.e., methotrexate, cyclosporine, acitretin, sulfasalazine)? <input type="checkbox"/> Yes <input type="checkbox"/> No	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
 For urgent or expedited requests please call 1-855-401-4262.
 This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Rinvoq® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information (required)					
<p>Select the diagnosis below:</p> <input type="checkbox"/> Moderately to severely active rheumatoid arthritis (RA) <input type="checkbox"/> Moderately to severely active ulcerative colitis <input type="checkbox"/> Active psoriatic arthritis <input type="checkbox"/> Active ankylosing spondylitis <input type="checkbox"/> Active atopic dermatitis <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
<p>Clinical information:</p> <p>Select if the requested medication is prescribed by or in consultation with one of the following specialists: <input type="checkbox"/> Dermatologist <input type="checkbox"/> Gastroenterologist <input type="checkbox"/> Rheumatologist <input type="checkbox"/> Other _____</p> <p>Will Rinvoq be used in combination with another biologic agent, Janus Kinus inhibitor e.g., Olumiant, Dupixent, Xeljanz/XR), or other potent immunosuppressants (e.g., azathioprine, cyclosporine, methotrexate, mycophenolate, etc)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>					
<p>For rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and ankylosing spondylitis also answer the following:</p> <p>Has the patient had an inadequate response to, intolerance to, or contraindication to one or more TNF blockers (e.g., Cimzia, Enbrel, Humira, Simponi, Remicade, etc)? _____</p>					
<p>For atopic dermatitis also answer the following:</p> <p>Has the patient had an inadequate response to, intolerance to, or contraindication to one or more systemic drug product for the treatment of atopic dermatitis (e.g., Adbry, Dupixent, etc)? _____</p>					

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
 For urgent or expedited requests please call 1-855-401-4262.
 This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Siliq® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand <input type="checkbox"/> Check if request is for continuation of therapy		Directions for Use:

Clinical Information (required)
<p>Select the diagnosis below:</p> <input type="checkbox"/> Moderate to severe chronic plaque psoriasis <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____
<p>Clinical information:</p> <p>Is Siliq prescribed by or in consultation with a dermatologist? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Will Siliq be used in combination with another biologic agent? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Has the patient had an inadequate response to, intolerance to, or contraindication to conventional therapy with at least one of the following: phototherapy or one or more oral systemic treatments (i.e., methotrexate, cyclosporine, acitretin, sulfasalazine)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Simponi® Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required) Provider Information (required)

Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)

Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)

Select the diagnosis below:

Active ankylosing spondylitis

Active psoriatic arthritis (PsA)

Moderately to severely active rheumatoid arthritis (RA)

Moderately to severely active ulcerative colitis

Other diagnosis: _____ ICD-10 Code(s): _____

Clinical information:

Select if the requested medication is prescribed by or in consultation with one of the following specialists:

Dermatologist Gastroenterologist Rheumatologist

Will the requested medication be used in combination with another biologic agent? Yes No

For active ankylosing spondylitis (AS), also answer the following:

Has the patient had an inadequate response, contraindication, or intolerance to one or more non-steroidal anti-inflammatory drugs (NSAIDs)? Yes No

For active psoriatic arthritis (PsA), also answer the following:

Has the patient had an inadequate response, contraindication, or intolerance to methotrexate? Yes No

For moderately to severely active rheumatoid arthritis (RA), also answer the following:

Has the patient had an inadequate response, contraindication, or intolerance to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs)? Yes No

For moderately to severely active ulcerative colitis, also answer the following:

Has the patient had an inadequate response, contraindication, or intolerance to conventional therapy with one or more of the following: corticosteroids (i.e., prednisone, methylprednisolone), 5-ASAs (i.e., mesalamine, sulfasalazine, balsalazide, olsalazine), non-biologic DMARDs (i.e., azathioprine, methotrexate, mercaptopurine)? Yes No

Quantity limit requests:

What is the quantity requested per MONTH? _____

What is the reason for exceeding the plan limitations?

Titration or loading dose purposes

Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)

Requested strength/dose is not commercially available

Patient requires a greater quantity for the treatment of a larger surface area **[Topical applications only]**

Other: _____



Skyrizi® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Moderate to severe plaque psoriasis	
<input type="checkbox"/> Active psoriatic arthritis	
<input type="checkbox"/> Moderately to severely active Crohn's disease	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	
Clinical information:	
Select if the requested medication is prescribed by or in consultation with one of the following specialists:	
<input type="checkbox"/> Dermatologist <input type="checkbox"/> Gastroenterologist <input type="checkbox"/> Rheumatologist <input type="checkbox"/> Other _____	
Will the requested medication be used in combination with another biologic agent? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Has the patient had an inadequate response to, intolerance to, or contraindication to conventional therapy with at least one of the following: phototherapy or one or more oral systemic treatments (list) _____	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
 For urgent or expedited requests please call 1-855-401-4262.
 This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Stelara® Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)

Select the diagnosis below:

Active psoriatic arthritis (PsA)

Moderate to severe chronic plaque psoriasis

Moderately to severely active Crohn's disease

Moderately to severely active ulcerative colitis

Other diagnosis: _____ ICD-10 Code(s): _____

Clinical information:

Select if the requested medication is prescribed by or in consultation with one of the following specialists:

Dermatologist

Gastroenterologist

Rheumatologist

Will the requested medication be used in combination with another biologic agent? Yes No

For active psoriatic arthritis (PsA), also answer the following:

Has the patient had an inadequate response to, intolerance to, or contraindication to methotrexate? Yes No

For moderate to severe chronic plaque psoriasis, also answer the following:

Has the patient had an inadequate response to, intolerance to, or contraindication to conventional therapy with at least one of the following: phototherapy or one or more oral systemic treatments (i.e., methotrexate, calcipotriene, cyclosporine, acitretin, sulfasalazine, tazarotene, corticosteroid)? Yes No

For moderately to severely active Crohn's disease, also answer the following:

Has the patient had an inadequate response to, intolerance to, or contraindication to one or conventional therapy (e.g., azathioprine, mercaptopurine, methotrexate, corticosteroids)? Yes No

For moderately to severely active Ulcerative Colitis, also answer the following:

Has the patient had an inadequate response to, intolerance to, or contraindication to one or more conventional therapy (e.g., corticosteroids, mesalamine, balsalazide, olsalazine, azathioprine, mercaptopurine, methotrexate)? Yes No



Stelara® Prior Authorization Request Form (Page 2 of 2)
DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Quantity limit requests:

What is the quantity requested per TREATMENT? _____ syringe every _____ weeks

What is the reason for exceeding the plan limitations?

- Titration or loading dose purposes
- Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)
- Requested strength/dose is not commercially available
- Other: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Taltz® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)
<p>Select the diagnosis below:</p> <p><input type="checkbox"/> Active ankylosing spondylitis</p> <p><input type="checkbox"/> Active psoriatic arthritis</p> <p><input type="checkbox"/> Moderate to severe plaque psoriasis</p> <p><input type="checkbox"/> Non-radiographic axial spondyloarthritis with objective of inflammation</p> <p><input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____</p>
<p>Clinical information:</p> <p>Select if the requested medication is prescribed by or in consultation with one of the following specialists:</p> <p><input type="checkbox"/> Dermatologist</p> <p><input type="checkbox"/> Rheumatologist</p> <p>Will the requested medication be used in combination with another biologic agent? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>For active ankylosing spondylitis or non-radiographic axial spondyloarthritis, also answer the following:</p> <p>Has the patient had an inadequate response to, intolerance to, or contraindication to one or more non-steroidal anti-inflammatory drugs (NSAIDs)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>For active psoriatic arthritis, also answer the following:</p> <p>Has the patient had an inadequate response to, intolerance to, or contraindication to methotrexate? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>For moderate to severe plaque psoriasis, also answer the following:</p> <p>Has the patient had an inadequate response to, intolerance to, or contraindication to conventional therapy with at least one of the following: phototherapy or one or more oral systemic treatments (i.e., methotrexate, cyclosporine, acitretin, sulfasalazine)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Tremfya® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Moderate to severe plaque psoriasis	
<input type="checkbox"/> Moderate to severe psoriatic arthritis	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	
Clinical information:	
Is Tremfya prescribed by or in consultation with a dermatologist? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Will Tremfya be used in combination with another biologic agent? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Has the patient had an inadequate response to, intolerance to, or contraindication to conventional therapy with at least one of the following: phototherapy or one or more oral systemic treatments (i.e., methotrexate, cyclosporine, acitretin, Sulfasalazine, calcipotriene, tazarotene, corticosteroid)? <input type="checkbox"/> Yes <input type="checkbox"/> No	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Xeljanz® & Xeljanz XR® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Active psoriatic arthritis	
<input type="checkbox"/> Moderately to severely active rheumatoid arthritis	
<input type="checkbox"/> Moderately to severely active ulcerative colitis	
<input type="checkbox"/> Moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA)	
<input type="checkbox"/> Active ankylosing spondylitis	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	
Clinical information:	
Select if the requested medication is prescribed by or in consultation with one of the following specialists:	
<input type="checkbox"/> Dermatologist	
<input type="checkbox"/> Gastroenterologist	
<input type="checkbox"/> Rheumatologist	
Will the requested medication be used in combination with another biologic agent? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Has the patient had an inadequate response to, intolerance to, or contraindication to one or more TNF blockers (e.g., Cimzia, Enbrel, Humira, Simponi, Avsola, Inflectra, Renflexis, Remicade)? If so, which one(s) _____	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Xolair® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information (required)					
Select the diagnosis below: <input type="checkbox"/> Asthma <input type="checkbox"/> Chronic idiopathic urticaria (CIU) <input type="checkbox"/> Nasal polyps with inadequate response to nasal steroid <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
For asthma, answer the following: Does the patient have a positive skin test or in vitro reactivity to a perennial aeroallergen? <input type="checkbox"/> Yes <input type="checkbox"/> No Does the patient have an elevated serum IgE level? <input type="checkbox"/> Yes <input type="checkbox"/> No Are the patient's symptoms inadequately controlled with inhaled corticosteroids? <input type="checkbox"/> Yes <input type="checkbox"/> No Is Xolair prescribed by or in consultation with a pulmonologist, allergist, or immunologist? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For chronic idiopathic urticaria, answer the following: Does the patient remain symptomatic despite H1 antihistamine treatment? <input type="checkbox"/> Yes <input type="checkbox"/> No Is Xolair prescribed by or in consultation with a dermatologist, rheumatologist, pulmonologist, allergist, or immunologist? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Quantity limit requests: What is the quantity requested per MONTH? _____ What is the reason for exceeding the plan limitations? <input type="checkbox"/> Titration or loading dose purposes <input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime) <input type="checkbox"/> Requested strength/dose is not commercially available <input type="checkbox"/> Other: _____					

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
 For urgent or expedited requests please call 1-855-401-4262.
 This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Juxtapid® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)
<p>Select the diagnosis below:</p> <p><input type="checkbox"/> Heterozygous familial hypercholesterolemia (HeFH)</p> <p><input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____</p>
<p>Clinical information:</p> <p>Is the patient's baseline LDL-C level greater than or equal to 190 mg/dL? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Is the requested medication prescribed by or in consultation with a cardiologist or endocrinologist? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Has the patient had trial and failure of Praluent or Repatha? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>If yes, what was the documented failure with Praluent or Repatha _____</p> <p>_____</p> <p>What is the medical rationale for use of Juxtapid over Praluent or Repatha? _____</p> <p>_____</p>

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Extina, Xolgel™ & Xolegel™ Duo Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Seborrheic dermatitis in immunocompetent patients	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	
Clinical information:	
Has the patient had a trial and failure (a minimum of 60 day trial) of ketoconazole cream or shampoo in the past 120 days? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Quantity limit requests:	
What is the quantity requested per MONTH? _____	
What is the reason for exceeding the plan limitations?	
<input type="checkbox"/> Patient requires a larger quantity to cover a larger surface area	
<input type="checkbox"/> Other: _____	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Topical onychomycosis agents Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)
Select the diagnosis below:
<input type="checkbox"/> Onychomycosis of the toenails
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____
Clinical information:
Has the patient had a trial and failure of 90 days of terbinafine tablets and 90 days of topical ciclopirox in the last 12 months? <input type="checkbox"/> Yes <input type="checkbox"/> No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Luzu® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)
What is the patient's diagnosis for the medication being requested? (Mandatory)

ICD-10 Code(s) [Mandatory]: _____
Medication history:
Has the patient tried and failed two topical antifungal agents in the last 365 days? <input type="checkbox"/> Yes <input type="checkbox"/> No
Has the patient tried and failed two oral antifungal agents in the last 365 days? <input type="checkbox"/> Yes <input type="checkbox"/> No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Oravig® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Local treatment of oropharyngeal candidiasis (OPC)	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	

Clinical information: Has the patient had a trial and failure of clotrimazole troches, fluconazole tablets/suspension, or nystatin suspension within the past 60 days? <input type="checkbox"/> Yes <input type="checkbox"/> No

Quantity limit requests: What is the quantity requested per DAY? _____
What is the reason for exceeding the plan limitations? <input type="checkbox"/> Titration or loading dose purposes <input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime) <input type="checkbox"/> Requested strength/dose is not commercially available <input type="checkbox"/> Other: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
 For urgent or expedited requests please call 1-855-401-4262.
 This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Vusion® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)
<p>Select the diagnosis below:</p> <p><input type="checkbox"/> Adjunctive treatment of diaper dermatitis complicated by candidiasis</p> <p><input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____</p>
<p>Clinical information:</p> <p>Has the patient had a trial and failure (a minimum of 14 day trial) to topical nystatin or topical OTC miconazole in the last 30 days? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Quantity limit requests:</p> <p>What is the quantity requested per MONTH? _____</p> <p>What is the reason for exceeding the plan limitations?</p> <p><input type="checkbox"/> Patient requires a larger quantity to cover a larger surface area</p> <p><input type="checkbox"/> Other: _____</p>

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Makena® SubQ Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)
<p>Select the diagnosis below:</p> <p><input type="checkbox"/> Pregnancy indication, preterm birth</p> <p><input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____</p>
<p>Clinical information:</p> <p>1. Does the patient have a history of previous singleton (single offspring) spontaneous perterm birth(s)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>2. Is the patient having a singleton pregnancy? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>3. Is the therapy starting between 16 weeks, 0 days and 20 weeks, 6 days of gestation? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>4. Will therapy be continued until week 37 (through 36 weeks, 6 days) of gestation or delivery, which ever occurs first? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.

Metozolv® ODT (metoclopramide orally disintegrating tablet [ODT]) Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)
<p>Select the diagnosis below:</p> <p><input type="checkbox"/> Diabetic gastroparesis (diabetic gastric stasis)</p> <p><input type="checkbox"/> Symptomatic gastroesophageal reflux disease</p> <p><input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____</p>
<p>Clinical information:</p> <p>Has the patient had a 30-day trial and failure of Brand Reglan or generic metoclopramide tablet or solution within the last 90 days? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Quantity limit requests:</p> <p>What is the quantity requested per DAY? _____</p> <p>What is the reason for exceeding the plan limitations?</p> <p><input type="checkbox"/> Titration or loading dose purposes</p> <p><input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)</p> <p><input type="checkbox"/> Requested strength/dose is not commercially available</p> <p><input type="checkbox"/> Other: _____</p>

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Multiple Sclerosis Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information <small>(required)</small>			Provider Information <small>(required)</small>		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information <small>(required)</small>		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information <small>(required)</small>				
Select the medication being requested:				
<input type="checkbox"/> Ampyra	<input type="checkbox"/> Briumvi	<input type="checkbox"/> Gilenya	<input type="checkbox"/> Mavenclad	<input type="checkbox"/> Rebif
<input type="checkbox"/> Aubagio	<input type="checkbox"/> Copaxone	<input type="checkbox"/> Glatiramer	<input type="checkbox"/> Mayzent	<input type="checkbox"/> Tascento ODT
<input type="checkbox"/> Avonex	<input type="checkbox"/> Dalfampridine ER	<input type="checkbox"/> Glatopa	<input type="checkbox"/> Plegridy	<input type="checkbox"/> Tecfidera
<input type="checkbox"/> Bafiertam	<input type="checkbox"/> Extavia	<input type="checkbox"/> Kesimpta	<input type="checkbox"/> Ponvory	<input type="checkbox"/> Vumerity
<input type="checkbox"/> Betaseron				<input type="checkbox"/> Zeposia

Select the diagnosis below:
<input type="checkbox"/> Multiple sclerosis _____
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____

Prescriber's specialty:
Select if the requested medication is prescribed by or in consultation with one of the following specialists:
<input type="checkbox"/> Neurologist
<input type="checkbox"/> Psychiatrist [Ampyra (dalfampridine ER) only]

For Ampyra (dalfampridine ER), also answer the following:
Does the patient have a history of seizures? <input type="checkbox"/> Yes <input type="checkbox"/> No

For Aubagio, Avonex, Bafiertam, Betaseron, Briumvi, Copaxone, Extavia, Gilenya, Glatiramer, Glatopa, Kesimpta, Lemtrada, Mayzent, Plegridy, Ponvory, Rebif, Tecfidera, or Vumerity, also answer the following:
Does the patient have a relapsing form of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease? <input type="checkbox"/> Yes <input type="checkbox"/> No

For mitoxantrone, also answer the following:
Select the form of multiple sclerosis that applies to the patient:
<input type="checkbox"/> Progressive relapsing multiple sclerosis
<input type="checkbox"/> Secondary progressive multiple sclerosis
<input type="checkbox"/> Worsening relapsing-remitting multiple sclerosis



Multiple Sclerosis Prior Authorization Request Form (Page 2 of 2)
DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

For Mavenclad, also answer the following:

Does the patient have a relapsing form of multiple sclerosis, including relapsing-remitting disease or active secondary progressive disease? Yes No

Has the patient already received the FDA-recommended lifetime limit of 2 treatment courses (or 4 treatment cycles total) of cladribine? Yes No

Select the disease-modifying therapies for multiple sclerosis the patient has failed after a trial of at least 4 weeks, has a contraindication to, or intolerance to:

- | | | |
|--|---|---|
| <input type="checkbox"/> Aubagio (teriflunomide) | <input type="checkbox"/> Extavia (interferon beta-1b) | <input type="checkbox"/> Plegridy (peginterferon beta-1a) |
| <input type="checkbox"/> Avonex (interferon beta-1a) | <input type="checkbox"/> Gilenya (fingolimod) | <input type="checkbox"/> Rebif (interferon beta-1a) |
| <input type="checkbox"/> Bafiertam (monomethyl fumarate) | <input type="checkbox"/> Kesimpta (ofatumumab) | <input type="checkbox"/> Tecfidera (dimethyl fumarate) |
| <input type="checkbox"/> Betaseron (interferon beta-1b) | <input type="checkbox"/> Lemtrada (alemtuzumab) | <input type="checkbox"/> Tysabri (natalizumab) |
| <input type="checkbox"/> Briumvi (ublituximab-xiiy) | <input type="checkbox"/> Mayzent (siponimod) | <input type="checkbox"/> Vumerity (diroximel) |
| <input type="checkbox"/> Copaxone/Glatopa (glatiramer acetate) | <input type="checkbox"/> Ocrevus (ocrelizumab) | <input type="checkbox"/> Zeposia (ozanimod) |

Quantity limit requests:

What is the quantity requested per MONTH? _____

What is the reason for exceeding the plan limitations?

- Titration or loading dose purposes
- Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)
- Requested strength/dose is not commercially available
- Other: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Tysabri® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Multiple Sclerosis (type) _____	ICD-10 Code(s): _____
<input type="checkbox"/> Crohn's Disease (severity level) _____	ICD-10 Code(s): _____
<input type="checkbox"/> Other _____	ICD-10 Code(s): _____
Prescriber's specialty:	
Select if the requested medication is prescribed by or in consultation with one of the following specialists:	
<input type="checkbox"/> Neurologist	
<input type="checkbox"/> Gastroenterologist	
<input type="checkbox"/> Other _____	
Quantity limit requests:	
What is the quantity requested per MONTH? _____	
What is the reason for exceeding the plan limitations?	
<input type="checkbox"/> Titration or loading dose purposes	
<input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)	
<input type="checkbox"/> Requested strength/dose is not commercially available	
<input type="checkbox"/> Other: _____	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Nascobal® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information (required)					
Has the patient had a trial and failure of injectable cyanocobalamin within the past 6 months? <input type="checkbox"/> Yes <input type="checkbox"/> No					

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Nuplazid™ Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)
Select the diagnosis below:
<input type="checkbox"/> Hallucinations and delusions associated with Parkinson's disease psychosis
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____
Clinical information:
Is Nuplazid prescribed by or in consultation with a neurologist or psychiatrist? <input type="checkbox"/> Yes <input type="checkbox"/> No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Nuessa™ Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information (required)					
Has the patient had a trial and failure of metronidazole vaginal gel 0.75% within the past 30 days? <input type="checkbox"/> Yes <input type="checkbox"/> No					

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Hetlioz® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Non-24-Hour Sleep-Wake Disorder	
<input type="checkbox"/> Nighttime sleep disturbances in Smith-Magenis syndrome	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	
Medication history:	
Has the patient tried and failed a generic sedative-hypnotic (estazolam, eszopiclone, temazepam, triazolam, zaleplon, zolpidem) within the last 120 days? <input type="checkbox"/> Yes <input type="checkbox"/> No	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.

Nuvigil® (armodafinil) and Provigil® (modafinil) Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome	
<input type="checkbox"/> Narcolepsy	
<input type="checkbox"/> Shift work sleep disorder	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	
Quantity limit requests:	
What is the quantity requested per DAY? _____	
What is the reason for exceeding the plan limitations?	
<input type="checkbox"/> Titration or loading dose purposes	
<input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)	
<input type="checkbox"/> Requested strength/dose is not commercially available	
<input type="checkbox"/> Other: _____	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Sunosi™ & Wakix® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Narcolepsy with excessive daytime sleepiness	
<input type="checkbox"/> Obstructive sleep apnea	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	
For narcolepsy with excessive daytime sleepiness, answer the following:	
Has the patient had a previous trial of at least one of the following standard stimulant agents: amphetamine/dextroamphetamine, armodafinil, modafinil, dextroamphetamine, methylphenidate? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Quantity limit requests:	
What is the quantity requested per DAY? _____	
What is the reason for exceeding the plan limitations?	
<input type="checkbox"/> Titration or loading dose purposes	
<input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)	
<input type="checkbox"/> Requested strength/dose is not commercially available	
<input type="checkbox"/> Patient requires a greater quantity for the treatment of a larger surface area [Topical applications only]	
<input type="checkbox"/> Other: _____	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Xyrem® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information (required)					
Select the diagnosis below: <input type="checkbox"/> Narcolepsy with cataplexy <input type="checkbox"/> Narcolepsy with excessive daytime sleepiness <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
Clinical Information: Is the patient enrolled in the Xyrem Success Program? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For narcolepsy with excessive daytime sleepiness, answer the following: Has the patient had a previous trial of at least one of the following standard stimulant agents: amphetamine/dextroamphetamine, armodafinil, modafinil, dextroamphetamine, methylphenidate? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Quantity limit requests: What is the quantity requested per DAY? _____ What is the reason for exceeding the plan limitations? <input type="checkbox"/> Titration or loading dose purposes <input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime) <input type="checkbox"/> Requested strength/dose is not commercially available <input type="checkbox"/> Patient requires a greater quantity for the treatment of a larger surface area [Topical applications only] <input type="checkbox"/> Other: _____					

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
 For urgent or expedited requests please call 1-855-401-4262.
 This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Onfi® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)
<p>Select the diagnosis below:</p> <p><input type="checkbox"/> Intractable treatment-resistant seizure disorder</p> <p><input type="checkbox"/> Seizures associated with Lennox-Gastaut syndrome (LGS)</p> <p><input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____</p>
<p>Prescriber specialty:</p> <p>Is Onfi prescribed by or in consultation with a neurologist? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Bepreve[®], Lastacaft[®], Pataday[®], Patanol[®], Pazeo[®]
Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Allergic conjunctivitis	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	
Medication history:	
Has the patient had a 5 day trial of azelastine, emedastine, epinastine, generic olopatadine, or ketotifen in the last 120 days? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Quantity limit requests:	
What is the quantity requested per MONTH? _____	
What is the reason for exceeding the plan limitations?	
<input type="checkbox"/> Titration or loading dose purposes	
<input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)	
<input type="checkbox"/> Requested strength/dose is not commercially available	
<input type="checkbox"/> Other: _____	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Opzelura™ Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)
<p>Select the diagnosis below:</p> <p><input type="checkbox"/> Atopic dermatitis</p> <p><input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____</p>
<p>Clinical information: _____</p> <p>1. Does the patient have greater than or equal to 3% body surface area involvement? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>2. Does it involve sensitive body areas (e.g., face, hands, feet, scalp, groin)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>3. Greater than or equal to 90 days of topical drug therapy with one of the following: corticosteroids, pimecrolimus and/or tacrolimus, crisaborole? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>4. Is the patient using concurrently with therapeutic biologics, other Janus kinase inhibitors, or potent immunosuppressants such as azathioprine or cyclosporine? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>5. What is the requested quantity? _____</p> <p>6. How long will the patient be using Opzelura? _____</p>

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Oracea[®], Seysara[®], and Solodyn[®] Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Inflammatory lesions of non-nodular moderate to severe acne vulgaris [Seysara and Solodyn only]	
<input type="checkbox"/> Inflammatory lesions (papules and pustules) of rosacea [Oracea only]	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	
Clinical information:	
Has the patient had a trial and failure (a minimum of 90 day trial) of doxycycline monohydrate, doxycycline hyclate, minocycline immediate-release, or tetracycline in the last 180 days? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Quantity limit requests:	
What is the quantity requested per DAY? _____	
What is the reason for exceeding the plan limitations?	
<input type="checkbox"/> Titration or loading dose purposes	
<input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)	
<input type="checkbox"/> Requested strength/dose is not commercially available	
<input type="checkbox"/> Other: _____	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Otrexup® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Active polyarticular juvenile idiopathic arthritis (pJIA)	
<input type="checkbox"/> Severe, active rheumatoid arthritis (RA)	
<input type="checkbox"/> Severe, recalcitrant, disabling psoriasis	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	
For active polyarticular juvenile idiopathic arthritis (pJIA) or severe, active rheumatoid arthritis (RA), answer the following:	
Is the patient intolerant of or has had an inadequate response to first-line therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Has the patient tried and failed one month of a standard dosage form of methotrexate (e.g., oral, injectable) within the last 180 days? <input type="checkbox"/> Yes <input type="checkbox"/> No	
For severe, recalcitrant, disabling psoriasis, answer the following:	
Has the patient had inadequate response to other forms of therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Has the patient tried and failed one month of a standard dosage form of methotrexate (e.g., oral, injectable) within the last 180 days? <input type="checkbox"/> Yes <input type="checkbox"/> No	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Praluent® & Repatha® Prior Authorization Request Form
DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)
<p>Select the diagnosis below:</p> <p><input type="checkbox"/> Heterozygous familial hypercholesterolemia (HeFH)</p> <p><input type="checkbox"/> Homozygous familial hypercholesterolemia (HoFH) [Repatha only]</p> <p><input type="checkbox"/> Hyperlipidemia in a high risk patient with clinical arteriosclerotic cardiovascular disease (ASCVD)</p> <p><input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____</p>
<p>Clinical information:</p> <p>Is the patient's baseline LDL-C level greater than or equal to 70 mg/dL? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Has the patient been receiving high dose statin therapy for at least 3 months (i.e., atorvastatin tab 40 mg, atorvastatin tab 80 mg, rosuvastatin tab 20 mg, rosuvastatin tab 40 mg)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Is the patient a non-candidate for high dose statin therapy (e.g., labeled contraindication to all statins, patient has experienced rhabdomyolysis or muscle symptoms with statin treatment with creatine kinase elevations greater than 10 times upper limit of normal [ULN])? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Is the requested medication prescribed by or in consultation with a cardiologist or endocrinologist? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Reauthorization:</p> <p>If this is a reauthorization request, answer the following:</p> <p>Is there documentation of positive clinical response to therapy with LDL level less than 70 mg/dl or decreased 30% from baseline? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Proton Pump Inhibitor Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information (required)					
Select the diagnosis below: <input type="checkbox"/> Barrett's esophagitis <input type="checkbox"/> Erosive esophagitis <input type="checkbox"/> Zollinger-Ellison Syndrome <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
For Aciphex Sprinkle, Nexium oral packet, Prevacid Solutab (lansoprazole orally disintegrating tablet [ODT]), Prilosec delayed release suspension pack, Protonix packet, and Zegerid oral packet (omeprazole/sodium bicarbonate oral packet) requests, answer the following: Does the patient have a diagnosis which confirms a difficulty in swallowing? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For Dexilant, esomeprazole strontium capsule, Nexium capsule (esomeprazole magnesium capsule), Prevpac oral pack (lansoprazole-amoxicillin-clarithromycin oral pack), Protonix tablet, and Zegerid capsule (omeprazole-sodium bicarbonate capsule) requests, answer the following: Has the patient had a trial and failure (after a minimum of 14 days) in the past year with at least one of the following generics: Lansoprazole, omeprazole, pantoprazole, or rabeprazole? <input type="checkbox"/> Yes <input type="checkbox"/> No Has the patient experienced an adverse reaction (must be documented on a MedWatch form), allergy or contraindication to ALL of the following: Lansoprazole, omeprazole, pantoprazole, and rabeprazole? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Quantity limit requests: What is the quantity requested per DAY? _____ What is the reason for exceeding the plan limitations? <input type="checkbox"/> Titration or loading dose purposes <input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime) <input type="checkbox"/> Requested strength/dose is not commercially available <input type="checkbox"/> Other: _____					

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
 For urgent or expedited requests please call 1-855-401-4262.
 This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Duexis® & Vimovo® Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)
<p>Select the diagnosis below:</p> <p><input type="checkbox"/> Ankylosing spondylitis [Vimovo only]</p> <p><input type="checkbox"/> Osteoarthritis</p> <p><input type="checkbox"/> Rheumatoid arthritis</p> <p><input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____</p>
<p>Clinical information:</p> <p>Does the patient have a history of peptic ulcer disease/gastrointestinal (GI) bleed? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Does the patient have one additional risk factor for gastrointestinal adverse events (e.g., use of anticoagulants, chronic corticosteroids)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Does the patient have a history of asthma or urticaria after taking aspirin or other NSAIDs? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>For Duexis requests, please also answer the following:</p> <p>Has the patient had a 30 day trial of a preferred generic H2-receptor blocker (e.g., famotidine, cimetidine, ranitidine, nizatidine) AND a generic NSAID within the last 180 days? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>For Vimovo requests, please also answer the following:</p> <p>Has the patient had a 30 day trial of a preferred generic proton pump inhibitor (e.g., omeprazole, lansoprazole, pantoprazole) AND a generic NSAID within the last 180 days? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Quantity limit requests:</p> <p>What is the quantity requested per DAY? _____</p> <p>What is the reason for exceeding the plan limitations?</p> <p><input type="checkbox"/> Titration or loading dose purposes</p> <p><input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)</p> <p><input type="checkbox"/> Requested strength/dose is not commercially available</p> <p><input type="checkbox"/> Other: _____</p>



Qualaquin® (quinine) Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)
<p>Select the diagnosis below:</p> <p><input type="checkbox"/> Malaria</p> <p><input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____</p>
<p>Quantity limit requests: What is the quantity requested per DAY? _____</p> <p>What is the reason for exceeding the plan limitations?</p> <p><input type="checkbox"/> Titration or loading dose purposes</p> <p><input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)</p> <p><input type="checkbox"/> Requested strength/dose is not commercially available</p> <p><input type="checkbox"/> Other: _____</p>

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Rayos® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)
Has the patient had a trial and failure of generic prednisone tablets in the past 60 days? <input type="checkbox"/> Yes <input type="checkbox"/> No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Relistor® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)

Medication Name:		Strength:		Dosage Form:	
<input type="checkbox"/> Check if requesting brand		Directions for Use:			
<input type="checkbox"/> Check if request is for continuation of therapy					

Clinical Information (required)

Select the diagnosis below:

- Opioid-induced constipation in adult patients with advanced illness
- Other diagnosis: _____ ICD-10 Code(s): _____

Clinical Information:

Does the patient require palliative care? **Yes** **No**

Has the patient had at least a 10 day trial and failure of one other laxative (e.g., stimulant, osmotic, bulk forming, etc.) in the last 30 days? **Yes** **No**

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Soma® 250 (carisoprodol) Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Acute painful musculoskeletal condition	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	

Medication history: Has the patient had a 6 month trial of carisoprodol 350 mg within the last 120 days? <input type="checkbox"/> Yes <input type="checkbox"/> No

Quantity limit requests: What is the quantity requested per DAY? _____
What is the reason for exceeding the plan limitations?
<input type="checkbox"/> Titration or loading dose purposes
<input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)
<input type="checkbox"/> Requested strength/dose is not commercially available
<input type="checkbox"/> Other: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Tivorbex™ Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)
Has the patient had a trial and failure (a minimum of a combined 30 day trial) of two generic prescription strength nonsteroidal anti-inflammatory drugs (NSAIDs) in the past 180 days? <input type="checkbox"/> Yes <input type="checkbox"/> No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



**Conzip[®], Synapryn[®], Ultram[®] ER (tramadol ER biphasic capsule or tablet)
Prior Authorization Request Form**

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information <small>(required)</small>			Provider Information <small>(required)</small>		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information <small>(required)</small>		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information <small>(required)</small>
Clinical information:
Is the patient currently stable on tramadol ER tablet or Ultram ER? <input type="checkbox"/> Yes <input type="checkbox"/> No
Is the patient currently stable on Conzip, Synapryn (tramadol suspension), tramadol ER biphasic capsule or tablet? <input type="checkbox"/> Yes <input type="checkbox"/> No
Has the patient failed a 30 day trial of immediate release tramadol in the last 120 days? <input type="checkbox"/> Yes <input type="checkbox"/> No
Has the patient had an adverse reaction to generic immediate-release tramadol and the prescriber has documented it on a MedWatch form? <input type="checkbox"/> Yes <input type="checkbox"/> No
Has the patient had a drug allergy or contraindication to generic immediate-release tramadol and the prescriber has documented it in the patient's chart notes/medical records? <input type="checkbox"/> Yes <input type="checkbox"/> No
Does the patient have a diagnosis of cancer in the past 365 days? <input type="checkbox"/> Yes <input type="checkbox"/> No
Does the patient have a diagnosis of a terminal illness? <input type="checkbox"/> Yes <input type="checkbox"/> No
Does the patient have an <u>illness</u> associated with significant pain (e.g., sickle cell anemia, etc)? <input type="checkbox"/> Yes <input type="checkbox"/> No
If yes , please list the diagnosis: _____
Does the patient have an <u>injury</u> associated with significant pain? <input type="checkbox"/> Yes <input type="checkbox"/> No
If yes , please list the diagnosis: _____
Have efforts been made to taper the patient to the lowest effective dose? <input type="checkbox"/> Yes <input type="checkbox"/> No
If yes , please provide documentation: _____

Reauthorization:
If this is a reauthorization request, answer the following:
Is the prescriber maintaining the most conservative, effective treatment? <input type="checkbox"/> Yes <input type="checkbox"/> No
If yes , please provide documentation: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Triptans Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Migraine with or without aura	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	
Medication history:	
Has the patient had a trial and failure of a generic triptan within the last 6 months? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Clinical information:	
Does the patient have a diagnosis which confirms a difficulty in swallowing? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Quantity limit requests:	
What is the quantity requested per MONTH? _____	
What is the reason for exceeding the plan limitations?	
<input type="checkbox"/> Titration or loading dose purposes	
<input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)	
<input type="checkbox"/> Requested strength/dose is not commercially available	
<input type="checkbox"/> Other: _____	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Onzetra® Xsail® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:	Dosage Form:	
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information (required)					
Has the patient had a trial and failure to at least six other triptans in the past 36 months? <input type="checkbox"/> Yes <input type="checkbox"/> No					

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Nurtec ODT™, Qulipta™, Reyvow®, Ubrelvy™ Prior Authorization Request Form
DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Acute treatment of migraine with or without aura	
<input type="checkbox"/> Preventive treatment of episodic migraine in adults	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	
Clinical information:	
Has the patient had a trial and failure of a triptan in the last 120 days? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Has the patient had an inadequate response, intolerance to, or contraindication to triptans? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Does the patient have cardiovascular disease? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Quantity limit requests:	
What is the quantity requested per DAY? _____	
What is the reason for exceeding the plan limitations?	
<input type="checkbox"/> Titration or loading dose purposes	
<input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)	
<input type="checkbox"/> Requested strength/dose is not commercially available	
<input type="checkbox"/> Other: _____	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Uloric Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Chronic gout	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	
Clinical information:	
Has the patient received an adequate trial of at least 1 month of allopurinol? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Does the patient have renal or hepatic dysfunction? <input type="checkbox"/> Yes <input type="checkbox"/> No	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Viberzi™ Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Irritable bowel syndrome with diarrhea (IBS-D)	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Xenazine® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)
Clinical information:
Does the patient have a confirmed diagnosis of chorea associated with Huntington's disease? <input type="checkbox"/> Yes <input type="checkbox"/> No
Is the requested medication prescribed by or in consultation with a neurologist or psychiatrist? <input type="checkbox"/> Yes <input type="checkbox"/> No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Xepi™ Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Impetigo due to <i>Staphylococcus aureus</i> or <i>Streptococcus pyogenes</i>	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	

Medication history: Has the patient had a 10 day trial and failure of mupirocin ointment/cream within the past 6 months? <input type="checkbox"/> Yes <input type="checkbox"/> No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Xifaxan® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Hepatic encephalopathy (HE)	
<input type="checkbox"/> Irritable bowel syndrome with diarrhea (IBS-D)	
<input type="checkbox"/> Travelers' diarrhea	
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____	

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Ambien CR[®], Edluar[™], Intermezzo[®] (zolpidem sublingual tablet [SL]), Zolpimist[™]
Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)

Select the diagnosis below:

Insomnia

Other diagnosis: _____ ICD-10 Code(s): _____

Medication history:

Has the patient had a trial (at least a 14 day trial in the last 365 days) and inadequate response, adverse reaction (prescriber must have documented it on a MedWatch form), or contraindication to generic immediate release oral zolpidem tablets or brand Ambien tablets? Yes No

Quantity limit requests:

What is the quantity requested per DAY? _____

What is the reason for exceeding the plan limitations?

Titration or loading dose purposes

Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)

Requested strength/dose is not commercially available

Other: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.



Belsomra[®], Dayvigo[®], Quviviq[™] Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)
<p>Select the diagnosis below:</p> <p><input type="checkbox"/> Insomnia</p> <p><input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____</p>
<p>Medication history:</p> <p>Has the patient had a trial (at least a 14 day trial in the last 180 days) and inadequate response, adverse reaction (prescriber must have documented it on a MedWatch form), or contraindication to generic immediate release oral zolpidem tablets or brand Ambien tablets? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Quantity limit requests:</p> <p>What is the quantity requested per DAY? _____</p> <p>What is the reason for exceeding the plan limitations?</p> <p><input type="checkbox"/> Titration or loading dose purposes</p> <p><input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)</p> <p><input type="checkbox"/> Requested strength/dose is not commercially available</p> <p><input type="checkbox"/> Other: _____</p>

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.

Therapeutic Class Overview

Attention-Deficit/Hyperactivity Disorder (ADHD) Agents

INTRODUCTION

- Attention-deficit/hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder among children, with an estimated prevalence of up to 10% in school-age children in the United States (US). It is more common in boys than girls and frequently persists into adulthood (*Centers for Disease Control and Prevention [CDC] 2021, Feldman et al 2014*). Epidemiologic studies of adult ADHD have estimated the current prevalence to be 4.4% in the US. (*Bukstein 2022*).
 - In children, this chronic disorder is characterized by symptoms of hyperactivity, impulsivity, and/or inattention. These symptoms affect cognitive, academic, behavioral, emotional, and social functioning (*Krull 2022a*). Common comorbid psychiatric disorders include oppositional defiant disorder, conduct disorder, depression, anxiety disorder, and learning disabilities (*Krull 2022b*). Approximately 20% of children with ADHD develop chronic tic disorders and approximately 50% of children with chronic tics or Tourette syndrome have comorbid ADHD (*Krull 2022c*).
 - ADHD in adults is characterized by symptoms of inattention, impulsivity, and restlessness. Impairment in executive function and emotional dysregulation frequently occur. Common comorbid psychiatric disorders include mood and anxiety disorders, substance use disorder, and intermittent explosive disorder (*Bukstein 2022*).
- For children < 17 years of age, the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) diagnosis of ADHD requires ≥ 6 symptoms of hyperactivity and impulsivity or ≥ 6 symptoms of inattention. For adolescents ≥ 17 years of age and adults, ≥ 5 symptoms of hyperactivity and impulsivity or ≥ 5 symptoms of inattention are required.
 - The symptoms of hyperactivity/impulsivity or inattention must occur often; be present in more than 1 setting; persist for at least 6 months; be present before the age of 12 years; impair function in academic, social, or occupational activities; and be excessive for the developmental level of the child.
 - Other physical, situational, or mental health conditions that could account for the symptoms must be excluded.
- Treatment of ADHD may involve behavioral/psychologic interventions, medication, and/or educational interventions, alone or in combination (*Krull 2022d*).
 - For preschool children (age 4 through 5 years), behavioral therapy is considered the first-line treatment; when medication is necessary, methylphenidate is generally recommended.
 - For children and adolescents with moderate to severe ADHD, medication and behavioral therapy are recommended. In general, stimulants are the first-line agents; however, nonstimulant medications may be more appropriate for certain children.
 - Some patients do not respond to or may not tolerate the initial stimulant treatment. At least one-half of children who do not respond to one type of stimulant will respond to the other. If there is still no improvement, consideration should be given to switching to or adding a nonstimulant ADHD medication (*Krull 2022e*).
- Multiple agents are currently approved by the Food and Drug Administration (FDA) for the treatment of ADHD. They include central nervous system (CNS) stimulants (amphetamine- and methylphenidate-based formulations), as well as nonstimulants: 2 selective norepinephrine reuptake inhibitors (SNRIs), atomoxetine and viloxazine extended-release (ER); and 2 alpha₂-adrenergic agonists, clonidine ER and guanfacine ER.
 - Due to the potential for abuse, the stimulant agents are classified as Schedule II controlled substances.
 - Several stimulants are also approved for the treatment of narcolepsy and exogenous obesity; the use of stimulants for the treatment of obesity will not be covered in this review. Lisdexamfetamine dimesylate is the only FDA-approved drug for the treatment of binge eating disorder (BED).
- Medispan Classes: ADHD Agents – Amphetamines, Dexmethylphenidate, Methylphenidate, Selective Alpha-Adrenergic Agonists, Selective Norepinephrine Reuptake Inhibitor

Table 1. Medications Included Within Class Review

Drug	Generic Availability
Stimulants	
Evekeo (amphetamine sulfate)	✓
Evekeo ODT (amphetamine sulfate)	-
Azstarys (serdexmethylphenidate/dexmethylphenidate)	-
Adderall (mixed amphetamine salts)	✓
Focalin (dexmethylphenidate hydrochloride [HCl])	✓
ProCentra (dextroamphetamine sulfate)	✓
Zenzedi (dextroamphetamine sulfate)	✓
Xelstrym (dextroamphetamine transdermal system)	■
Desoxyn (methamphetamine HCl)	✓
methylphenidate HCl chewable tablets	✓
Methylin Oral Solution (methylphenidate HCl)	✓
Ritalin (methylphenidate HCl)	✓
Dexedrine Spansule (dextroamphetamine sulfate sustained-release)	✓
Adzenys XR-ODT (amphetamine ER)	-
Dyanavel XR (amphetamine ER)	-
Adderall XR (mixed amphetamine salts ER)	✓
Mydayis (mixed amphetamine salts ER)	-
Focalin XR (dexmethylphenidate HCl ER)	✓
Vyvanse (lisdexamfetamine dimesylate)	-
Adhansia XR (methylphenidate HCl ER)*	-
Aptensio XR (methylphenidate HCl ER)	✓
Concerta (methylphenidate HCl ER)	✓
Cotempla XR-ODT (methylphenidate ER)	-
Jornay PM (methylphenidate HCl ER)	-
methylphenidate HCl ER (CD)	✓
methylphenidate HCl ER	✓
QuilliChew ER (methylphenidate HCl ER)	-
Quillivant XR (methylphenidate HCl ER)	-
Relexxii (methylphenidate HCl ER) (72 mg)	✓
Ritalin LA (methylphenidate HCl ER)	✓
Daytrana (methylphenidate transdermal system)	■
Nonstimulants	
Strattera (atomoxetine HCl)	✓
Kapvay (clonidine HCl ER)	✓
Intuniv (guanfacine HCl ER)	✓
Qelbree (viloxazine ER)	-

*Adhansia XR was discontinued by the manufacturer in July 2022.

(Drugs@FDA 2022, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations 2022, Clinical Pharmacology 2022)

INDICATIONS

Table 2. Food and Drug Administration Approved Indications

Indication	ADHD*	ADHD, as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, and social) for a stabilizing effect in pediatric patients with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal electroencephalogram (EEG) may or may not be present, and a diagnosis of CNS dysfunction may or may not be warranted.*	Treatment of ADHD as monotherapy and as adjunctive therapy to stimulant medications	Narcolepsy**	Exogenous obesity, as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction for patients refractory to alternative therapy (eg, repeated diets, group programs, and other drugs).†	Moderate to severe BED in adults
Evekeo (amphetamine sulfate)		✓		✓	✓	
Evekeo ODT (amphetamine sulfate)	✓					
Adzenys XR-ODT, Dyanavel XR (amphetamine)	✓					
Adderall (mixed amphetamine salts)	✓			✓		
Adderall XR, Mydayis (mixed amphetamine salts ER)	✓					
Strattera (atomoxetine HCl)	✓					
Kapvay (clonidine HCl ER)			✓			
Focalin (dexamethylphenidate IR); Focalin XR (dexamethylphenidate ER)	✓					
ProCentra, Zenzedi (dextroamphetamine sulfate IR); Dexedrine Spansule (dextroamphetamine sulfate SR)		✓		✓		
Intuniv (guanfacine HCl ER)			✓			
Vyvanse (lisdexamfetamine dimesylate)	✓					✓

Data as of October 11, 2022 HJ-U/KS-U/AVD

This information is considered confidential and proprietary to OptumRx. It is intended for internal use only and should be disseminated only to authorized recipients. The contents of the therapeutic class overviews on this website ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Clinicians should refer to the full prescribing information and published resources when making medical decisions.

Desoxyn (methamphetamine HCl)		✓			
Ritalin (methylphenidate HCl IR); methylphenidate HCl chewable tablets		✓		✓	
Methylin Oral Solution; methylphenidate ER tablets	✓			✓	
Adhansia XR, Aptensio XR, Concerta, Cotempla XR-ODT, Daytrana, Jornay PM, QuilliChew ER, Quillivant XR, Relexxii, Ritalin LA (methylphenidate ER)	✓				
Azstarys (serdexmethylphenidate/dexmethylphenidate)	✓				
Qelbree (viloxazine ER)	✓				
Xelstrym (dextroamphetamine transdermal)	✓				

(Prescribing Information: Adderall 2022, Adderall XR 2022, Adhansia XR 2021, Adzenys XR-ODT 2022, Aptensio XR 2021, Azstarys 2021, Concerta 2022, Cotempla XR-ODT 2021, Daytrana 2021, Desoxyn 2019, Dexedrine Spansule 2022, Dyanavel XR 2022, Evekeo 2022, Evekeo ODT 2021, Focalin 2021, Focalin XR 2021, Intuniv 2020, Jornay PM 2021, Kapvay 2020, Mydayis 2022, Methylin Oral Solution 2021, methylphenidate chewable tablets 2021, methylphenidate ER 2021, methylphenidate ER (CD) 2021, ProCentra 2021, Qelbree 2022, QuilliChew ER 2021, Quillivant XR 2021, Relexxii 2019, Ritalin 2021, Ritalin LA 2021, Strattera 2022, Vyvanse 2022, Xelstrym 2022, Zenzedi 2022)

*Adderall, Evekeo, ProCentra, and Zenzedi are approved for use in children 3 years of age and older. Evekeo ODT is approved for use in patients 3 to 17 years of age. Daytrana, Desoxyn, Dexedrine Spansule, Intuniv, and Kapvay are approved for use in children 6 years of age and older. Adderall XR, Adhansia XR, Adzenys XR-ODT, Aptensio XR, Azstarys, Dyanavel XR, Focalin, Focalin XR, Jornay PM, methylphenidate ER (CD), methylphenidate ER, Methylin Oral Solution, methylphenidate chewable tablets, Qelbree, QuilliChew ER, Quillivant XR, Ritalin, Strattera, Vyvanse, and Xelstrym are approved for use in patients 6 years of age and older. Cotempla XR-ODT is approved for use in pediatric patients 6 to 17 years of age. Ritalin LA is approved for use in pediatric patients 6 to 12 years of age. Concerta and Relexxii are approved for use in children 6 years of age and older, adolescents, and adults up to 65 years of age. Mydayis is approved for use in patients 13 years of age and older.

**These drugs are approved for use in patients 6 years of age and older.

†These drugs are not recommended for use in children under 12 years of age for treatment of exogenous obesity. The limited usefulness of these products should be weighed against possible risks inherent in use of the drugs.

- Limitation of use:
 - Aptensio XR: Pediatric patients younger than 6 years of age experienced higher plasma exposure than patients 6 years and older at the same dose and high rates of adverse events (AEs), most notably weight loss.
 - Lisdexamfetamine: Pediatric patients younger than 6 years of age experienced more long-term weight loss than patients 6 years and older. Lisdexamfetamine is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular (CV) AEs. The safety and effectiveness of this drug for the treatment of obesity have not been established.
 - Mydayis: Pediatric patients 12 years and younger experienced higher plasma exposure than patients 13 years and older at the same dose and experienced higher rates of AEs, mainly insomnia and decreased appetite.
 - Xelstrym: Pediatric patients younger than 6 years of age experienced more long-term weight loss than patients 6 years and older.
- Information on indications, mechanism of action, pharmacokinetics, dosing, and safety has been obtained from the prescribing information for the individual products, except where noted otherwise.

CLINICAL EFFICACY SUMMARY

- Randomized trials, systematic reviews, and meta-analyses have found stimulants, SNRIs (atomoxetine, viloxazine ER), and alpha₂-adrenergic agonists (clonidine ER, guanfacine ER) to be more efficacious than placebo in reducing the core symptoms of ADHD in children and adolescents.

Data as of October 11, 2022 HJ-U/KS-U/AVD

Page 157

This information is considered confidential and proprietary to OptumRx. It is intended for internal use only and should be disseminated only to authorized recipients. The contents of the therapeutic class overviews on this website ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Clinicians should refer to the full prescribing information and published resources when making medical decisions.

- Evekeo (amphetamine sulfate) was approved based on a randomized, double-blind (DB), multicenter (MC), placebo-controlled (PC) laboratory classroom study that was conducted in 107 children between the ages of 6 and 12 years (*Childress et al 2015*). The study found Evekeo to be associated with significant improvements in the average Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) combined score compared to placebo (least squares [LS] mean difference -7.9; 95% confidence interval [CI], -10.1 to -5.6; $p < 0.0001$).
 - Evekeo ODT, an orally disintegrating amphetamine tablet, was approved under the 505(b)(2) regulatory pathway. The safety and effectiveness of Evekeo ODT for the treatment of ADHD was established based on an adequate and well-controlled study of Evekeo (*Childress et al 2015*).
- Cotelpla XR-ODT, a new methylphenidate ER orally disintegrating tablet formulation, was approved based on a randomized, DB, MC, PC laboratory classroom study (*Childress et al 2017*) (N = 87) which found that the average SKAMP-combined score was significantly better for Cotelpla XR-ODT than for placebo (LS mean 14.3 [95% CI, 12.2 to 16.4] vs 25.3 [9% CI, 23.0 to 27.6], respectively; $p < 0.0001$).
- Adhansia XR (methylphenidate ER capsule) was approved via the 505(b)(2) regulatory pathway, and its efficacy was supported by 4 clinical studies in patients with ADHD including 2 studies conducted in adults, 1 study in adolescents 12 to 17 years of age, and 1 study in pediatric patients 6 to 12 years of age (*Adhansia XR FDA Clinical Review 2019*):
 - One randomized, DB, MC, PC 4-week study conducted in 368 adult patients with ADHD evaluated the safety and efficacy of 4 doses of Adhansia XR (25, 45, 70, and 100 mg) compared to placebo. The primary endpoint, change in the ADHD-Rating Scale (ADHD-RS)-5 total score from baseline to Week 5, was significantly improved compared to placebo in the Adhansia XR 45 mg group (LS mean difference, -6.9; 95% CI, -11.5 to -2.2; $p = 0.0013$), 100 mg group (LS mean difference, -8.1; 95% CI, -12.9 to -3.2; $p = 0.0002$), and when combining all dosage groups compared to placebo (LS mean difference, -4.7; 95% CI, -7.7 to -1.6; $p = 0.0026$). No significant difference was seen in the 25 mg or 70 mg groups compared to placebo.
- A second randomized, DB, crossover, PC study was conducted in 45 adults in an adult workplace environment (*Adhansia XR FDA Clinical Review 2019, Wigal et al 2020*). The study aimed to assess efficacy parameters for Adhansia XR vs placebo over 16 hours post-dose. Patients were titrated to an optimal dose of Adhansia XR (either 25, 35, 45, 55, 70, 85, or 100 mg) during an open-label (OL) treatment period between 2 and 7 weeks, then entered into a 1-week PC, DB treatment phase prior to the adult workplace environment session, followed by a 7-day washout period between crossover periods, then another 1-week treatment phase followed by another adult workplace environment session. The primary endpoint was the average Permanent Product Measure of Performance (PERMP) score for various time points up to 16 hours post-dose. When combining data from all time points, patients treated with Adhansia XR had significant improvements in the PERMP score compared to placebo (LS mean difference, 13.05; 95% CI, 3.88 to 22.23; $p = 0.0064$).
- A 4-week randomized, DB, PC trial assessed efficacy of Adhansia XR in 354 adolescent patients 12 to 17 years of age (*Adhansia XR FDA Clinical Review 2019*). The study compared Adhansia XR 25, 45, 70, and 85 mg to placebo and found significant improvements in the ADHD-5-RS score from baseline to Week 5 in adolescents treated with Adhansia XR 45 mg (LS mean difference, -5.4; 95% CI, -9.2 to -1.6; $p = 0.0052$), 70 mg (LS mean difference, -5.2; 95% CI, -9.0 to -1.4; $p = 0.0069$), and when combining all dosage groups compared to placebo (LS mean difference, -4.3; 95% CI, -7.3 to -1.3; $p = 0.0049$). Adolescents treated with Adhansia XR 25 or 85 mg did not achieve significant improvements in the ADHD-5-RS score compared to placebo.
 - A fourth study, which included a 6-week OL dose optimization period (majority of patients received between 45 and 55 mg of Adhansia XR) followed by a 1-week DB, PC study, was conducted to assess the efficacy of Adhansia XR in 147 children 6 to 12 years of age in an analog classroom setting. The primary endpoint, average SKAMP-C score (taken at various time points up to 13 hours post-dose), was significantly improved in children treated with Adhansia XR compared to placebo (LS mean difference, -8.6; 95% CI, -10.6 to -6.6).
- Jornay PM, an ER methylphenidate capsule formulation, was approved based on the results of 2 clinical studies conducted in patients 6 to 12 years of age with ADHD:
 - The first study was a 6-week OL dose-optimization study, followed by a 1-week DB, PC withdrawal phase where patients were randomized to continue treatment with Jornay PM or switch to placebo (*Childress et al 2020, Jornay PM Prescribing Information 2021*). The study, which was conducted in an analog classroom setting and included 117 children aged 6 to 12 years, found that Jornay PM was associated with a significant reduction in the SKAMP symptom score over a 12-hour period (LS mean difference, -5.9; 95% CI, -9.1 to -2.7).
 - A randomized, DB, MC, PC, parallel group, forced-dose titration trial was conducted over 3 weeks in 161 children 6 to 12 years of age with ADHD (*Pliszka et al 2017*). The study found that 40 to 80 mg/day of Jornay PM achieved significant improvements vs placebo in ADHD symptoms (LS mean ADHD rating scale-IV, 24.1 vs 31.2; $p = 0.002$)

at 3 weeks. Significant improvements were also seen vs placebo in key secondary outcomes including at-home early morning and late afternoon/evening functional impairment at 3 weeks. The most commonly reported treatment-emergent AEs were insomnia and decreased appetite.

- Mydayis, a mixed amphetamine salts product, was approved for the treatment of ADHD based on the results of 5 MC, DB, PC, randomized controlled trials (RCTs): 3 in adults and 2 in pediatric patients 13 to 17 years of age. The studies found that Mydayis demonstrated a statistically significant treatment effect compared with placebo on various ADHD outcomes measures (eg, ADHD-RS score, PERMP score) (*Mydayis Prescribing Information 2022, Weisler et al 2017, Wigal et al 2018a, Wigal et al 2018b, Wigal et al 2019*) (see results below in Table 3 below). An additional 6-week, randomized, PC, DB, forced dose titration trial in 411 adults with ADHD similarly found that Mydayis significantly improved ADHD-RS-IV scores compared to placebo (LS mean treatment difference for all Mydayis doses combined vs placebo, -10.6; 95% CI, -13.2 to -8.0; $p < 0.0001$) (*Frick et al 2020*).

Table 3. Summary of Primary Efficacy Results for Mydayis

Study Number (Age range)	Primary Endpoint	Treatment Group	Mean Baseline Score (SD)	LS Mean Change from Baseline	Placebo-subtracted Difference (95% CI)
Adult Studies					
Study 1 (18 to 55 years)	ADHD-RS	Mydayis 12.5 mg/day [§]	39.8 (6.38)	-18.5	-8.1 (-11.7 to -4.4)
		Mydayis 37.5 mg/day [§]	39.9 (7.07)	-23.8	
		Placebo	40.5 (6.52)	-10.4	
Study 2 (18 to 55 years)	Average PERMP	Mydayis 50 mg/day [§]	239.2 (75.6) [†]	293.23*	18.38 (11.28 to 25.47)
		Placebo	249.6 (76.7) [†]	274.85*	
Study 3 (18 to 55 years)	Average PERMP	Mydayis 25 mg/day [§]	217.5 (59.6) [†]	267.96*	19.29 (10.95 to 27.63)
		Placebo	226.9 (61.7) [†]	248.67*	
Pediatric Studies					
Study 4 (13 to 17 years) [‡]	ADHD-RS-IV	Mydayis 12.5 to 25 mg/day [§]	36.7 (6.15)	-20.3	-8.7 (-12.6 to -4.8)
		Placebo	38.3 (6.67)	-11.6	
Study 5 (13 to 17 years)	Average PERMP	Mydayis 25 mg/day [§]	214.5 (87.8) [†]	272.67*	41.26 (32.24 to 50.29)
		Placebo	228.7 (101) [†]	231.41*	

SD = standard deviation; LS = least squares; CI = confidence interval

[†]Pre-dose PERMP total score

*LS mean for PERMP is post-dose average score over all sessions of the treatment day, rather than change from baseline

[‡]Results are for a subgroup of study 4 and not the total population

[§]Doses statistically significant for placebo

- Azstarys, a combination of serdexmethylphenidate and dexamethylphenidate, was approved based on results from a randomized, DB, PC analog classroom study (*Kollins et al 2021*). A total of 150 patients aged 6 to 12 years were enrolled. Following an OL, 3-week dose titration phase, patients were randomly assigned during a 1-week parallel treatment period to either the optimized dose Azstarys or placebo. After 1 week, evaluations were done using the SKAMP rating scale over 13 hours in a classroom setting. Mean change in SKAMP from baseline (primary outcome) was significantly greater with Azstarys compared with placebo (placebo-subtracted difference -5.41; 95% CI, -7.10 to -3.71; $p < 0.001$). The efficacy of Azstarys in adults and pediatric patients 13 to 17 years of age was established by pharmacokinetic bridging between Azstarys and Focalin XR (dexamethylphenidate ER) capsules.
- Qelbree (viloxazine ER), an SNRI, was shown to be superior to placebo in 3 DB, MC, randomized, PC trials in pediatric patients with ADHD.
 - Trial 1 enrolled 313 patients aged 6 to 11 years who were randomized to treatment with viloxazine ER 200 or 400 mg or placebo once daily for 8 weeks (*Nasser 2021b*). Improvements in ADHD-RS-5 total scores were reported, with LS mean changes from baseline of -17.6, -17.5 and -11.7 for viloxazine ER 200 mg, 400 mg, and placebo, respectively ($p < 0.05$ for both comparisons to placebo).

- Trial 2 enrolled 477 patients aged 6 to 11 years who were randomized to either viloxazine ER 100 mg or 200 mg or placebo once daily for 6 weeks (*Nasser 2020*). LS mean changes from baseline in ADHD-RS-5 total scores were -16.6, -17.7, and -10.9 for viloxazine ER 100 mg, 200 mg, and placebo, respectively ($p < 0.05$ and $p < 0.0001$ for viloxazine ER 100 mg and 200 mg vs placebo, respectively).
- A third trial evaluated viloxazine ER in 310 patients aged 12 to 17 years of age who were randomized to viloxazine ER 200 mg, 400 mg, or placebo (*Nasser 2021a*). After 6 weeks of treatment, viloxazine ER 200 mg and 400 mg resulted in LS mean changes from baseline in ADHD-RS-5 total scores of -16.0, -16.5, and -11.4 for viloxazine ER 200 mg, 400 mg, and placebo, respectively ($p < 0.05$ vs placebo for both comparisons).
- The Dyanavel XR (amphetamine ER) tablet was approved in November 2021 for the treatment of patients 6 years and older. The pharmacokinetic profile of the Dyanavel XR tablet was established to be bioequivalent to that of the Dyanavel XR oral suspension (*Dyanavel XR Prescribing Information 2022*). The safety and efficacy of the ER tablet were evaluated in a randomized, DB, PC, fixed-dose study in 130 adult patients with ADHD (*Cutler et al 2022a*). Patients entered a 5-week, DB, dose-titration phase in which they were randomized to receive Dyanavel XR tablet or matching placebo once daily in the morning. The starting dose of 5 mg was titrated in 5-mg increments per week, and patients received a final dose of 20 mg for 14 ± 3 days before visit 5. The primary endpoint of mean PERMP-Total score (PERMP-T) across all postdose time points at visit 5 was significantly higher (improved) in the Dyanavel XR tablet group compared to the placebo group (302.8 vs 279.6; $p = 0.0043$).
- Xelstrym (dextroamphetamine transdermal system) was approved by the FDA in 2022 for the treatment of ADHD in adults and pediatric patients aged 6 to 17 years. Its efficacy was supported by previous, well-controlled studies of lisdexamfetamine in pediatric and adult patients, in addition to a MC, DB, randomized, PC, modified analog classroom study in pediatric patients aged 6 to 17 years (*Cutler et al 2022b*). The study was conducted in 2 periods, and Xelstrym patches delivering different doses (5, 10, 15, and 20 mg) were evaluated. Patients were enrolled in a 5-week, OL, stepwise dose-optimization period in which they were started on a 5-mg patch and evaluated weekly for possible adjustments to the next dose level. Once the optimal dose was reached, it was maintained during a 2-week, crossover, DB treatment period. A total of 106 patients entered the DB treatment period. The study found Xelstrym to be associated with significant improvement in the SKAMP total score compared to placebo (LS mean difference -5.87; 95% CI, 6.76 to -4.97; $p < 0.001$).
- A systematic (Cochrane) review of 185 RCTs (*Storebø et al 2015*) ($N = 12,245$) in children and adolescents with ADHD found that methylphenidate may improve teacher-rated ADHD symptoms, teacher-reported general behavior, and parent-reported quality of life (QOL) vs placebo. However, the evidence was of low quality.
- An RCT called the Preschool ADHD Treatment Study (PATS) (*Greenhill et al 2006*) evaluated the efficacy of methylphenidate immediate-release (IR) in 303 preschool children with ADHD and found that it demonstrated significant reductions on ADHD symptom scales; however, the effect sizes (0.4 to 0.8) were smaller than those generally reported for school-age children.
- A systematic (Cochrane) review of 23 PC, RCTs (*Punja et al 2016*) ($N = 2675$) found that amphetamines were effective at improving the core symptoms of ADHD, but they were also associated with a higher risk of AEs compared to placebo. There was no evidence that one kind of amphetamine was better than another and there was no difference between short-acting and long-acting formulations.
- A meta-analysis of 25 DB, PC, RCTs (*Schwartz et al 2014*) ($N = 3928$) in children and adolescents with ADHD found atomoxetine to be superior to placebo for overall ADHD symptoms, with a medium effect size (-0.64).
- A meta-analysis of 25 RCTs (all rated as low or very low quality evidence) in children with autism and concurrent ADHD symptoms concluded that methylphenidate and atomoxetine both reduced parent-rated hyperactivity and inattention (*Rodrigues et al 2021*). Methylphenidate also reduced teacher-rated hyperactivity and inattention, but atomoxetine only reduced teacher-rated inattention.
- A meta-analysis of 12 RCTs (*Hirota et al 2014*) ($N = 2276$) in pediatric patients with ADHD found that alpha₂-adrenergic agonists were significantly superior to placebo for overall ADHD symptoms both as monotherapy and, to a lesser extent, as augmentation therapy to stimulants.
 - Meta-analytic results failed to demonstrate a significant difference in efficacy between alpha₂-adrenergic agonists. In sub-analyses of individual formulations, the ER formulations separated robustly from placebo whereas the IR formulations did not separate from placebo.
- A systematic review of 16 RCTs and 1 meta-analysis (*Chan et al 2016*) ($N = 2668$) found evidence supporting the use of methylphenidate ER and amphetamine ER formulations, atomoxetine, and guanfacine ER for the treatment of ADHD in adolescents. For the primary outcome measure of mean change in ADHD-RS total symptom score, both stimulant and nonstimulant medications led to clinically significant reductions of 14.93 to 24.60 points.

- For the treatment of ADHD in children and adolescents, stimulants typically have a slightly larger treatment effect size (standardized mean difference [SMD]) than nonstimulants (approximately 1.0 vs approximately 0.7 for both atomoxetine and alpha₂-adrenergic agonists). However, there is insufficient evidence to definitively conclude that one stimulant is more efficacious than another (*Krull 2022e, Wolraich et al 2019*).
 - An Agency for Healthcare Research and Quality (AHRQ) review of 78 studies (*Jadad et al 1999*) evaluating the efficacy of various interventions for the treatment of ADHD in children and adults found few, if any, differences between methylphenidate and dextroamphetamine.
 - A meta-analysis of 23 DB, PC trials (*Faraone 2010a*) comparing the efficacy of methylphenidate and amphetamine formulations found that amphetamine products may be moderately more efficacious than methylphenidate products.
 - A DB, PC, RCT (*Newcorn et al 2008*) (N = 516) comparing the efficacy of atomoxetine vs methylphenidate ER (osmotic-release formulation) in patients 6 to 16 years of age with ADHD found that both drugs were superior to placebo in terms of response rate, and that methylphenidate ER was superior to atomoxetine.
 - A meta-analysis of 29 DB, PC trials (*Faraone et al 2006*) evaluated the efficacy of various medications (methylphenidate and amphetamine compounds, atomoxetine, pemoline [no longer available in the US], bupropion, and modafinil) for the treatment of ADHD. The effect sizes for nonstimulant medications were significantly less than those for IR stimulants or long-acting stimulants. The 2 classes of stimulant medications did not differ significantly from one another.
 - A meta-analysis of 28 DB, PC, RCTs (*Stuhec et al 2015*) (N = 4699) compared the efficacy of various medications for the treatment of ADHD in children and adolescents. Efficacy in reducing ADHD symptoms compared to placebo was small for bupropion (SMD, -0.32; 95% CI, -0.69 to 0.05), modest for atomoxetine (SMD, -0.68; 95% CI, -0.76 to -0.59) and methylphenidate (SMD, -0.75; 95% CI, -0.98 to -0.52), and highest for lisdexamfetamine (SMD, -1.28; 95% CI, -1.84 to -0.71).
 - A network meta-analysis and mixed treatment comparison of 36 RCTs (*Joseph et al 2017*) evaluating the comparative efficacy and safety of ADHD pharmacotherapies in children and adolescents found that lisdexamfetamine had greater efficacy than guanfacine ER, atomoxetine, and methylphenidate ER. Guanfacine ER had a high posterior probability of being more efficacious than atomoxetine, but their credible intervals overlapped.
 - A network meta-analysis of 48 DB, RCTs (*Padilha et al 2018*) compared the safety and efficacy of various ADHD medications in children and adolescents. Of the 12 trials that were evaluated for efficacy, analysis was performed using the Clinical Global Impression Improvement (CGI-I) scale for 3 drugs, which showed that methylphenidate was more effective than atomoxetine (MD, 3.15; 95% CI, 0.75 to 13.71) and guanfacine (MD, 1.92; 95% CI, 0.64 to 5.94). Thirty-three trials were evaluated for safety. Ranking of AEs showed that lisdexamfetamine was more likely to cause sleep disorders, loss of appetite, and behavior problems compared to other treatments.
- Alpha₂-adrenergic agonists have been associated with improvements in ADHD symptoms and comorbid tics.
 - A meta-analysis of 9 DB, PC, RCTs (*Bloch et al 2009*) (N = 477) was conducted to determine the relative efficacy of different medications in treating ADHD and tic symptoms in children with both Tourette syndrome and ADHD.
 - Methylphenidate seemed to offer the greatest improvement of ADHD symptoms and did not seem to worsen tic symptoms.
 - Alpha₂-adrenergic agonists offered the best combined improvement in both tic and ADHD symptoms.
 - Atomoxetine significantly improved both tic and ADHD severity compared to placebo.
 - One small study found that tic severity was significantly increased with higher doses of dextroamphetamine treatment.
 - A Cochrane review of 8 RCTs (*Osland et al 2018*) including 510 children with both ADHD and a chronic tic disorder found low-quality evidence for improvement of ADHD symptoms with methylphenidate, atomoxetine, and clonidine, and very low-quality evidence for desipramine, dextroamphetamine, guanfacine, and deprenyl. Tic symptoms improved with guanfacine, desipramine, methylphenidate, clonidine, and a combination of methylphenidate and clonidine. The authors noted that in 1 study with a short duration (3 weeks), high doses of dextroamphetamine worsened tics.
- There are limited efficacy data regarding the treatment of ADHD in the adult population. Comparison of effect sizes in clinical trials suggests that stimulant medications are more efficacious in adult ADHD than nonstimulants.
 - In April 2022, the FDA approved an expanded indication for Qelbree for the treatment of ADHD in adults based on the results of a DB, MC, randomized, PC, flexible-dose, parallel-group monotherapy trial (*Qelbree Prescribing Information 2022, Nasser 2022*). A total of 374 patients with ADHD aged 18 to 65 years were randomized to receive viloxazine ER (flexible dose of 200 to 600 mg/day) or matching placebo for 6 weeks. The primary and secondary endpoints were the change in the Adult ADHD Investigator Symptom Rating Scale (AISRS) total score and the Clinical Global Impressions-Severity of Illness (CGI-S) score, respectively, from baseline at end of study. Patients in the viloxazine

ER group had a greater reduction in the AISRS total score than the placebo group (LS mean change, -15.5 vs -11.7; $p = 0.0040$). A significantly greater reduction in the CGI-S score was also seen in patients treated with viloxazine ER compared to placebo (LS mean change, -1.4 vs -1.0; $p = 0.0023$).

- In a meta-analysis of 12 clinical trials (*Cunill et al 2013*) (N = 3375) comparing atomoxetine with placebo in adult ADHD, atomoxetine led to a modestly greater reduction in ADHD symptom severity but was associated with higher all-cause discontinuation.
- A meta-analysis (*Faraone 2010b*) of 19 randomized trials of 13 medications for adult ADHD found a greater average effect size for reduction in ADHD symptoms in patients receiving short- and long-acting stimulant medications (vs placebo; 0.86 and 0.73, respectively) compared with patients receiving nonstimulant medication (vs placebo; 0.39). No difference in effect size was found between short- and long-acting stimulants.
- A meta-analysis of 20 randomized trials (*Stuhec et al 2019*) compared the efficacy, acceptability, and tolerability of lisdexamfetamine, mixed amphetamine salts, methylphenidate, and modafinil in the treatment of ADHD in adults. The highest effect size in reducing ADHD symptoms was found with lisdexamfetamine (SMD -0.89; 95% CI, -1.09 to -0.70), while moderate reductions in symptoms were seen with mixed amphetamine salts (SMD -0.64; 95% CI, -0.83 to -0.45) and methylphenidate (SMD -0.50; 95% CI, -0.58 to -0.41). No efficacy was reported with modafinil.
- A Cochrane review of 19 studies (*Castells et al 2018*, N = 2521) comparing dextroamphetamine, lisdexamfetamine, and mixed amphetamine salts for the treatment of ADHD in adults found that overall, amphetamines reduced the patient- and clinician-rated severity of ADHD symptoms compared to placebo; however, they did not improve retention in treatment. Amphetamines were associated with an increased proportion of patients who withdrew because of AEs. When comparing different types of amphetamines, lisdexamfetamine and mixed amphetamine salts reduced the severity of ADHD symptoms as rated by clinicians, but dextroamphetamine did not. No differences in any outcome were found when comparing immediate- and sustained-release formulations.
- A systematic review and network meta-analysis (*Elliot et al 2020*) of 81 RCTs compared methylphenidate, atomoxetine, dexamfetamine, lisdexamfetamine, guanfacine, mixed amphetamine salts, modafinil, and bupropion for the treatment of ADHD in adults. Treatment with any ADHD pharmacotherapy was associated with statistically significant improvement in patient-reported clinical response vs placebo. When drugs were analyzed individually, only atomoxetine was found to significantly improve patient-reported clinical response compared to placebo (mean difference [MD], -5.9; 95% CI, -12.6 to -0.4). Atomoxetine (MD, -3.7; 95% CI, -6.7 to -0.9), sustained-release methylphenidate (MD, -5.7; 95% CI, -11.2 to -0.3), and low-dose methylphenidate (MD, -10.4; 95% CI, -19.0 to -2.1) were found to improve clinician-assessed clinical response compared to placebo. No significant differences were observed between individual medications when response was considered as a continuous outcome.
- Another meta-analysis (*Cortese et al 2018*) of 133 RCTs comparing the use of amphetamines, atomoxetine, bupropion, clonidine, guanfacine, methylphenidate, and modafinil for the treatment of ADHD found that all drugs were superior to placebo for ADHD core symptoms as rated by clinicians in children and adolescents, and all drugs except for modafinil were more efficacious than placebo in adults.
 - When comparing the various drugs based on teachers' ratings in children and adolescents, only methylphenidate and modafinil were found to be more efficacious than placebo.
 - In head-to-head comparisons, differences in efficacy based on clinicians' ratings were found, favoring amphetamines over modafinil (SMD, -0.39; 95% CI -0.67 to -0.12), atomoxetine (SMD, -0.46; 95% CI, -0.65 to -0.27), and methylphenidate (SMD, -0.24; 95% CI, -0.44 to -0.05) in children and adolescents. Efficacy results based on clinicians' ratings were similar for adults, and favored amphetamines over modafinil (SMD, -0.94; 95% CI -1.43 to -0.46), atomoxetine (SMD, -0.34; 95% CI, -0.58 to -0.10), and methylphenidate (SMD, -0.29; 95% CI, -0.54 to -0.05).
- Lisdexamfetamine dimesylate has demonstrated efficacy in the treatment of BED. Direct comparison trials between lisdexamfetamine and other drugs used off-label to treat BED are lacking.
 - In 2 Phase 3, 12-week, randomized, DB, PC trials (*McElroy et al 2016*) (N = 773) in patients with moderate to severe BED, lisdexamfetamine-treated patients had a statistically significantly greater reduction from baseline in mean number of binge days per week at week 12 vs placebo (treatment difference in study 1: -1.35; 95% CI, -1.70 to -1.01; study 2: -1.66; 95% CI, -2.04 to -1.28; both $p < 0.001$).
 - A 12-month, OL extension study (*Gasior et al 2017*) (N = 599) in adults with BED found that the long-term safety and tolerability of lisdexamfetamine were generally consistent with the safety profile observed in 3 previous short-term trials in BED as well as its established profile for ADHD. Common treatment-emergent AEs included dry mouth, headache, insomnia, and upper respiratory tract infection. Weight loss and increases in blood pressure and pulse rate were also observed.

- In a Phase 3, DB, randomized, PC, withdrawal study (*Hudson et al 2017*) (N = 418) in adults with moderate to severe BED, responders to lisdexamfetamine during a 12-week OL phase were randomized to placebo or continued lisdexamfetamine during a 26-week, DB phase. The percentage of patients meeting relapse criteria was 3.7% with lisdexamfetamine vs 32.1% with placebo; time to relapse statistically favored lisdexamfetamine ($p < 0.001$). The hazard ratio (HR) was 0.09 (95% CI, 0.04 to 0.23).
- A systematic review and meta-analysis of 14 clinical and 7 preclinical trials concluded that lisdexamfetamine effectively treats BED and reduces both symptoms (MD, 0.93; 95% CI, 0.74 to 1.12) and body weight (based on systematic review only) (*Schneider et al 2021*).
- A systematic review and meta-analysis of 9 waitlist-controlled psychological trials and 25 PC trials evaluating pharmacologic (n = 19) or combination (n = 6) treatment for BED (*Brownley et al 2016*) found that therapist-led cognitive behavioral therapy (CBT), lisdexamfetamine, and second-generation antidepressants (SGAs) increased binge-eating abstinence (relative risk [RR], 4.95 [95% CI, 3.06 to 8.00], 2.61 [95% CI, 2.04 to 3.33], and 1.67 [95% CI, 1.24 to 2.26], respectively), while lisdexamfetamine and SGAs decreased binge-eating frequency (MD in days/week, -1.35 [95% CI, -1.77 to -0.93] and -0.67 [95% CI, -1.26 to -0.09], respectively). Topiramate and other forms of CBT also increased abstinence and reduced binge-eating frequency.
- A 2018 systematic review and meta-analysis of 45 RCTs (*Ghaderi et al 2018*) compared various psychological, pharmacological, and combined treatments for BED, and found moderate support for the efficacy of CBT and CBT-guided self-help (moderate quality of evidence), and low-quality evidence to support interpersonal psychotherapy, selective serotonin reuptake inhibitors (SSRIs), and lisdexamfetamine for the cessation of or reduction in the frequency of binge eating. Only lisdexamfetamine showed a modest effect on weight loss (SMD for body mass index -5.23; 95% CI, -6.52 to -3.94).

CLINICAL GUIDELINES

ADHD

- Several clinical guidelines have provided recommendations on the treatment of ADHD in children and adolescents.
 - According to the American Academy of Pediatrics (AAP) guidelines (*Wolraich et al 2019*), the evidence is particularly strong for stimulant medications, and sufficient but less strong for atomoxetine, guanfacine ER, and clonidine ER (in that order; newer agents such as serdexmethylphenidate/dexmethylphenidate [Azstarys] and viloxazine [Qelbree] are not addressed in the current guidelines). Guanfacine ER and clonidine ER have evidence to support their use as adjunctive therapy with stimulant medications. Methylphenidate is recommended for preschool-aged children who have had an inadequate response to behavioral interventions.
 - The Society for Developmental and Behavioral Pediatrics guideline on assessment and treatment of children and adolescents with complex ADHD states that treatment should aim to improve functional impairment and include skill development in self-management strategies (*Barbaresi et al 2020*). Multimodal treatment with both behavioral and pharmacologic therapies may be needed. Specific pharmacologic classes are discussed in the context of learning disorder, for which the guideline recommends both stimulants and atomoxetine, with stimulants having a greater strength of evidence, and autism, for which a stimulant is recommended first followed by an alpha₂-adrenergic agonist or atomoxetine. Stimulant use is also endorsed in children with intellectual disability, tics, anxiety or depression, and disruptive behavior disorders.
 - The Medical Letter recommends that treatment of ADHD in school-age children or adults should begin with a stimulant, either a methylphenidate- or amphetamine-based formulation (*Med Lett Drugs Ther 2020*). Mixing short- and long-acting stimulants can be helpful to achieve an immediate effect for early-morning school classes or for reducing rebound irritability or overactivity, especially in the evening. Nonstimulants can be used in combination with stimulants or when stimulants are contraindicated, ineffective, or not tolerated.
 - According to the American Academy of Neurology guidelines for treatment of tics (*Pringsheim et al 2019*), physicians should counsel individuals with tics and comorbid ADHD that alpha₂-adrenergic agonists may provide benefit for both conditions. Alpha₂-adrenergic agonists and topiramate should be prescribed for the treatment of tics when the benefits of treatment outweigh the risks, while antipsychotics and botulinum toxin may be prescribed when the benefits outweigh the risks.
 - The American Academy of Child and Adolescent Psychiatry (AACAP) practice parameter for the treatment of children and adolescents with tic disorders (*Murphy et al 2013*) states that alpha₂-adrenergic agonists have demonstrated an effect size of 0.5 for the amelioration of tics and may be preferred by some prescribers over antipsychotics due to their relatively favorable AE profile.

Narcolepsy

- The American Academy of Sleep Medicine (AASM) practice parameters (*Maski et al 2021*) recommend various drugs for the treatment of daytime sleepiness in adults due to narcolepsy including modafinil, pitolisant, sodium oxybate, solriamfetol (strongly recommended), and armodafinil, dextroamphetamine, and methylphenidate (conditionally recommended). Idiopathic hypersomnia in adults should be treated with modafinil (strongly recommended), clarithromycin, methylphenidate, pitolisant, or sodium oxybate (conditionally recommended). Recommended therapies for children with narcolepsy include modafinil and sodium oxybate (both conditionally recommended),

BED

- According to the American Psychiatric Association (APA) practice guidelines on eating disorders (*Yager et al 2006, Yager et al 2012* [guideline watch update], now categorized as a legacy guideline), treatment of BED may include the following:
 - Nutritional rehabilitation and counseling
 - Psychosocial treatment
 - CBT, behavior therapy, dialectical behavior therapy (DBT), and interpersonal therapy (IPT) have all been associated with binge frequency reduction rates of 67% or more and significant abstinence rates during active treatment.
 - Self-help programs using self-guided, professionally designed manuals have been effective in reducing the symptoms of BED in the short-run for some patients and may have long-term benefit.
 - Medications
 - Antidepressant treatment is associated with short-term reductions in binge-eating but generally does not result in substantial weight loss. SSRIs have the fewest difficulties with AEs and the most evidence for efficacy when used at the high end of the recommended dose range.
 - Topiramate can reduce bingeing and decrease weight, but its use may be limited by AEs.
 - Combination psychotherapy and pharmacotherapy
 - For most patients, adding antidepressant therapy to a behavioral weight control and/or CBT regimen does not have a significant effect on binge suppression.
 - Although limited evidence is available, combined treatment is frequently used in clinical practice.
- The American Association of Clinical Endocrinologists and the American College of Endocrinology (AACE/ACE) guidelines for medical care of patients with obesity (*Garvey et al 2016*) recommend the following for patients with overweight or obesity who have BED:
 - Patients should be treated with a structured behavioral/lifestyle program, combined with CBT or other psychological interventions
 - Treatment with orlistat or approved medications containing topiramate or bupropion may be considered in conjunction with structured lifestyle therapy, CBT, and/or psychological interventions
- The Task Force on Eating Disorders of the World Federation of Societies of Biological Psychiatry (*Aigner et al 2011*) concluded that for the treatment of BED, grade A evidence supports the use of imipramine (moderate risk-benefit ratio), sertraline (good risk-benefit ratio), citalopram/escitalopram (good risk-benefit ratio), orlistat (low to moderate risk-benefit ratio), and topiramate (moderate risk-benefit ratio). Atomoxetine has grade B evidence supporting its use.

SAFETY SUMMARY

- Due to the potential for abuse, the stimulants are classified as Schedule II controlled substances. Atomoxetine, clonidine ER, guanfacine ER, and viloxazine ER are not classified as controlled substances.
- Various stimulants are contraindicated for use in patients with advanced arteriosclerosis, symptomatic CV disease, moderate to severe hypertension, hyperthyroidism, hypersensitivity to sympathomimetic amines, glaucoma, agitated states, history of drug abuse, tics, and in those using monoamine oxidase inhibitors (MAOIs). The stimulants carry a boxed warning for potential drug abuse and dependence. They also have warnings for increased risks of serious CV reactions, psychiatric AEs, suppression of growth, seizures, visual disturbance, peripheral vasculopathy, and priapism. Amphetamines have a warning for risk of serotonin syndrome when used in combination with other drugs affecting the serotonergic neurotransmitter systems.
 - Common AEs of stimulants include anorexia, decreased weight, tachycardia, anxiety, irritability, and insomnia.
 - Refer to the prescribing information for details on warnings, precautions, and AEs for individual products. For example:
 - QuilliChew ER can be harmful to patients with phenylketonuria (PKU) since it contains phenylalanine.

- Because Concerta and Relexxii tablets are nondeformable and do not appreciably change in shape in the gastrointestinal tract, they should not ordinarily be administered to patients with preexisting severe gastrointestinal narrowing.
- The use of Daytrana and Xelstrym may lead to contact sensitization; in addition, exposure of the application site to external heat sources should be avoided due to increased absorption of the drug. Daytrana use may result in chemical leuokoderma.
- Adhansia XR capsules contain FD&C yellow No. 5 dye (tartrazine), which may cause allergic-type reactions in susceptible patients.
- Atomoxetine is contraindicated for use in patients with narrow angle glaucoma, pheochromocytoma, severe CV disorders, hypersensitivity to any component of the product, and in those taking MAOIs. It carries a boxed warning for a rare increased risk of suicidal ideation in children and adolescents. It also has warnings for serious CV events, effects on blood pressure and heart rate, effects on growth, psychotic or manic symptoms, aggressive behavior or hostility, rare cases of severe liver injury, urinary retention, and priapism. Patients should be screened for a personal or family history of bipolar disorder prior to use of atomoxetine due to the risk of activation of mania or hypomania.
 - Common AEs associated with atomoxetine include somnolence, nausea, and vomiting.
- Viloxazine ER is contraindicated with concurrent use of MAOIs and sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic index. Viloxazine ER carries a boxed warning for suicidal thoughts and behavior in patients treated with the drug. It also has warnings for effects on heart rate and blood pressure and the potential for somnolence and fatigue. Patients should be screened for bipolar disorder prior to use of viloxazine ER due to the risk of activation of mania or hypomania.
 - Common AEs associated with viloxazine ER include somnolence, nausea, and vomiting.
- The alpha₂-adrenergic agonists are contraindicated in patients known to be hypersensitive to any constituent of the product. They carry warnings for increased risk of hypotension, bradycardia, and syncope; sedation and somnolence; rebound hypertension; and cardiac conduction abnormalities.
 - Common AEs associated with clonidine ER include somnolence, fatigue, and irritability while common AEs with guanfacine ER include somnolence, fatigue, and hypotension.

DOSING AND ADMINISTRATION

Table 4. Dosing and Administration

Drug	Duration of action*	Available Formulations	Route	Usual Recommended Frequency	Comments
Stimulants					
Evekeo (amphetamine)	4 to 6 h	Tablets	Oral	<i>ADHD, narcolepsy</i> : Daily up to divided doses daily <i>Exogenous obesity</i> : Divided doses daily	<i>ADHD and narcolepsy</i> The first dose should be given upon awakening; additional doses at intervals of 4 to 6 hours.
Evekeo ODT (amphetamine)	4 to 6 h	Orally disintegrating tablets	Oral	Once or twice daily in the morning	As soon as the blister pack is opened, the tablet should be placed on the patient's tongue and allowed to disintegrate without chewing or crushing. The tablet will disintegrate in saliva so that it can be swallowed.

Data as of October 11, 2022 HJ-U/KS-U/AVD

Page 165

This information is considered confidential and proprietary to OptumRx. It is intended for internal use only and should be disseminated only to authorized recipients. The contents of the therapeutic class overviews on this website ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Clinicians should refer to the full prescribing information and published resources when making medical decisions.

Drug	Duration of action*	Available Formulations	Route	Usual Recommended Frequency	Comments
Adzenys XR-ODT (amphetamine ER)	10 to 12 h	Orally disintegrating tablets	Oral	Daily in the morning	As soon as the blister pack is opened, the tablet should be placed on the patient's tongue and allowed to disintegrate without chewing or crushing. The tablet will disintegrate in saliva so that it can be swallowed.
Dyanavel XR (amphetamine ER)	Up to 13 h	Suspension, ER tablets	Oral	Daily in the morning	The bottle should be shaken before administration. ER tablets may be chewed or swallowed whole. The 5 mg tablet may be split along the score line.
Adderall (mixed amphetamine salts)	4 to 6 h	Tablets	Oral	<u>ADHD, narcolepsy</u> : Daily up to divided doses daily	The first dose should be given on awakening, then additional doses at intervals of 4 to 6 hours.
Adderall XR (mixed amphetamine salts ER)	10 to 12 h	Capsules	Oral	Daily in the morning	Capsules may be taken whole, or the capsule may be opened and the entire contents sprinkled on applesauce and consumed immediately. The dose of a single capsule should not be divided.
Mydayis (mixed amphetamine salts ER)	16 h	Capsules	Oral	Daily in the morning	Dosage adjustment is needed for severe renal impairment. Use in end stage renal disease (ESRD) is not recommended. Capsules may be taken whole, or the

Drug	Duration of action*	Available Formulations	Route	Usual Recommended Frequency	Comments
					capsule may be opened and the entire contents sprinkled on applesauce and consumed immediately in its entirety without chewing. The dose of a single capsule should not be divided.
Focalin (dexamethylphenidate)	3 to 5 h	Tablets	Oral	Twice daily	Separate doses by at least 4 hours.
Focalin XR (dexamethylphenidate ER)	8 to 12 h	Capsules	Oral	Daily in the morning	ER capsules may be taken whole, or the capsule may be opened and the entire contents sprinkled on applesauce and consumed immediately in its entirety without chewing. The dose of a single capsule should not be divided.
ProCentra, Zenzedi (dextroamphetamine)	4 to 6 h	Solution (ProCentra) Tablets (Zenedi)	Oral	<u>ADHD, narcolepsy</u> : Daily up to divided doses daily	The first dose should be given upon awakening; additional doses at intervals of 4 to 6 hours
Dexedrine Spansule (dextroamphetamine SR)	6 to 8 h	Capsules	Oral	<u>ADHD</u> Daily or twice daily <u>Narcolepsy</u> Daily	
Xelstrym (dextroamphetamine transdermal system)	Up to 12 h	Transdermal system	Transdermal	The patch should be applied 2 hours before an effect is needed and removed within 9 hours.	Dose titration and final dosage should be individualized depending on clinical response and tolerability. Dosage adjustment is needed for renal impairment/ESRD.

Drug	Duration of action*	Available Formulations	Route	Usual Recommended Frequency	Comments
Vyvanse (lisdexamfetamine)	10 to 12 h	Capsules, chewable tablets	Oral	<u>ADHD, BED:</u> Daily in the morning	<p>Dosage adjustment is needed for renal impairment/ESRD.</p> <p>The capsules may be swallowed whole or can be opened, emptied, and mixed with yogurt, water, or orange juice and consumed immediately. A single capsule should not be divided.</p> <p>The chewable tablets must be chewed thoroughly before swallowing. A single dose should not be divided.</p>
Desoxyn (methamphetamine)	4 to 5 h	Tablets	Oral	Daily to twice daily	
Methylin, Ritalin (methylphenidate)	3 to 5 h	Chewable tablets, tablets (Ritalin), solution (Methylin)	Oral	Twice daily to 3 times daily	<p>The chewable tablets should be taken with at least 8 ounces (a full glass) of water or other fluid.</p> <p>The liquid and chewable tablets should be given 30 to 45 minutes before meals.</p>
Methylphenidate ER	8 h	Tablets			<p>The ER tablets may be used in place of the IR tablets when the 8-hour dosage of the ER product corresponds to the titrated 8-hour dosage of the IR products.</p> <p>The ER tablets must be swallowed</p>

Drug	Duration of action*	Available Formulations	Route	Usual Recommended Frequency	Comments
					whole and never crushed or chewed.
Adhansia XR (methylphenidate ER)	13 h	Capsules	Oral	Daily in the morning	<p>The capsules may be taken whole or they can be opened and sprinkled onto applesauce or yogurt; the entire contents of the mixture should be consumed within 10 minutes, and should not be chewed.</p> <p>The dose of a single capsule should not be divided.</p>
Aptensio XR (methylphenidate ER)	12 h	Capsules	Oral	Daily in the morning	<p>The capsules may be taken whole or they can be opened and sprinkled onto applesauce; the applesauce should be consumed immediately and it should not be chewed.</p> <p>The dose of a single capsule should not be divided.</p>

Drug	Duration of action*	Available Formulations	Route	Usual Recommended Frequency	Comments
Concerta (methylphenidate ER)	12 h	Tablets	Oral	Daily in the morning	The tablets should not be chewed or crushed.
Methylphenidate ER					<p>Note: An FDA analysis of methylphenidate ER products manufactured by UCB/Kremers (formerly Kudco) and Mallinckrodt indicated that in some individuals, they may deliver the drug in the body at a slower rate during the 7- to 12-hour range. As a result, the FDA changed the therapeutic equivalence of these products from AB to BX. Because these manufacturers have subsequently failed to demonstrate that their products are bioequivalent to the brand-name reference drug, the FDA proposed to withdraw their approval (<i>FDA 2016</i>).</p>
Cotempla XR-ODT (methylphenidate ER)	12 h	Orally disintegrating tablets	Oral	Daily in the morning	As soon as the blister pack is opened, the tablet should be placed on the patient's tongue and allowed to disintegrate without chewing or crushing. The tablet will disintegrate in saliva so that it can be swallowed.

Drug	Duration of action*	Available Formulations	Route	Usual Recommended Frequency	Comments
Jornay PM (methylphenidate ER)	10 h	Capsules	Oral	Daily in the evening	The capsule may be swallowed whole or it may be opened and the contents sprinkled onto applesauce and given immediately. The capsule contents must not be crushed or chewed, the dose of a single capsule should not be divided, and the contents of the entire capsule should be taken at the same time.
Methylphenidate ER (CD)	6 to 9 h	Capsules	Oral	Daily in the morning	The capsule may be swallowed whole or it may be opened and the contents sprinkled onto a small amount (one tablespoon) of applesauce and given immediately, followed by some fluids. The capsule contents must not be crushed or chewed.
QuilliChew ER (methylphenidate ER)	8 h	Chewable tablets	Oral	Daily in the morning	A 10 mg or 15 mg dose can be achieved by breaking in half the functionally scored 20 mg and 30 mg tablets, respectively.
Quillivant XR (methylphenidate ER)	12 h	Suspension	Oral	Daily in the morning	The bottle of Quillivant XR should be shaken vigorously for 10 seconds prior to administration. The suspension is stable for up to 4

Drug	Duration of action*	Available Formulations	Route	Usual Recommended Frequency	Comments
					months once reconstituted.
Relexxii (methylphenidate ER 72 mg)	12 h	Tablet	Oral	Daily in the morning	The tablet must be swallowed whole with the aid of liquids, and must not be chewed, divided, or crushed.
Ritalin LA (methylphenidate ER)	6 to 9 h	Capsules	Oral	Daily in the morning	The capsule may be swallowed whole or may be administered by sprinkling the capsule contents on a small amount of applesauce; the contents should not be crushed, chewed, or divided. The mixture should be consumed immediately.
Daytrana (methylphenidate transdermal system)	Up to 12 h	Transdermal system	Transdermal	The patch should be applied 2 hours before an effect is needed and removed within 9 hours. It may be removed earlier than 9 hours if a shorter duration of effect is desired or late day side effects appear.	
Azstarys (serdexmethylphenidate/ dexmethylphenidate)	10 to 13 h	Capsules	Oral	Daily in the morning	The capsule may be swallowed whole or may be administered by sprinkling the capsule contents over 2 tablespoons of applesauce or 50 mL of water. The mixture should be consumed immediately.
Non-stimulants					
Strattera (atomoxetine)	At least 10 to 12 h	Capsules	Oral	Daily in the morning or	Dosage adjustment is recommended for

Drug	Duration of action*	Available Formulations	Route	Usual Recommended Frequency	Comments
				divided dose in the morning and late afternoon/ early evening	patients with moderate or severe hepatic insufficiency, for use with strong CYP2D6 inhibitors, and for patients known to be CYP2D6 poor metabolizers. The capsules are not intended to be opened and should be taken whole.
Kapvay (clonidine ER)	At least 10 to 12 h	Tablets	Oral	Daily at bedtime or twice daily divided doses	With twice daily dosing, either an equal or higher split dosage should be given at bedtime. The tablets should not be crushed, chewed, or broken prior to swallowing. The initial dosage should be based on the degree of renal impairment.
Intuniv (guanfacine ER)	At least 8 to 12 h	Tablets	Oral	Daily in the morning or evening	The tablets should not be crushed, chewed, or broken prior to swallowing; they should not be administered with high fat meals, due to increased exposure. It may be necessary to reduce the dosage in patients with significant renal and hepatic impairment.
Qelbree (viloxazine ER)	Throughout the day (specific duration)	Capsules	Oral	Daily	The capsule may be swallowed whole or may be administered by

Drug	Duration of action*	Available Formulations	Route	Usual Recommended Frequency	Comments
	not reported)				sprinkling the capsule contents over a teaspoon of applesauce. The mixture should be consumed within 2 hours, without chewing.

See the current prescribing information for full details

*References: Prescribing information for individual products, *Medical Letter 2020*, *Pharmacist's Letter 2021*, *Krull 2022d*.

CONCLUSION

- Both CNS stimulants and nonstimulants may be used for the treatment of ADHD. In general, stimulants are first-line treatment due to their superior efficacy. Clinical evidence suggests that methylphenidate and amphetamines are equally efficacious, but some patients may respond to one stimulant and not the other. Various short-, intermediate- and long-acting formulations (eg, tablets/capsules, chewable/orally disintegrating tablets, solution/suspension, transdermal patch) are available to provide a range of dosing options. Although nonstimulants such as atomoxetine and alpha₂-adrenergic agonists have smaller effect sizes, they may be used in patients who have failed or are intolerant to stimulants or when there is concern about possible abuse or diversion. The efficacy of the nonstimulant viloxazine ER in comparison to other nonstimulants is unknown. The alpha₂-adrenergic agonists are approved both as monotherapy and as adjunctive therapy to stimulants, and they have been shown to improve both tic and ADHD symptoms in patients with comorbid tic disorder.
 - Current consensus clinical guidelines for the treatment of children and adolescents with ADHD recommend that stimulants are highly effective for reducing core symptoms of ADHD in children (*Wolraich et al 2019*).
- Ultimately, the choice of the initial agent for treatment of ADHD depends upon various factors such as: duration of desired coverage; ability of the child to swallow pills; coexisting tic disorder (use of alpha₂-adrenergic agonists may be warranted); potential AEs, history of substance abuse in the patient or household member (eg, avoid stimulants or use stimulants with less potential for abuse [eg, lisdexamfetamine, osmotic-release preparation, methylphenidate patch]); and preference of the patient and parent/guardian (*Krull 2022b*).
- Various stimulants are indicated for treatment of narcolepsy and are generally considered to be second-line agents after modafinil/armodafinil due to their sympathomimetic AEs (*Scammell 2021*).
- Lisdexamfetamine is the only FDA-approved drug indicated for the treatment of moderate to severe BED, with demonstrated efficacy in reduction of mean binge days per week vs placebo. Direct comparison trials between lisdexamfetamine and other drugs used off-label to treat BED are lacking.

REFERENCES

- Adderall [package insert], Parsippany, NJ: Teva Pharmaceuticals USA, Inc.; February 2022.
- Adderall XR [package insert], Lexington, MA: Takeda Pharmaceuticals America, Inc.; February 2022.
- Adhansia XR FDA clinical review. Food and Drug Administration website. January 29, 2019. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212038Orig1s000MedR.pdf. Accessed October 10, 2022.
- Adhansia XR [package insert], Wilson, NC: Purdue Pharmaceuticals L.P.; June 2021.
- Adzenys XR-ODT [package insert], Grand Prairie, TX: Neos Therapeutics, Inc.; March 2022.
- Aigner M, Treasure J, Kaye W, Kasper S; WFSBP Task Force on Eating Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. *World J Biol Psychiatry*. 2011;12(6):400-443.
- Aptensio XR [package insert], Coventry, RI: Rhodes Pharmaceuticals, L.P.; June 2021.
- Azstarys [package insert], Grand Rapids, MI: Corium, Inc.; June 2021.
- Barbaresi WJ, Campbell L, Diekroger EA, et al. Society for Developmental and Behavioral Pediatrics clinical practice guideline for the assessment and treatment of children and adolescents with complex attention-deficit/hyperactivity disorder. *J Dev Behav Pediatr*. 2020;41 Suppl 2S:S35-S57. doi:10.1097/DBP.0000000000000770
- Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. *J Am Acad Child Adolesc Psychiatry*. 2009;48(9):884-893. doi:10.1097/CHI.0b013e3181b26e9f

- Brownley KA, Berkman ND, Peat CM, et al. Binge-eating disorder in adults: A systematic review and meta-analysis. *Ann Intern Med.* 2016;165(6):409-420.
- Bukstein O. Attention deficit hyperactivity disorder in adults: Epidemiology, pathogenesis, clinical features, course, assessment, and diagnosis. UpToDate Web site. 2022. <http://www.uptodate.com>. Updated April 7, 2022. Accessed October 4, 2022.
- Castells X, Blanco-Silvente L, Cunill R. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. *Cochrane Database Syst Rev.* 2018;8:CD007813. doi: 10.1002/14651858.CD007813.pub3.
- Centers for Disease Control and Prevention (CDC). Attention Deficit Hyperactivity Disorder (ADHD). National Center for Health Statistics. <https://www.cdc.gov/nchs/fastats/adhd.htm>. Reviewed June 11, 2021. Accessed October 4, 2022.
- Chan E, Fogler JM, Hammerness PG. Treatment of attention-deficit/hyperactivity disorder in adolescents: a systematic review. *JAMA.* 2016;315(18):1997-2008.
- Childress AC, Brams M, Cutler AJ, et al. The efficacy and safety of Evekeo, racemic amphetamine sulfate, for treatment of attention-deficit/hyperactivity disorder symptoms: a multicenter, dose-optimized, double-blind, randomized, placebo-controlled crossover laboratory classroom study. *J Child Adolesc Psychopharmacol.* 2015;25(5):402-414. doi: 10.1089/cap.2014.0176
- Childress AC, Cutler AJ, Marraffino A, et al. A randomized, double-blind, placebo-controlled study of HLD200, a delayed-release and extended-release methylphenidate, in children with attention-deficit/hyperactivity disorder: An evaluation of safety and efficacy throughout the day and across settings. *J Child Adolesc Psychopharmacol.* 2020;30(1):2-14.
- Childress AC, Kollins SH, Cutler AJ, Marraffino A, Sikes CR. Efficacy, safety, and tolerability of an extended-release orally disintegrating methylphenidate tablet in children 6-12 years of age with attention-deficit/hyperactivity disorder in the laboratory classroom setting. *J Child Adolesc Psychopharmacol.* 2017;27(1):66-74.
- Clinical Pharmacology Website. <https://www.clinicalkey.com/pharmacology/login>. Accessed October 4, 2022.
- Concerta [package insert], Titusville, NJ: Janssen Pharmaceuticals, Inc.; April 2022.
- Cotempla XR-ODT [package insert], Grand Prairie, TX: Neos Therapeutics Brands, LCC; June 2021.
- Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. *Lancet Psychiatry.* 2018;5(9):727-738. doi: 10.1016/S2215-0366(18)30269-4.
- Cunill R, Castells X, Tobias A, Capellà D. Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression. *Pharmacoepidemiol Drug Saf.* 2013;22(9):961-969.
- Cutler AJ, Childress AC, Pardo A, et al. Randomized, double-blind, placebo-controlled, fixed-dose study to evaluate the efficacy and safety of amphetamine extended-release tablets in adults with attention-deficit/hyperactivity disorder. *J Clin Psychiatry.* 2022a;83(5):22m14438. doi:10.4088/JCP.22m14438
- Cutler AJ, Suzuki K, Starling B, et al. Efficacy and safety of dextroamphetamine transdermal system for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: results from a pivotal phase 2 study. *J Child Adolesc Psychopharmacol.* 2022b;32(2):89-97. doi:10.1089/cap.2021.0107
- Daytrana [package insert], Miami, FL: Noven Therapeutics, LLC; June 2021.
- Desoxyin [package insert], Lebanon, NJ: Recordati Rare Diseases Inc.; March 2019.
- Dexedrine Spansule [package insert], Bridgewater, NJ: Amneal Pharmaceuticals LLC; January 2022.
- Drugs@FDA [database on the Internet], Rockville (MD): Food and Drug Administration (US), Center for Drug Evaluation and Research; 2022. Available from: <http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>. Accessed October 4, 2022.
- Drugs for ADHD. *Med Lett Drugs Ther.* 2020;62 (1590):9-16.
- Dyanavel XR [package insert], Monmouth Junction: Tris Pharma, Inc.; May 2022.
- Elliott J, Johnston A, Husereau D, et al. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis. *PLoS One.* 2020;15(10):e0240584. doi: 10.1371/journal.pone.0240584
- Evekeo [package insert], Atlanta, GA: Arbor Pharmaceuticals, LLC; October 2019.
- Evekeo ODT [package insert], Atlanta, GA: Arbor Pharmaceuticals, LLC; April 2021.
- Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. *MedGenMed.* 2006;8(4):4.
- Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. *Eur Child Adolesc Psychiatry.* 2010a;19(4):353-364.
- Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. *J Clin Psychiatry.* 2010b;71(6):754-763.
- Feldman HM, Reiff MI. Clinical practice. Attention deficit-hyperactivity disorder in children and adolescents. *N Engl J Med.* 2014;370(9):838-846.
- Focalin [package insert], East Hanover, NJ: Novartis Pharmaceuticals Corporation.; June 2021.
- Focalin XR [package insert], East Hanover, NJ: Novartis Pharmaceuticals Corporation.; June 2021.
- Food and Drug Administration. Methylphenidate Hydrochloride Extended Release Tablets (generic Concerta) made by Mallinckrodt and Kudco. FDA Web site. <https://www.fda.gov/drugs/drug-safety-and-availability/methylphenidate-hydrochloride-extended-release-tablets-generic-concerta-made-mallinckrodt-and-kudco>. Updated November 4, 2016. Accessed October 4, 2022.
- Frick G, Yan B, Adler LA. Triple-bead mixed amphetamine salts (SHP465) in adults with ADHD: results of a phase 3, double-blind, randomized, forced-dose trial. *J Atten Disord.* 2020;24(3):402-413. doi: 10.1177/1087054717696771
- Garvey WT, Mechanick JL, Brett EM, et al; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. *Endocr Pract.* 2016;22 Suppl 3:1-203. doi: 10.4158/EP161365.GL.
- Gasior M, Hudson J, Quintero J, Ferreira-Cornwell MC, Radewonuk J, McElroy SL. A phase 3, multicenter, open-label, 12-month extension safety and tolerability trial of lisdexamfetamine dimesylate in adults with binge eating disorder. *J Clin Psychopharmacol.* 2017;37(3):315-322.
- Ghaderi A, Odeberg J, Gustafsson S, et al. Psychological, pharmacological, and combined treatments for binge eating disorder: a systematic review and meta-analysis. *PeerJ.* 2018;6:e5113. doi:10.7717/peerj.5113.
- Greenhill L, Kollins S, Abikoff H, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. *J Am Acad Child Adolesc Psychiatry.* 2006;45(11):1284-1293.

- Hirota T, Schwartz S, Correll CU. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. *J Am Acad Child Adolesc Psychiatry*. 2014;53(2):153-173.
- Intuniv [package insert], Lexington, MA: Shire US Inc.; August 2020.
- Hudson JI, McElroy SL, Ferreira-Cornwell MC, Radewonuk J, Gasior M. Efficacy of lisdexamfetamine in adults with moderate to severe binge-eating disorder: A randomized clinical trial. *JAMA Psychiatry*. 2017;74(9):903-910.
- Jadad AR, Boyle M, Cunningham C, Kim M, Schachar R. Treatment of attention-deficit/hyperactivity disorder. *Evid Rep Technol Assess (Summ)*. 1999;(11):i-viii, 1-341.
- Jornay PM [package insert], Cherry Hill, NJ: Ironshore Pharmaceuticals, Inc.; June 2021.
- Joseph A, Ayyagari R, Xie M, et al. Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison. *Eur Child Adolesc Psychiatry*. 2017;26(8):875-897.
- Kapvay [package insert], St. Michael, Barbados: Concordia Pharmaceuticals, Inc.; February 2020.
- Kollins SH, Braeckman R, Guenther S, et al. A Randomized, controlled laboratory classroom study of serdexmethylphenidate and d-methylphenidate capsules in children with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol*. 2021;31(9):597-609.
- Krull KR. Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis. UpToDate Web site. 2022a. <http://www.uptodate.com>. Updated May 31, 2022. Accessed October 4, 2022.
- Krull KR. Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis. UpToDate Web site. 2022b. <http://www.uptodate.com>. Updated May 16, 2022. Accessed October 4, 2022.
- Krull KR. Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis. UpToDate Web site. 2022d. <http://www.uptodate.com>. Updated June 6, 2022. Accessed October 4, 2022.
- Krull KR. Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications. UpToDate Web site. 2022e. <http://www.uptodate.com>. Updated August 10, 2022. Accessed October 4, 2022.
- Krull KR. Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents. UpToDate Web site. 2022c. <http://www.uptodate.com>. Updated August 10, 2022. Accessed October 4, 2022.
- Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. *J Clin Sleep Med*. 2021;17(9):1881-1893. doi:10.5664/jcsm.9328
- McElroy SL, Hudson J, Ferreira-Cornwell MC, Radewonuk J, Whitaker T, Gasior M. Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder: Results of two pivotal phase 3 randomized controlled trials. *Neuropsychopharmacology*. 2016;41(5):1251-1260.
- Methylin oral solution [package insert], Florham Park, NJ: Shionogi Inc.; July 2021.
- Methylphenidate chewable tablets [package insert], Central Islip, NY: Ascent Pharmaceuticals, Inc.; August 2021.
- Methylphenidate ER [package insert], Newtown, PA: KVK-Tech, Inc.; April 2021.
- Methylphenidate ER (CD) [package insert], Philadelphia, PA: Lannett Company, Inc.; May 2021.
- Methylphenidate hydrochloride extended-release tablets (generic Concerta) made by Mallinckrodt and Kudco. FDA Web site. November 4, 2016.
- Murphy TK, Lewin AB, Storch EA, Stock S; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with tic disorders. *J Am Acad Child Adolesc Psychiatry*. 2013;52(12):1341-1359.
- Mydayis [package insert], Lexington, MA: Shire US Inc.; January 2022.
- Nasser A, Hull JT, Chaturvedi SA, et al. A phase III, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of viloxazine extended-release capsules in adults with attention-deficit/hyperactivity disorder. *CNS Drugs*. 2022;36(8):897-915. doi:10.1007/s40263-022-00938-w
- Nasser A, Liranso T, Adewole T, et al. A Phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit/hyperactivity disorder in school-age children. *Clin Ther*. 2020;42(8):1452-1466.
- Nasser A, Liranso T, Adewole T, et al. A phase 3, placebo-controlled trial of once-daily viloxazine extended-release capsules in adolescents with attention-deficit/hyperactivity disorder. *J Clin Psychopharmacol*. 2021a;41(4):370-380. doi:10.1097/JCP.0000000000001404
- Nasser A, Liranso T, Adewole T, et al. Once-daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: A Phase III randomized, controlled trial. *Clin Ther*. 2021b;S0149-2918(21)00054-0.
- Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine/Methylphenidate Comparative Study Group. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. *Am J Psychiatry*. 2008;165(6):721-730.
- Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Food and Drug Administration Web site. <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>. Accessed October 4, 2022.
- Osland ST, Steeves TD, Pringsheim T. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. *Cochrane Database Syst Rev*. 2018;6:CD007990. doi:10.1002/14651858.CD007990.pub3.
- Padilha SCOS, Virtuoso S, Tonin FS, Borba HHL, Pontarolo R. Efficacy and safety of drugs for attention deficit hyperactivity disorder in children and adolescents: a network meta-analysis. *Eur Child Adolesc Psychiatry*. 2018;27(10):1335-1345. doi: 10.1007/s00787-018-1125-0.
- PL Detail-Document. Comparison of ADHD medications. *Pharmacist's Letter/Prescriber's Letter*. September 2021.
- Pliszka SR, Wilens TE, Bostrom S, et al. Efficacy and safety of HLD200, delayed-release and extended-release methylphenidate, in children with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol*. 2017;27(6):474-482. doi: 10.1089/cap.2017.0084.
- Practice parameter for the assessment and treatment of children and adolescents with tic disorders. *J Am Acad Child Adolesc Psychiatry*. 2013;52(12):1341-1359.
- Pringsheim T, Okun MS, Müller-Vahl K, et al. Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. *Neurology*. 2019;92(19):896-906.
- ProCentra [package insert], Newport, KY: Independence Pharmaceuticals, LLC; December 2021.
- Punja S, Shamsseer L, Hartling L, et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. *Cochrane Database Syst Rev*. 2016;2:CD009996.
- Qelbree [package insert], Rockville, MD: Supernus Pharmaceuticals, Inc.; April 2022.
- QuillChew ER [package insert], Monmouth Junction, NJ: Tris Pharma, Inc.; June 2021.

- Quillivant XR [package insert], Monmouth Junction, NJ: Tris Pharma, Inc.; June 2021.
- Relexxii [package insert], Alpharetta, GA: Vertical Pharmaceuticals, LLC; November 2021.
- Rodrigues R, Lai MC, Beswick A, et al. Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis. *J Child Psychol Psychiatry*. 2021;62(6):680-700. doi:10.1111/jcpp.13305
- Ritalin [package insert], East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2021.
- Ritalin LA [package insert], East Hanover, NJ: Novartis Pharmaceuticals Corporation.; June 2021.
- Scammell TE. Treatment of narcolepsy in adults. UpToDate Web site. 2022. <http://www.uptodate.com>. Updated September 2, 2022. Accessed October 4, 2022.
- Schneider E, Higgs S, Dourish CT. Lisdexamfetamine and binge-eating disorder: A systematic review and meta-analysis of the preclinical and clinical data with a focus on mechanism of drug action in treating the disorder. *Eur Neuropsychopharmacol*. 2021;53:49-78. doi:10.1016/j.euroneuro.2021.08.001
- Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. *J Am Acad Child Adolesc Psychiatry*. 2014;53(2):174-187.
- Storebø OJ, Ramstad E, Krogh HB, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). *Cochrane Database Syst Rev*. 2015;11:CD009885.
- Stratterra [package insert], Indianapolis, IN: Lilly USA, Inc.; January 2022.
- Stuhec M, Lukić P, Locatelli I. Efficacy, acceptability, and tolerability of lisdexamfetamine, mixed amphetamine salts, methylphenidate, and modafinil in the treatment of attention-deficit hyperactivity disorder in adults: a systematic review and meta-analysis. *Ann Pharmacother*. 2019;53(2):121-133. doi:10.1177/1060028018795703.
- Stuhec M, Munda B, Svab V, Locatelli I. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion. *J Affect Disord*. 2015;178:149-159.
- Vyvanse [package insert], Lexington, MA: Takeda Pharmaceuticals America, Inc.; January 2022.
- Weisler RH, Greenbaum M, Arnold V, et al. Efficacy and safety of SHP465 mixed amphetamine salts in the treatment of attention-deficit/hyperactivity disorder in adults: results of a randomized, double-blind, placebo-controlled, forced-dose clinical study. *CNS Drugs*. 2017;31(8):685-697.
- Wigal T, Brams M, Frick G, Yan B, Madhoo M. A randomized, double-blind study of SHP465 mixed amphetamine salts extended-release in adults with ADHD using a simulated adult workplace design. *Postgrad Med*. 2018a;130(5):481-493. doi: 10.1080/00325481.2018.1481712
- Wigal T, Childress A, Frick G, Yan B, Wigal S, Madhoo M. Effects of SHP465 mixed amphetamine salts in adults with ADHD in a simulated adult workplace environment. *Postgrad Med*. 2018b;130(1):111-121. doi: 10.1080/00325481.2018.1389227
- Wigal T, Lopez F, Frick G, Yan B, Robertson B, Madhoo M. A randomized, double-blind, 3-way crossover, analog classroom study of SHP465 mixed amphetamine salts extended-release in adolescents with ADHD. *Postgrad Med*. 2019;131(3):212-224. doi: 10.1080/00325481.2019.1574402
- Wigal SB, Wigal T, Childress A, Donnelly GAE, Reiz JL. The time course of effect of multilayer-release methylphenidate hydrochloride capsules: a randomized, double-blind study of adults with ADHD in a simulated adult workplace environment. *J Atten Disord*. 2020;24(3):373-383. doi: 10.1177/1087054716672335
- Wolraich ML, Hagan JF Jr., Allan C, et al; Subcommittee on Children and Adolescents with Attention-Deficit/Hyperactive Disorder. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. *Pediatrics*. 2019;144(4):e20192528. doi: 10.1542/peds.2019-2528
- Yager J, Devlin MF, Halmi KA, et al. Guideline watch (August 2012): Practice guideline for the treatment of patients with eating disorders, 3rd edition. Psychiatry Online Web site. <http://psychiatryonline.org/guidelines>. Accessed October 4, 2022.
- Yager J, Devlin MF, Halmi KA, et al. Practice guideline for the treatment of patients with eating disorders, 3rd edition (2006). Psychiatry Online Web site. <http://psychiatryonline.org/guidelines>. Accessed October 4, 2022.
- Zenedi [package insert], Atlanta, GA: Arbor Pharmaceuticals, LLC; January 2022.
- Xelstrym [package insert], Miami, FL: Noven Pharmaceuticals, Inc.; March 2022.

Publication Date: October 31, 2022